

FLORetina 2024

UNDER THE PATRONAGE OF

Gemelli

COMUNE DI FIRENZE

UNIVERSITÀ CATTOLICA del Sacro Cuore

ICOOR

12° International Congress on OCT and OCT angiography

Program



ORGANIZER AND CHAIR: **STANISLAO RIZZO**
CO-CHAIR: **FRANCESCO FARALDI**
SCIENTIFIC SECRETARIAT: **DANIELA BACHERINI**

SCIENTIFIC COMMITTEE AND COURSE ORGANIZERS:

Carl Awh
Sophie J. Bakri
Francesco Bandello
Adiel Barak
Leroy Bart
Aya Barzelay
Enrico Borrelli
Francesco Boscia
Elodie Bousquet
Tomaso Caporossi
Usha Chakravarthy
Jay Chhablani
David Chow
Donald D'amico
Roberto Dell'Omo
Michele Della Corte
Rita Ehrlich
Ehab El Rayes
Orly Gal-Or
José García-Arumí
Fabrizio Giansanti
Andrea Govetto
David Huang
Maja Kostic
Paolo Lanzetta
Domenico Lepore
Sarit Lesnik-Oberstein
Anat Loewenstein
Marco Lupidi
Robert Maclaren
Cesare Mariotti
Rodolfo Mastropasqua
Leonardo Mastropasqua
Edoardo Midena
Marion Munk
Quan Dong Nguyen
Daniel Pauleikhoff
Alfredo Pece
Grazia Pertile
Tunde Peto
Elisabetta Pilotto
Giuseppe Querques
Aleksandra Rachitskaya
Emilio Rapizzi
Michele Reibaldi
Kourous Rezaei
Mario Romano
Srinivas Sadda
David Sarraf
Maria Cristina Savastano
Alfonso Savastano
Ursula Schmidt-Erfurth
Francesca Simonelli
Richard Spaide
Paulo Eduardo Stanga
Giovanni Staurenghi
Francesco Testa
Daniel Ting
Daniele Tognetto
Lisa Toto
Omer Trivizki
Adnan Tufail
Lejla Vajzovic
Demetrios Vavvas
Pasquale Viggiano
Stela Vujosevic
Dinah Zur

SURGICAL CENTERS:

ROME (ITALY) - FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
ROME (ITALY) -OSPEDALE ISOLA TIBERINA – GEMELLI ISOLA
PISA (ITALY) - CASA DI CURA DI SAN ROSSORE
ATHENS (GREECE) – MY RETINA ATHENS EYE CENTER ATHINAIKI GENERAL HOSPITAL
BEIJING (CHINA) - BEIJING TONGREN HOSPITAL, CMU
ESSEN (GERMANY) - UNIVERISTY HOSPITAL
KINSHASA (CONGO) - AVE KIN CLINIQUE OPHTALMOLOGIQUE EUROPÉEN
MARSEILLE (FRANCE) - CLINIQUE JUGE
MESA (AZ – USA) - BARNET DULANEY PERKINS EYE CENTER
MEXICO CITY (MEXICO) - ASOCIACION PARA EVITAR LA CEGUERA

SCIENTIFIC SOCIETIES GENERAL PATRONAGE AND PATRONIZED SESSIONS

AIMO · ESASO · EURETINA · ASRS American Society of Retina Specialists · RETINA WORLD CONGRESS · YORIS · SOCIETÀ OFTALMOLOGI UNIVERSITARI · Givre · S.I.R. Società Italiana della Retina

INTERNATIONAL EXPERT GROUPS AND FORUM

VISION ACADEMY · INTRAVITREAL EXPERT GROUP

BRUNO LUMBROSO LECTURE SELECTION COMMITTEE:

Quan Dong Nguyen (Palo Alto, USA)

Albert Augustin (Karlsruhe, Germany)
Francesco Bandello (Milan, Italy)
Alain Gaudric (Paris, France)
David Huang (Portland, USA)
Marco Rispoli (Rome, Italy)
Philip Rosenfeld (Miami, USA)
SriniVas Sadda (Los Angeles, USA)

BRUNO LUMBROSO LECTURE AWARD 2024: AMANI FAWZI

Image gallery: **Joseph Carroll**

Live Surgery Program Coordinator: **Umberto De Vico**

Lumbroso, Barca and Packo Award Committee
Floretina Society Scientific Board

Floretina.com and Retinafutura.com Digital Provider
GDS Communication
Key Account Manager: Rossella Salvoni

Official Annual Meeting Organizer
A.P. Meetings

FACULTY

ABDALLA MARAM ***UNITED KINGDOM***
ACCORINTI MASSIMO ***ITALY***
AL SABTI KHALID ***KUWAIT***
AL-DIBHI HASSAN ***SAUDI ARABIA***
ALMEIDA DAVID ***USA***
AMORE FILIPPO ***ITALY***
AMOROSO FRANCESCA ***FRANCE***
ANOVER FRANCES ANDREA ***PHILIPPINES***
AREVALO J. FERNANDO ***USA***
ARRIGO ALESSANDRO ***ITALY***
ASLAM TARIQ ***UNITED KINGDOM***
AUDO ISABELLE ***FRANCE***
AUGUSTIN ALBERT ***GERMANY***
AVCI REMZI ***TURKEY***
AVITABILE TERESIO ***ITALY***
AWH CARL ***USA***
AZZOLINI CLAUDIO ***ITALY***
BACHERINI DANIELA ***ITALY***
BADAWI ABDULRAHMAN ***SAUDI ARABIA***
BAKHOUM MATHIEU ***USA***
BAKRI SOPHIE J. ***USA***
BAINBRIDGE JAMES ***UNITED KINGDOM***
BALCIUNIENE VILMA JURATE ***LITHUANIA***
BALESTRAZZI EMILIO ***ITALY***
BALESTRAZZI ALESSANDRA ***ITALY***
BALI ERNESTO ***BELGIUM***
BANDELLO FRANCESCO ***ITALY***
BARAK ADIEL ***ISRAEL***
BARAK YOREH ***ISRAEL***
BARCA FRANCESCO ***ITALY***
BAROSCO GUIDO ***ITALY***
BARZELAY AYA ***USA***
BATTAGLIA PARODI MAURIZIO ***ITALY***
BAUMAL CAROLINE ***USA***
BECHRAKIS NIKOLAOS ***GERMANY***
BEGOVIC EMINA ***BOSNIA AND HERZEGOVINA***
BEHAR COHEN FRANCINE ***FRANCE***
BERNARDINI RENATO ***ITALY***
BERNI ALESSANDRO ***ITALY***
BERROCAL AUDINA M. ***USA***
BILLI BERNARDO ***ITALY***
BLENGIO CARLA ***ITALY***
BONFIGLIO VINCENZA ***ITALY***
BORKAR DURGA ***USA***
BORRELLI ENRICO ***ITALY***
BOSCIA FRANCESCO ***ITALY***
BOUSQUET ELODIE ***FRANCE***
BRADDON MARK ***UNITED KINGDOM***
BREAZZANO MARK ***USA***
BRESSLER SUSAN ***USA***
BROWN DAVID ***USA***
BRUCKER ALEXANDER J. ***USA***
BUZZONETTI LUCA ***ITALY***
CABRAL DIOGO ***PORTUGAL***
CALCAGNI ANTONIO ***UNITED KINGDOM***
CAMPBELL PETER ***USA***
CAPONE ANTONIO ***USA***
CAPOROSSI TOMASO ***ITALY***
CAPUTO GEORGES ***FRANCE***
CARDILLO PICCOLINO FELICE ***ITALY***
CARETTI LUIGI ***ITALY***
CARLEVALE CARLO ***ITALY***
CARNEIRO ANGELA ***PORTUGAL***
CARROLL JOSEPH ***USA***
CENNAMO GILDA ***ITALY***
CEREDA MATTEO GIUSEPPE ***ITALY***
CHAKRAVARTHY USHA ***UNITED KINGDOM***
CHANDRA AMAN ***UNITED KINGDOM***
CHARLES STEVE ***USA***
CHATZIRALLI IRINI ***GREECE***
CHELAZZI PAOLO ***ITALY***
CHEUNG CAROL ***HONG KONG***
CHEUNG GEMMY ***SINGAPORE***
CHHABLANI JAY ***USA***
CHOW DAVID ***CANADA***
CIARDELLA ANTONIO ***ITALY***
CICINELLI MARIA VITTORIA ***ITALY***
CIMINO LUCA ***ITALY***
CLAES CARL ***BELGIUM***
COASSIN MARCO ***ITALY***
COHEN YVES SALOMON ***FRANCE***
COPPOLA MICHELE ***ITALY***
COZZI MARIANO ***ITALY***
COUTURIER AUDE ***FRANCE***
CRINCOLI EMANUELE ***ITALY***
CURCIO CHRISTINE A. ***USA***
CUSUMANO ANDREA ***ITALY***
DA CRUZ LYNDON ***UNITED KINGDOM***
DAMATO BERTIL ***UNITED KINGDOM***
D'AMICO DONALD J. ***USA***
DE CILLA' STEFANO ***ITALY***
DE MOLFETTA VITO ***ITALY***
DE SMET MARC ***SWITZERLAND***
DE-BOER CHARLES ***USA***
DELLA CORTE MICHELE ***ITALY***
DELL'OMO ROBERTO ***ITALY***
DEMIREL SIBEL ***TURKEY***
DEUTSCH NATHAN ***SWITZERLAND***
DEVIN FRANCOIS ***FRANCE***
DHOOT DILSHER ***USA***
DI SIMPLICIO SANDRO ***UNITED KINGDOM***
DO DIANA V. ***USA***
DOLLFUS HELENE ***FRANCE***
DOLZ-MARCO ROSA ***SPAIN***
DRAWNEL FAYE ***SWITZERLAND***
EANDI CHIARA ***ITALY***
ECKARDT CLAUS ***GERMANY***
EHRLICH RITA ***ISRAEL***
EL MAFTOUHI ADIL ***SWITZERLAND***
EL RAYES EHAB ***EGYPT***
ELDEM BORA ***TURKEY***
ERDOGAN GURKAN ***TURKEY***
ERGINAY ALI ***FRANCE***
ERSÖZ GIRAY ***TURKEY***
ETER NICOLE ***GERMANY***
FABIANI CLAUDIA ***ITALY***
FARALDI FRANCESCO ***ITALY***
FASSER CHRISTINA ***SWITZERLAND***
FAWZI AMANI ***USA***
FAYYAD FAISAL ***JORDAN***
FEKRAT SHARON ***USA***
FEO ALESSANDRO ***ITALY***
FERRARA DANIELA ***USA***
FERRARA MARIANTONIA ***ITALY***
FERRARA VINCENZO ***ITALY***
FERRONE PHILIP ***USA***



FACULTY

FIGUEROA MARTA ***SPAIN***
FIGUS MICHELE ***ITALY***
FIORE TITO ***ITALY***
FIORMONTE FABIO ***ITALY***
FISCHER DOMINIK ***GERMANY***
FISHER YALE ***USA***
FLORENTZIS MILTIADIS ***GREECE***
FORLINI MATTEO ***ITALY***
FOSSATARO FEDERICA ***ITALY***
FOSSATARO CLAUDIA ***ITALY***
FOUAD YOUSEF ***EGYPT***
FRAGIOTTA SERENA ***ITALY***
FRANCONE ANIBAL ***ARGENTINA***
FRANKLIN ALAN ***USA***
FRIBERG THOMAS ***USA***
FRISINA RINO ***ITALY***
FRIZZIERO LUISA ***ITALY***
FUJIMOTO JAMES ***USA***
FULDA GRAUE EMILIANO ***MEXICO***
GALE RICHARD ***UNITED KINGDOM***
GAL-OR ORLY ***ISRAEL***
GARCÍA-ARUMÍ JOSÉ ***SPAIN***
GAUDRIC ALAIN ***FRANCE***
GIANNOPOULOS THEODOROS ***GREECE***
GIANSANTI FABRIZIO ***ITALY***
GINI GIAMPAOLO ***ITALY***
GISBERT RICHARD ***GERMANY***
GLITTENBERG CARL ***SWITZERLAND***
GOLDSTEIN MICHAELLA ***ISRAEL***
GOTZARIDIS STRATOS ***GREECE***
GOVETTO ANDREA ***ITALY***
GRABOWSKA ANNA ***UNITED KINGDOM***
GRAFF JORDAN ***USA***
GUARNACCIA GIUSEPPE ***SWITZERLAND***
GUIGOU SEBASTIEN ***FRANCE***
HADJISTILIANOU DORIS ***ITALY***
HADZIAHMETOVIC MAJDA ***USA***
HAGEMAN GREGORY S. ***USA***
HAI LU ***CHINA***
HASSAN TAREK ***USA***
HEIER JEFFREY S. ***USA***
HEIMANN HEINRICH ***UNITED KINGDOM***
HO ALLEN ***USA***
HOLZ FRANK ***GERMANY***
HUANG DAVID ***USA***
HUANG SUBER ***USA***
HUNG JIA-HORUNG ***TAIWAN***
HUSSAIN RUMANA ***UNITED KINGDOM***
HWANG YUNCHAN ***USA***
INTROINI UGO ***ITALY***
INVERNIZZI ALESSANDRO ***ITALY***
IOVINO CLAUDIO ***ITALY***
JAKI MEKJAVIC POLONA ***SLOVENIA***
JAMPOL LEE MERRILL ***USA***
JOUSSEN ANTONIA ***GERMANY***
KAISER PETER ***USA***
KARACA IRMAK ***USA***
KASHANI AMIR H. ***USA***
KEEGAN DAVID ***IRELAND***
KITCHENS JOHN ***USA***
KOROBELNIK JEAN-FRANÇOIS ***FRANCE***
KOSS MICHAEL ***GERMANY***
KOSTIC MAJA ***USA***
KUPPERMANN BARUCH ***USA***
KUTZER CORNELIA ***AUSTRIA***
LAM WAI-CHING ***CANADA***
LANZETTA PAOLO ***ITALY***
LATTANZIO ROSANGELA ***ITALY***
LAVIA CARLO ALESSANDRO ***ITALY***
LAZIC RATIMIR ***CROATIA***
LE MER YANNICK ***FRANCE***
LEINGANG OLIVER ***AUSTRIA***
LENG THEODORE ***USA***
LENGYEL IMRE ***UNITED KINGDOM***
LEO SEO WEI ***SINGAPORE***
LEPORE DOMENICO ***ITALY***
LEROY BART ***BELGIUM***
LESNIK-OBERSTEIN SARIT ***UNITED KINGDOM***
LESNONI GUIDO ***ITALY***
LOEWENSTEIN ANAT ***ISRAEL***
LORENZI UMBERTO ***FRANCE***
LUPIDI MARCO ***ITALY***
MACLAREN ROBERT ***UNITED KINGDOM***
MAHMOUD TAMER ***USA***
MAIA ANDRE ***BRAZIL***
MALTSEV DMITRII ***RUSSIA***
MARCHINI GIORGIO ***ITALY***
MARINO ANTONIO ***ITALY***
MARIOTTI SILVIO PAOLO ***SWITZERLAND***
MARIOTTI CESARE ***ITALY***
MASTROPASQUA LEONARDO ***ITALY***
MASTROPASQUA RODOLFO ***ITALY***
MATONTI FREDERIC ***FRANCE***
MATSUMIYA WATARU ***JAPAN***
MAVI YILDIZ AYSEGUL ***TURKEY***
MENDOZA CARLOS ***USA***
MERCIECA KARL ***UNITED KINGDOM***
MEYER CARSTEN H. ***SWITZERLAND***
MICHIELETTO PAOLO ***ITALY***
MIDENA EDOARDO ***ITALY***
MIDENA GIULIA ***ITALY***
MIERE ALEXANDRA ***FRANCE***
MILLER JOHN ***USA***
MINNELLA ANGELO MARIA ***ITALY***
MISEROCCHI ELISABETTA ***ITALY***
MISHEV LUKAN ***BULGARIA***
MONES JORDI ***SPAIN***
MORALES CANTÓN VIRGILIO ***MEXICO***
MOSHFEGHI DARIUS M. ***USA***
MREJEN SARAH ***FRANCE***
MUNK MARION ***SWITZERLAND***
MURA MARCO ***ITALY***
MURRO VITTORIA ***ITALY***
NAGIEL AARON ***USA***
NASSISI MARCO ***ITALY***
NAWROCKA ZOFIA ***POLAND***
NERINCKX FANNY ***BELGIUM***
NGUYEN QUAN DONG ***USA***
NICOLÓ MASSIMO ***ITALY***
NIKOLAKOPOULOS ATHANASIOS ***GREECE***
NUCCI PAOLO ***ITALY***
NUDLEMAN ERIC ***USA***
OR CHRISTOPHER ***USA***
OSHIMA YUSUKE ***JAPAN***
PAGLIARA MONICA ***ITALY***
PANICO CLAUDIO ***ITALY***
PANOZZO GIACOMO ***ITALY***
PAPATHOMAS THOMAS ***GREECE***
PARMEGGIANI FRANCESCO ***ITALY***
PAROLINI BARBARA ***ITALY***

FACULTY

PARRAVANO MARIACRISTINA ***ITALY***
PARROZZANI RAFFAELE ***ITALY***
PATELLI FABIO ***ITALY***
PAULEIKHOFF DANIEL ***GERMANY***
PEARCE IAN ***UNITED KINGDOM***
PECE ALFREDO ***ITALY***
PEIRETTI ENRICO ***ITALY***
PELAYES DAVID ***ARGENTINA***
PERTILE GRAZIA ***ITALY***
PETO TUNDE ***UNITED KINGDOM***
PETROPOULOS IOANNIS ***SWITZERLAND***
PETROU PETROS ***GREECE***
PFAU KRISTINA ***SWITZERLAND***
PICHI FRANCESCO ***UAE***
PIERRO LUISA ***ITALY***
PILERI MARCO ANDREA ***ITALY***
PILOTTO ELISABETTA ***ITALY***
PIRCHER MICHAEL ***AUSTRIA***
POPOVIC MARKO ***CANADA***
PRIGIONE GUIDO ***ITALY***
PRIGLINGER SIEGFRIED ***GERMANY***
QUERQUES GIUSEPPE ***ITALY***
QUEZADA RUIZ CARLOS ***MEXICO***
RACHITSKAYA ALEKSANDRA ***USA***
RADICE PAOLO ***ITALY***
RAMTOHUL PRITHVI ***FRANCE***
RAPIZZI EMILIO ***ITALY***
REGILLO CARL D. ***USA***
REIBALDI MICHELE ***ITALY***
REITER GREGOR ***AUSTRIA***
RESNIKOFF SERGE ***AUSTRALIA***
REZAEI KOUROUS ***USA***
REZENDE FLAVIO ***CANADA***
RIEMANN CHRISTOPHER D. ***USA***
RISPOLI MARCO ***ITALY***
RIZZO STANISLAO ***ITALY***
ROMANO ANDRÉ ***BRAZIL***
ROMANO FRANCESCO ***ITALY***
ROMANO MARIO ***ITALY***
ROMERO-MORALES VERONICA ***MEXICO***
ROSA NICOLA ***ITALY***
ROSEN RICHARD ***USA***
ROSSI ERNESTO ***ITALY***
ROSSI SETTIMIO ***ITALY***
ROSSI TOMMASO ***ITALY***
RUIZ BILBAO SUSANA ***SPAIN***
RUIZ MORENO JOSÉ MARIA ***SPAIN***
RUSSO ANDREA ***ITALY***
SACCONI RICCARDO ITALY
SADDA SRINIVAS ***USA***
SAENGSIRINAVIN AIM-ON ***USA***
SAIDKASIMOVA SHOHISTA ***UNITED KINGDOM***
SALADINO ANDREA ***UNITED KINGDOM***
SARAO VALENTINA ***ITALY***
SARRAF DAVID ***USA***
SATIRTAV GUNHAL ***TURKEY***
SAVASTANO ALFONSO ***ITALY***
SAVASTANO MARIA CRISTINA ***ITALY***
SCHMIDT-ERFURTH URSULA ***AUSTRIA***
SCHWARTZ ROY ***UNITED KINGDOM***
SCHWARTZ SHULAMIT ***ISRAEL***
SCHWARTZ STEVEN D. ***USA***
SCORCIA VINCENZO ***ITALY***
SCUPOLA ANDREA ***ITALY***
SEPAH YASIR ***USA***
SERMET FIGEN ***TURKEY***
SHAH RAJIV EDLAGAN ***USA***
SILVESTRI VALERIA ***ITALY***
SIMONELLI FRANCESCA ***ITALY***
SIVAPRASAD SOBHA ***UNITED KINGDOM***
SOLER VINCENT ***FRANCE***
SOUIED ERIC ***FRANCE***
SPAIDE RICHARD ***USA***
STALMANS PETER ***BELGIUM***
STANGA PAULO EDUARDO ***UNITED KINGDOM***
STANZEL BORIS ***GERMANY***
STAURENGHI GIOVANNI ***ITALY***
STEEL DAVID H. ***UNITED KINGDOM***
SZURMAN PETER ***GERMANY***
TABANDEH HOMAYOUN ***USA***
TALKS JAMES ***UNITED KINGDOM***
TAMBURRELLI CIRO ***ITALY***
TESTA FRANCESCO ***ITALY***
THAN NGOC TRONG TUONG ***VIETNAM***
THNG ZHENG XIAN ***SINGAPORE***
TING DANIEL ***SINGAPORE***
TOGNETTO DANIELE ***ITALY***
TORO MARIO ***ITALY***
TOSI GIAN MARCO ***ITALY***
TOTH CYNTHIA ***USA***
TOTO LISA ***ITALY***
TRIVIZKI OMER ***ISRAEL***
TSILIMBARIS MILTIADIS ***GREECE***
TUFAIL ADNAN ***UNITED KINGDOM***
TURCO SIMONA ***ITALY***
VAGGE ALDO ***ITALY***
VAIANO AGOSTINO ***ITALY***
VAJZOVIC LEJLA ***USA***
VALSECCHI NICOLA ***ITALY***
VAN OVERDAM KOEN ***NETHERLANDS***
VANNOZZI LORENZO ***ITALY***
VAVVAS DEMETRIOS ***USA***
VENTRE LUCA
VERITTI DANIELE ***ITALY***
VIGGIANO PASQUALE ***ITALY***
VILLANI GIANFRANCESCO ***ITALY***
VIOLA FRANCESCO ***ITALY***
VIRGILI GIANNI ***ITALY***
VOICHANSKI SHILO ***ISRAEL***
VUJOSEVIC STELA ***ITALY***
WAHEED NADIA ***USA***
WALDSTEIN SEBASTIAN ***AUSTRIA***
WILLIAMSON TOM ***UNITED KINGDOM***
WOLF SEBASTIAN ***SWITZERLAND***
WOLF ARMIN ***GERMANY***
WOLFENSBERGER THOMAS ***SWITZERLAND***
WONG DAVID ***CANADA***
WYKOFF CHARLES C. ***USA***
YOO WOONG-SUN ***SOUTH KOREA***
YZER SUZANNE ***NETHERLANDS***
ZACKS DAVID N. ***USA***
ZAMBROWSKI OLIVIA ***FRANCE***
ZARRANZ-VENTURA JAVIER ***SPAIN***
ZUCCARINI SILVIO ***ITALY***
ZUR DINAH ***ISRAEL***
ZWEIFEL SANDRINE ***SWITZERLAND***



Florence
December 5,6,7 and 8, 2024

Fortezza da Basso

FLORetina 2024
ICOOR
12° International Congress on OCT and OCT angiography

THURSDAY 5 DECEMBER

	SANTA MARIA NOVELLA	SAN GIOVANNI	SANTA CROCE	SAN FREDIANO	SANTO SPIRITO	SAN LORENZO	ORSANMICHELE	PALAZZO VECCHIO	PALAZZO STROZZI	PALAZZO RUCELLAI
13:00 - 13:15			13:00 - 14:00 NOVEL APPROACHES TO IMAGE ANALYSIS Organizers: VUJOSEVIC STELA, TING DANIEL	13:15 - 14:00 FREE PAPERS - HIGHLIGHTED NEW DRUGS DME	13:00 - 14:15 EPISCLERAL SURGERY COURSE: THE IMPORTANCE OF THE BASICS Organizers: GIANSANTI FABRIZIO, TOGNETTO DANIELE	13:00 - 14:00 FREE PAPERS - ARTIFICIAL INTELLIGENCE				
13:15 - 13:30										
13:30 - 13:45										
13:45 - 14:00										
14:00 - 14:15		14:00 - 15:00 OCTA COURSE: ABCs Organizer: SAVASTANO MARIA CRISTINA	14:00 - 15:00 ARTIFICIAL INTELLIGENCE IN DIABETIC RETINOPATHY Organizer: MIDENA EDOARDO	14:00 - 15:00 FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 1	14:15 - 15:15 FACTORS INFLUENCING CLINICAL AND SURGICAL OUTCOMES IN RHEGMATOGENOUS RETINAL DETACHMENT Organizer: DELL'OMO ROBERTO	14:00 - 15:15 FREE PAPERS - RETINAL DETACHMENT	14:00 - 15:00 AUTOIMMUNE RETINOPATHIES Organizer: TUFAIL ADNAN			
14:15 - 14:30	14:15 - 15:30 TRAUMA COURSE									
14:30 - 14:45										
14:45 - 15:00										
15:00 - 15:15		15:00 - 16:00 SIGNATURE OCT 2024: NEW DISEASES AND NOVEL DIAGNOSTIC FINDINGS Organizer: SARRAF DAVID	15:00 - 15:45 OCULOMICS	15:00 - 15:45 FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 2	15:15 - 16:15 CURRENT APPLICATIONS OF SUBTHRESHOLD LASER IN RETINAL DISEASES Organizers: TOTO LISA, MASTROPASQUA RODOLFO	15:15 - 16:15 FREE PAPERS - TRAUMA, ENDOPHTHALMITIS, COMPLEX SURGERY	15:00 - 16:00 MACULAR DYSTROPHIES Organizer: ZUR DINAH			
15:15 - 15:30										
15:30 - 15:45	15:30 - 19:00 LIVE SURGERY									
15:45 - 16:00			15:45 - 17:30 FLORETINA A-I DISTRICT: AI APPLIED TO OPHTHALMOLOGICAL DISEASES AND OCULOMICS							
16:00 - 16:15		16:00 - 17:00 STATE OF THE ART IMAGING OF THE POSTERIOR AND PERIPHERAL RETINA AND VITREORETINAL INTERFACE Organizers: STANGA PAULO EDUARDO, HUANG DAVID					16:00 - 17:00 FUNCTION AND MORPHOLOGY IN GEOGRAPHIC ATROPHY Organizer: PILOTTO ELISABETTA			
16:15 - 16:30										
16:30 - 16:45										
16:45 - 17:00										
17:00 - 17:15										
17:15 - 17:30										
17:30 - 17:45		17:30 - 18:45 FLORETINA X - CASES CONFERENCE								
17:45 - 18:00										
18:00 - 18:15										
18:15 - 18:30										
18:30 - 18:45										
18:45 - 19:00										

FRIDAY 6 DECEMBER

	SANTA MARIA NOVELLA	SAN GIOVANNI	SANTA CROCE	SAN FREDIANO	SANTO SPIRITO	SAN LORENZO	ORSANMICHELE	PALAZZO VECCHIO	PALAZZO STROZZI	PALAZZO RUCELLAI
07:00 - 07:15					07:00 - 08:00 MORNING SYMPOSIUM (TowardPI) - 400kHz OFFICIALLY COMES, APPLICATION OF CE CLEARED TowardPI OCT					
07:15 - 07:30										
07:30 - 07:45										
07:45 - 08:00										
08:00 - 08:15	08:00 - 12:30 LIVE SURGERY	08:00 - 08:45 DIABETIC RETINA IMAGING: NEW BIOMARKERS		08:00 - 09:30 RESIDENT'S COURSE 1 (SOU COURSE)		08:00 - 08:45 FREE PAPERS - TUMORS	08:00 - 09:00 MACULAR COMPLICATIONS DETERMINING SUBOPTIMAL OUTCOMES AFTER ANTI-VEGF THERAPIES FOR NEOVASCULAR AMD Organizer: BORRELLI ENRICO, REIBALDI MICHELE			
08:15 - 08:30										
08:30 - 08:45					08:30 - 09:45 NEW ROLE OF MULTIMODAL IMAGING IN POSTERIOR NON-INFECTIOUS UVEITIS Organizers: ACCORINTI MASSIMO, NGUYEN QUAN DONG	08:45 - 09:45 FREE PAPERS - RETINAL VASCULAR DISEASES				
08:45 - 09:00		08:45 - 09:30 DIABETIC MACULAR EDEMA: TREATMENT 1					09:00 - 10:00 FIBROSIS AND MACULAR ATROPHY IN NAMD – TWO SIDES OF ONE MEDAL? Organizers: PAULEIKHOFF DANIEL, SADDA SRINIVAS	08:30 - 10:30 WET LAB - ALCON - GROUP A	09:00 - 10:30 WET LAB - BAUSCH & LOMB - GROUP A	
09:00 - 09:15										
09:15 - 09:30										
09:30 - 09:45		09:30 - 10:15 BREAKFAST SYMPOSIUM (ZEISS) - CLINICAL UTILIZATION OF DIAGNOSTICS AND SURGICAL VISUALIZATION TO ADDRESS MYOPIC COMPLICATIONS		09:30 - 10:30 TIPS AND TRICKS FOR OCT READING Organizer: VAVVAS DEMETRIOS						
09:45 - 10:00					09:45 - 11:00 INFECTIOUS UVEITIS: TIP AND TRICKS FROM LABORATORY TO MANAGEMENT Organizers: ACCORINTI MASSIMO, NGUYEN QUAN DONG	BOOTH	10:00 - 10:45 BREAKFAST SYMPOSIUM (EYEPOINT) - EYP-1901: SUSTAINED RELEASE PAN-VEGF RECEPTOR INHIBITOR (TKI) IN DEVELOPMENT			
10:00 - 10:15		10:15 - 11:00 DIABETIC MACULAR EDEMA: TREATMENT 2		10:30 - 11:30 AI-BASED MEDICAL IMAGING Organizer: SCHMIDT-ERFURTH URSULA						
10:30 - 10:45										
10:45 - 11:00					11:00 - 12:00 SYMPOSIUM (EVERADS) - FURTHER PROGRESS ON SUPRACHOROIDAL DELIVERY FOR OCULAR THERAPEUTICS	10:45 - 12:15 HIGH RESOLUTION OCT Organizer: STAURENGHI GIOVANNI	10:45 - 11:30 FREE PAPERS - EPIRETINAL MEMBRANES	10:45 - 12:45 WET LAB - ALCON - GROUP B	10:45 - 12:15 WET LAB - BAUSCH & LOMB - GROUP B	
11:00 - 11:15		11:00 - 12:30 RETINA FUTURA - SESSION 1								
11:15 - 11:30				11:30 - 12:30 CROSSFIRE - INTERESTING CASE DISCUSSION BASED ON IMAGING Organizer: CHHABLANI JAY			11:30 - 12:45 FREE PAPERS - MACULAR HOLE			
11:30 - 11:45										
11:45 - 12:00					12:00 - 13:15 CURRENT AND POTENTIALLY FUTURE THERAPY FOR NON-INFECTIOUS UVEITIS Organizers: ACCORINTI MASSIMO, NGUYEN QUAN DONG	12:15 - 13:15 AIORAO COURSE - INNOVATION IN THE IMAGINING OF RETINAL DISEASES: THE ROLE OF THE ORTHOPTIST				
12:00 - 12:15										
12:15 - 12:30										
12:30 - 12:45	12:30 - 13:15 LUNCH SYMPOSIUM (ALCON) - EYE TO EYE			BOOTH						
12:45 - 13:00		12:45 - 13:30 LUNCH SYMPOSIUM (ABBVIE) - SHAPING THE FUTURE OF DME AND RVO: FROM PATHOPHYSIOLOGY TO PERSONALISED CARE								
13:00 - 13:15									13:00 - 14:30 WET LAB - BAUSCH & LOMB - GROUP C	
13:15 - 13:30				13:15 - 14:00 LUNCH SYMPOSIUM (INTALIGHT)	BOOTH	13:15 - 14:15 PACHYCHOROID IMAGING				13:30 - 15:00 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 1
13:30 - 13:45		13:30 - 15:00 RETINA FUTURA - SESSION 2								
13:45 - 14:00			13:45 - 14:45 HOW DO I DO IT Organizer: EL RAYES EHAB				13:45 - 14:45 NEW CONCEPTS IN THE EVALUATION OF EPIRETINAL MEMBRANES Organizer: SARRAF DAVID			
14:00 - 14:15				14:00 - 14:45 MYOPIA: PATHOGENESIS AND IMAGING		14:15 - 15:30 PACHYCHOROID TREATMENT				
14:15 - 14:30										
14:30 - 14:45								14:30 - 16:30 WET LAB - ALCON - GROUP C		
14:45 - 15:00			14:45 - 15:45 EPIRETINAL MACULAR MEMBRANES	14:45 - 15:45 MYOPIA PREVENTION	14:45 - 15:45 ADVANCED RETINAL IMAGING CONSENSUS: EXPERT GUIDELINES AND STANDARDIZED TERMINOLOGY MASTERY Organizer: MUNK MARION		14:45 - 15:45 RETINAL DEBATES Organizer: LESNIK-OBERSTEIN SARIT		14:45 - 16:15 WET LAB - BAUSCH & LOMB - GROUP D	
15:00 - 15:15		15:00 - 15:45 AFTERNOON SYMPOSIUM (ROCHE) - CHANGING THE DME GAMEPLAN WITH FARICIMAB - DUAL PATHWAY, DRYING AND DURABILITY				BOOTH				
15:15 - 15:30										15:15 - 16:45 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 2
15:30 - 15:45										
15:45 - 16:00		15:45 - 16:45 DIABETIC RETINOPATHY TREATMENT	15:45 - 17:00 RETINAL DETACHMENT	15:45 - 16:30 AFTERNOON SYMPOSIUM (ZEISS VISION CARE) - ZEISS LENS SOLUTION FOR MYOPIA MANAGEMENT: AN IN-DEPTH DISCUSSION	15:45 - 16:30 AFTERNOON SYMPOSIUM (ANNEXON) - PROTECTION OF FUNCTION AND STRUCTURE IN DRY AMD / GA WITH C1Q INHIBITION		15:45 - 16:45 SURGICAL TECHNIQUE FOR SUBRETINAL DELIVERY OF GENE THERAPY Organizer: DELLA CORTE MICHELE			
16:00 - 16:15										
16:15 - 16:30				16:30 - 17:15 PATHOLOGIC MYOPIA	16:30 - 18:30 PIONEERING INNOVATION: MASTERING CLINICAL TRIALS AT FLORETINA 2024 Organizers: BAIKI SOPHIE J., VAIZOVIC LEJLA	16:15 - 17:45 IMAGING TECHNOLOGICAL INNOVATIONS			16:30 - 18:00 WET LAB - BAUSCH & LOMB - GROUP E	
16:30 - 16:45										
16:45 - 17:00		16:45 - 17:45 WET AMD IMAGING 1	17:00 - 17:45 ENDOPHTHALMITIS	17:15 - 18:45 REGIONAL AND INDUSTRY PERSPECTIVES ON THE MANAGEMENT OF VITREOUS FLOATERS AND OPACITIES Organizers: D'AMICO DONALD J., STANGA PAULO EDUARDO			16:45 - 18:45 NEAR LIVE SURGERY COURSE Organizer: PERTILE GRAZIA	16:45 - 18:45 WET LAB - ALCON - GROUP D		
17:00 - 17:15										
17:15 - 17:30										
17:30 - 17:45		17:45 - 18:45 WET AMD TREATMENT 1	17:45 - 18:45 LATEST UPDATE ON INTRAOCULAR TAMPONADES			17:30 - 18:45 FREE PAPERS - ANTERIOR SEGMENT				
17:45 - 18:00										
18:00 - 18:15										
18:15 - 18:30										
18:30 - 18:45										
18:45 - 19:00										



Florence
December 5,6,7 and 8, 2024

Fortezza da Basso

FLORetina 2024
ICOOR
12° International Congress on OCT and OCT angiography

SATURDAY 7 DECEMBER

	SANTA MARIA NOVELLA	SAN GIOVANNI	SANTA CROCE	SAN FREDIANO	SANTO SPIRITO	SAN LORENZO	ORSANMICHELE	PALAZZO VECCHIO	PALAZZO STROZZI	PALAZZO RUCELLAI
08:00 - 08:15										
08:15 - 08:30										
08:30 - 08:45										
08:45 - 09:00										
09:00 - 09:15										
09:15 - 09:30										
09:30 - 09:45										
09:45 - 10:00										
10:00 - 10:15										
10:15 - 10:30										
10:30 - 10:45										
10:45 - 11:00										
11:00 - 11:15										
11:15 - 11:30										
11:30 - 11:45										
11:45 - 12:00										
12:00 - 12:15										
12:15 - 12:30										
12:30 - 12:45										
12:45 - 13:00										
13:00 - 13:15										
13:15 - 13:30										
13:30 - 13:45										
13:45 - 14:00										
14:00 - 14:15										
14:15 - 14:30										
14:30 - 14:45										
14:45 - 15:00										
15:00 - 15:15										
15:15 - 15:30										
15:30 - 15:45										
15:45 - 16:00										
16:00 - 16:15										
16:15 - 16:30										
16:30 - 16:45										
16:45 - 17:00										
17:00 - 17:15										
17:15 - 17:30										
17:30 - 17:45										
17:45 - 18:00										
18:00 - 18:15										
18:15 - 18:30										
18:30 - 18:45										
18:45 - 19:00										

SANTA MARIA NOVELLA

- 08:00 - 12:30 — LIVE SURGERY
- 12:30 - 13:15 — LUNCH SYMPOSIUM (ROCHE) - CHANGING THE NAMD GAMEPLAN WITH FARICIMAB - DUAL PATHWAY, DRYING AND DURABILITY
- 13:15 - 14:15 — RETINAWS — Organizer: REZAEI KOUROUS

SAN GIOVANNI

- 08:00 - 09:00 — VASCULAR PATHOLOGIES
- 09:00 - 09:45 — WET AMD IMAGING 2
- 09:45 - 10:30 — BREAKFAST SYMPOSIUM (BAYER) - INNOVATION IN RETINAL CARE: THE TURNING POINT IS NOW
- 10:30 - 11:30 — WET AMD TREATMENT 2
- 11:30 - 12:30 — NEW HORIZONS IN RETINAL DIAGNOSIS AND TREATMENTS
- 12:30 - 13:15 — INTERMEDIATE AMD
- 13:15 - 14:00 — LUNCH SYMPOSIUM (REGENXBIO) - 2017: BACK TO THE FUTURE
- BOOTH
- 14:25 - 14:45 — BRUNO LUMBROSO LECTURE *live* - FAWZI AMANI
- 14:45 - 15:30 — GEOGRAPHIC ATROPHY: ANATOMICAL-FUNCTIONAL BIOMARKERS
- 15:30 - 16:30 — AFTERNOON SYMPOSIUM (OCULAR THERAPEUTIX) - TKIs IN THE FUTURE OF RETINAL DISEASE MANAGEMENT
- 16:30 - 18:10 — DRY AMD: TREATMENT
- 18:10 - 19:00 — NON-EXUDATIVE - NON NEOVASCULAR AMD

SANTA CROCE

- 14:45 - 15:45 — SURGICAL AMD TREATMENT
- 15:45 - 16:45 — MACULAR HOLE: PRIMARY
- 16:45 - 17:45 — MACULAR HOLE: REFRACTORY
- 17:45 - 18:45 — FIX THAT RETINA BATTLE — Organizer: REZAEI KOUROUS

SAN FREDIANO

- 08:15 - 09:15 — UPDATE IN THE DIAGNOSIS OF INTRAOCULAR TUMORS (OCULAR ONCOLOGY DIAGNOSIS)
- 09:15 - 10:30 — OCULAR ONCOLOGY TREATMENT
- BOOTH
- 10:45 - 11:45 — EN FACE OCT: CLINICAL APPLICATION AND PATHOANATOMICAL INSIGHTS — Organizer: SARRAF DAVID
- 11:45 - 12:45 — ARTIFICIAL INTELLIGENCE IN RETINA: A TRUSTED DEVELOPMENT OR A SMOKESCREEN — Organizer: CHAKRAVARTHY USHA
- 12:45 - 13:45 — UNRAVELING BIOMARKERS IN DRY AGE-RELATED MACULAR DEGENERATION — Organizers: LOEWENSTEIN ANAT, TRIVIZKI OMER
- 13:45 - 14:30 — LUNCH SYMPOSIUM (ASTELLAS) - WHAT DOES THE FUTURE HOLD FOR THE MANAGEMENT OF GA?
- 14:30 - 14:45 — BRUNO LUMBROSO LECTURE *from SAN GIOVANNI room* - FAWZI AMANI
- 14:45 - 15:45 — VISION ACADEMY AT FLORETINA 2024 — A BRAVE NEW WORLD: THE REAL IMPACT AND IMPLICATIONS OF THE EXTENDED TREATMENT PARADIGM — SESSION 1 - NEW TREATMENT REGIMENS
- 15:45 - 16:45 — VISION ACADEMY SESSION 2 - FOCUSING ON OUTCOMES
- 16:45 - 17:45 — VISION ACADEMY SESSION 3 - FOCUSING ON THE PATIENT: ADHERENCE TO TREATMENT AND MONITORING
- 17:45 - 18:45 — IVEG COURSE: THE PATIENT'S JOURNEY IN THE CHANGING LANDSCAPE OF AMD — Organizer: LANZETTA PAOLO

SANTO SPIRITO

- 08:00 - 09:00 — THE "GAME" OF GENES — Organizers: KOSTIC MAJA, MENDOZA CARLOS
- 09:00 - 09:45 — INHERITED RETINAL DISEASES IMAGING AND DIAGNOSIS
- 09:45 - 10:30 — BREAKFAST SYMPOSIUM (Johnson&Johnson) - INHERITED RETINAL DISEASES – WHERE DO WE STAND?
- 10:30 - 11:30 — INHERITED RETINAL DISEASES TREATMENTS
- 11:30 - 12:30 — INHERITED RETINAL DYSTROPHY: FROM DIAGNOSIS TO THERAPY — Organizer: TESTA FRANCESCO
- 12:30 - 13:15 — CLINICAL TRIALS IN RETINAL GENE THERAPY — Organizer: MACLAREN ROBERT
- 13:15 - 14:00 — TRANSFORMING RETINAL SURGERY- INTRODUCTION INTO SURGICAL ROBOTICS SYSTEMS: THE FUTURE IS HERE — Organizer: BARZELAY AYA
- 14:00 - 14:45 — GLAUCOMA IN VITREORETINAL SURGERY — Organizers: FIGUS MICHELE, MARCHINI GIORGIO
- 14:45 - 16:00 — PRE AND INTRAOPERATIVE IMAGING
- 16:00 - 16:45 — DIGITAL SURGERY
- 16:45 - 17:45 — OPTIMIZING THE USE OF VITAL DYES IN VITREORETINAL SURGERY — Organizers: FARALDI FRANCESCO, ROMANO MARIO
- 17:45 - 18:45 — MASTERING INTRAOPERATIVE OCT FOR VITREORETINAL SURGERIES — Organizer: BARAK ADIEL

SAN LORENZO

- 08:30 - 09:30 — SYMPOSIUM BY NATIONAL LOW VISION REHABILITATION CENTRE, WHO COLLABORATION CENTER TITLE: "VISION REHABILITATION'S NEW TECHNOLOGIES: IMPACT AND EFFICACY" — Organizers: AMORE FILIPPO, TURCO SIMONA
- 09:30 - 10:15 — FREE PAPERS - UVEITIS 1
- BOOTH
- 10:45 - 11:30 — FREE PAPERS - UVEITIS 2
- 12:30 - 13:15 — FREE PAPERS - SURGICAL TECH
- 13:15 - 13:45 — FREE PAPERS - PEDIATRIC
- 13:45 - 15:00 — PEDIATRIC RETINA
- 15:00 - 16:00 — FUTURE ROP — Organizer: LEPORE DOMENICO
- 16:00 - 17:25 — SURGICAL INNOVATIONS
- 17:25 - 18:45 — RETINAL DETACHMENT WITH PVR

ORSANMICHELE

- 08:00 - 08:45 — FREE PAPERS - AMD TREATMENT 1
- 08:45 - 09:45 — FREE PAPERS - DIABETIC RETINOPATHY IMAGING
- 09:45 - 11:00 — FREE PAPERS - DIABETIC RETINOPATHY TREATMENT
- 11:00 - 11:45 — FREE PAPERS - MYOPIA
- 12:00 - 13:00 — FREE PAPERS - PACHYCHOROID
- 13:00 - 13:45 — FREE PAPERS - AMD IMAGING 1
- 13:45 - 14:30 — LUNCH SYMPOSIUM (ESPANSIONE) - LMI® ILLT PHOTOBIOMODULATION (PBM): EYE CARE FRONT AND BACK
- 14:30 - 14:45 — BRUNO LUMBROSO LECTURE *from SAN GIOVANNI room* - FAWZI AMANI
- 14:45 - 15:45 — ULTRAWIDE OPTICAL COHERENCE TOMOGRAPHY - THE NEW FRONTIER — Organizer: SPAIDE RICHARD
- 15:45 - 16:30 — AFTERNOON SYMPOSIUM (NIKON) - TECHNOLOGY IN PEDIATRIC OPHTHALMOLOGY AND ONCOLOGY:ULTRAWIDEFIELD MULTIMODAL IMAGING
- 16:30 - 17:30 — FUNDUS AUTOFLUORESCENCE IMAGING – A TOOL IN DIAGNOSIS AND DISEASE MONITORING — Organizers: GALOR ORLY, LOEWENSTEIN ANAT
- 17:30 - 18:45 — FREE PAPERS - INHERITED RETINAL DYSTROPHIES

PALAZZO VECCHIO

- 08:30 - 10:30 — ADVANCED WET LAB - ALCON - GROUP E
- 10:45 - 12:45 — ADVANCED WET LAB - ALCON - GROUP F
- 14:45 - 16:15 — MASTERING YOUR MACHINE - ADVANCED PEARLS ON USING NGENUITY / CONSTELLATION

PALAZZO STROZZI

- 09:00 - 10:30 — WET LAB - BAUSCH & LOMB - GROUP F
- 10:45 - 12:15 — WET LAB - BAUSCH & LOMB - GROUP G
- 13:00 - 14:30 — WET LAB - BAUSCH & LOMB - GROUP H
- 14:45 - 16:15 — WET LAB - BAUSCH & LOMB - GROUP I

PALAZZO RUCELLAI

- 13:30 - 15:00 — BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 3
- 15:15 - 16:45 — BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 4

SUNDAY 8 DECEMBER

	SANTA MARIA NOVELLA	SAN GIOVANNI	SANTA CROCE	SAN FREDIANO	SANTO SPIRITO	SAN LORENZO	ORSANMICHELE	PALAZZO VECCHIO	PALAZZO STROZZI	PALAZZO RUCELLAI
08:00 - 08:15										
08:15 - 08:30										
08:30 - 08:45										
08:45 - 09:00										
09:00 - 09:15										
09:15 - 09:30										
09:30 - 09:45										
09:45 - 10:00										
10:00 - 10:15										
10:15 - 10:30										
10:30 - 10:45										
10:45 - 11:00										
11:00 - 11:15										
11:15 - 11:30										
11:30 - 11:45										
11:45 - 12:00										
12:00 - 12:15										
12:15 - 12:30										
12:30 - 12:45										
12:45 - 13:00										
13:00 - 13:15										
13:15 - 13:30										
13:30 - 13:45										
13:45 - 14:00										

SANTA CROCE

- 08:30 - 09:30 — MY SURGICAL TECHNIQUE 1: TIPS AND TRICKS IN PARS PLANA VITRECTOMY
- 09:30 - 10:45 — MY SURGICAL TECHNIQUE 2: TIPS AND TRICKS IN PARS PLANA VITRECTOMY
- 10:45 - 11:45 — PROLIFERATIVE VITREORETINOPATHY: SURGICAL MANAGEMENT AND IMPROVED TECHNIQUES — Organizer: GARCÍA-ARUMÍ JOSÉ
- 11:45 - 13:00 — SECONDARY IOL IMPLANTATION — Organizers: BOSCIA FRANCESCO, LANZETTA PAOLO

SAN FREDIANO

- 08:30 - 09:30 — FONDAZIONE ITALIANA MACULA INTERNATIONAL CSCR COURSE — Organizers: BOUSQUET EUDOR, LUPIDI MARCO
- 09:30 - 10:30 — PROGRESSION FROM INTERMEDIATE TO ADVANCED AMD: NOVEL IMAGING INSIGHTS AND TREATMENT — Organizer: QUERQUES GIUSEPPE
- 10:30 - 11:30 — RETICULAR PSEUDODRUSEN (RPD) — Organizer: TUFAIL ADNAN
- 11:30 - 12:30 — YORIS BREAKING NEWS: FOCUS ON GEOGRAPHIC ATROPHY - unconditional support of Apellis
- 12:30 - 13:15 — ADVANCED IMAGING OF DIABETIC RETINOPATHY

SANTO SPIRITO

- 08:00 - 09:30 — BASIC COURSE IN SURGICAL FUNDAMENTALS FROM YOUNG TO YOUNG — Organizers: RAPIZZI EMILIO, SAVASTANO ALFONSO
- 09:30 - 10:30 — LAMELLAR MACULAR HOLE
- 10:30 - 11:30 — REVISITING OLD TECHNIQUES IN RETINAL SURGERY — Organizer: EHRLICH RITA
- 11:30 - 12:30 — HOW TO DEAL WITH MACULAR EDEMA IN SURGICAL RETINAL PATHOLOGY: CLINICAL INSIGHTS AND MANAGEMENT — Organizer: GOVETTO ANDREA

SAN LORENZO

- 08:30 - 09:30 — EXPLORING THE LIMITS AND POTENTIAL OF OCT ANGIOGRAPHY IN RETINAL PATHOLOGIES: AN INSTRUCTIONAL IMAGING COURSE — Organizer: VIGGIANO PASQUALE
- 09:30 - 10:30 — COURSE OF CLINICAL RETINAL CASES. WOM-MYSTERY — Organizers: PECE ALFREDO, FOSSATARO FEDERICA
- 10:30 - 12:00 — RESIDENT'S COURSE 2 (SOU COURSE)

ORSANMICHELE

- 08:30 - 09:30 — FREE PAPERS - VIDEO SESSION 1
- 09:30 - 10:30 — FREE PAPERS - VIDEO SESSION 2
- 10:30 - 11:30 — FREE PAPERS - AMD TREATMENT 2
- 11:30 - 12:00 — FREE PAPERS - OCULOMICS
- 12:00 - 12:45 — FREE PAPERS - AMD IMAGING 2

Alcon at FLORetina ICOOR Meeting 2024

5-8 December



Fortezza da Basso, Florence

Alcon Eye to Eye: Leading Surgical Retina Solutions

LIVE IN 3D

Friday **6** Dec.

12:30 - 13:15

Room: Santa Maria Novella

Welcome and introductions



Moderator

Stanislao Rizzo (Italy)

Enhancing your procedure with Alcon Technologies



Aude Couturier (France)



Sibel Demirel (Turkey)



Jean Antoine Pournaras (Switzerland)

Elevating VR surgery with NGENUITY® 1.5



Lukan Mishev (Bulgaria)

Industry Talks

Saturday **7** Dec. | **11:30 - 12:30**

Room: San Giovanni

Alcon: A New Dawn on the Horizon in Vitreoretinal and Phaco Surgery



Rozina Camarudin

Eye on Innovation: Alcon's Pathway to Transformative Solutions



Seba Leoni

Alcon Sponsored Live Surgeries

5-7 Dec.

From China:	H. Lu
Greece:	G. Erdoğan, P. Petrou, S. Gotzaridis
Rome:	A. Marino, D. Tognetto, M. Cereda, V. Ferrara, T. Caporossi, S. Di Simplicio
France:	F. Matonti, F. Devin
Germany:	N. Bechrakis, M. Florentzis
Pisa:	F. Barca, S. Rizzo, C. Mariotti

Wetlab Vitreo Basic & Advanced

6-7 Dec.

Room: Wetlab 2 – 1st floor

9:00 - 12:30 / 14:00 - 17:30

Get a deep understanding of **Alcon vitreoretinal technologies**

FOR MORE INFORMATION

VISIT OUR WEBSITE

Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant product's instructions for use for complete list of indications, contraindications, and warnings.

© 2024 Alcon Inc. 10/24 IMG-SG-2400069

Visit our **booth** #64

THURSDAY 5 DECEMBER

SANTA MARIA NOVELLA ROOM

14.15-15.30 TRAUMA COURSE
CHAIRS: CLAES CARL, TAMBURRELLI CIRO, RIZZO STANISLAO

14:15 *BARAK ADIEL* Trauma Management During Wartime Conflict: Lessons Learned from the Frontlines
14:20 *FAYYAD FAISAL* Severe Ocular Trauma Management
14:25 *PELAYES DAVID* Traumatic macular hole, therapeutic options
14:30 *LORENZI UMBERTO* IOFB removal: trick and tips for a safe way
14:35 *PRIGIONE GUIDO* How to deal with an intraocular foreign body
14:40 *SZURMAN PETER* Long-term study after Artificial iris implantation in aniridic trauma eyes
14:45 *WOLF ARMIN* Large epiretinal amniotic membranes for traumatic retinal detachments
14:50 *CLAES CARL* Large foreign body removal
14:55 Case presentation

15.30-19.00 LIVE SURGERY
MODERATORS FROM AUDITORIUM: CHARLES STEVE, D'AMICO DONALD J., ECKARDT CLAUS, PERTILE GRAZIA, RACHITSKAYA ALEKSANDRA, VAJZOVIC LEJLA

MORALES CANTÓN VIRGILIO LIVE SURGERY FROM *MEXICO (Mexico City)*
HAI LU LIVE SURGERY FROM *CHINA (Beijing)*
FRANKLIN ALAN LIVE SURGERY FROM *ITALY (Pisa)*
CLAES CARL LIVE SURGERY FROM *ITALY (Pisa)*
BALI ERNESTO LIVE SURGERY FROM *CONGO (Kinshasa)*
REZENDE FLAVIO LIVE SURGERY FROM *CONGO (Kinshasa)*
GRAFF JORDAN LIVE SURGERY FROM *USA (Mesa)*
WILLIAMSON TOM LIVE SURGERY FROM *GREECE (Athens)*
GIANNOPOULOS THEODOROS LIVE SURGERY FROM *GREECE (Athens)*
PAPATHOMAS THOMAS LIVE SURGERY FROM *GREECE (Athens)*
ERDOGAN GURKAN LIVE SURGERY FROM *GREECE (Athens)*
PETROU PETROS LIVE SURGERY FROM *GREECE (Athens)*
GOTZARIDIS STRATOS LIVE SURGERY FROM *GREECE (Athens)*

SAN GIOVANNI ROOM

14.00-15.00 OCTA COURSE: ABCs
ORGANIZER: SAVASTANO MARIA CRISTINA
CHAIRS: FUJIMOTO JAMES, RISPOLI MARCO

14:00 *BAUMAL CAROLINE* Characteristic OCT findings
14:06 *QUERQUES GIUSEPPE* OCTA: when to do FA and ICG?
14:12 *SOUIED ERIC* OCTA follow-up in exudative AMD?
14:18 *RISPOLI MARCO* OCTA widefield: a new era
14:24 *ROSEN RICHARD* *Jammin' in the Dark!* - Illuminating Sub-Clinical Sickle Cell Activities using Dynamic OCT Angiography and Adaptive Optics SLO
14:30 **Clinical Cases: the usefulness of OCTA**
14:30 *ZWEIFEL SANDRINE* Tricky cases
14:36 *CICINELLI MARIA VITTORIA* Masquerade syndrome: how to suspect them with OCTA
14:42 *FUJIMOTO JAMES OCTA* for mapping vascular connectivity and flow alterations
14:48 Discussion

THURSDAY 5 DECEMBER

SAN GIOVANNI ROOM

15.00-16.00 SIGNATURE OCT 2024: NEW DISEASES AND NOVEL DIAGNOSTIC FINDINGS

ORGANIZER AND MODERATOR: SARRAF DAVID
MODERATOR: NAGIEL AARON

15:00 *SARRAF DAVID* Multifocal Vitelliform Paravascular Retinopathy (MVPR)
15:08 *IOVINO CLAUDIO* PachyVitelliform Maculopathy (PVM)
15:16 *RAMTOHUL PRITHVI* Stellate Multiform Amelanotic Choroidopathy (SMACH)
15:24 *NAGIEL AARON* Benign Inner Retinal Tumor (BLIP)
15:32 *BAKHOUM MATHIEU* Retinal ischemic perivascular lesion (RIPL)
15:40 *FEO ALESSANDRO* Stellate nonhereditary idiopathic foveomacular retinoschisis (SNIFR)
15:48 Discussion

16.00-17.00 STATE OF THE ART: IMAGING OF THE POSTERIOR AND PERIPHERAL RETINA AND VITREORETINAL INTERFACE

ORGANIZERS AND CHAIRS: HUANG DAVID, STANGA PAULO EDUARDO

16:00 *HUANG DAVID* Two ways to measure the angular field-of-view in ultrawide-field fundus imaging
16:10 *SALADINO ANDREA* New findings using a novel RGB "True Colour" ultra widefield imaging technology
16:20 *ERGINAY ALI* New developments in OCT Angiography
16:30 *CAMPBELL PETER* Ultra-widefield OCT in paediatric retinal diseases
16:40 *STANGA PAULO EDUARDO* Ultra widefield fundus fluorescein or indocyanine green angiography with simultaneous navigated central and peripheral OCT imaging of the vitreoretinal interface and retinal periphery and choroid
16:50 Roundtable

17.30-18.45 FLORETINA X - CASES CONFERENCE

FLORetina X Cases

CHAIRS: BAKRI SOPHIE J., SARRAF DAVID, SPAIDE RICHARD, ZWEIFEL SANDRINE

17:30 *BAKRI SOPHIE J.* Mystery Case
17:33 Discussion
17:35 *BRUCKER ALEXANDER J.* Choroidal infiltrates of Unknown etiology
17:38 Discussion
17:40 *JOUSSEN ANTONIA* Tumor Case
17:43 Discussion
17:45 *KEEGAN DAVID* A Celtic Conundrum
17:48 Discussion
17:50 *LANZETTA PAOLO* An Unusual Case of Sub-RPE Lesion
17:53 Discussion
17:55 *PETO TUNDE* Pregnancy in diabetes – do not take your eyes off the ball too soon!
17:58 Discussion
18:00 *SARRAF DAVID* Mystery Case
18:03 Discussion
18:05 *SPAIDE RICHARD* NAD
18:08 Discussion
18:10 *SOUIED ERIC* Mystery Case
18:13 Discussion
18:15 *STAURENGHI GIOVANNI* Mystery Case
18:18 Discussion
18:20 *TUFAIL ADNAN* Mystery Case
18:23 Discussion
18:25 *ZWEIFEL SANDRINE* Mystery Case
18:28 Discussion
18:30 Final Discussion

THURSDAY 5 DECEMBER

SANTA CROCE ROOM

13.00-14.00 NOVEL APPROACHES TO IMAGE ANALYSIS
ORGANIZERS: VUJOSEVIC STELA, TING DANIEL

13:00 *PARRAVANO MARIACRISTINA* Adaptive Optics and Retinal Function in Diabetic Retinopathy
13:08 *ZARRANZ-VENTURA JAVIER* AI-based analysis of OCT-Angiography Images in retinal diseases
13:16 *VUJOSEVIC STELA* Deep Dive into Color Autofluorescence
13:24 *CHHABLANI JAY* Novel insights into choroidal image evaluation
13:32 *TING DANIEL* Retina Specialist in the era of Generative AI
13:40 Discussion

14.00-15.00 ARTIFICIAL INTELLIGENCE IN DIABETIC RETINOPATHY
ORGANIZER: MIDENA EDOARDO

14:00 *MIDENA EDOARDO* Introduction
14:03 *ZARRANZ-VENTURA JAVIER* AI in the screening of diabetic retinopathy: are we ready for daily practice application ?
14:11 *COUTURIER AUDE* AI may predict the progression of diabetic retinopathy: the state of art
14:19 *CHEUNG CAROL* AI in diabetic macular ischemia
14:27 *FRIZZIERO LUISA* AI in the clinical setting of diabetic macular edema
14:35 *MIDENA GIULIA* Aqueous humor proteomics in DR: the AI perspective
14:40 Discussion

15.00-15.45 OCULOMICS
CHAIRS: BACHERINI DANIELA, FARALDI FRANCESCO, PETO TUNDE, ZWEIFEL SANDRINE

15:00 *AREVALO J. FERNANDO* Age-related macular degeneration and neurodegenerative disorders
15:04 *CENNAMO GILDA* Updates on the role of OCT and OCTA in Parkinson's disease
15:08 *KASHANI AMIR H.* Retinal Amyloid and Corresponding Histopathology in Alzheimer's Disease
15:12 *VIOLA FRANCESCO* Drusen-like Deposits in Patients with Systemic Lupus Erythematosus: A Long-Term Follow-Up
15:16 *ZWEIFEL SANDRINE* Nailfold Capillaroscopy and Retinal Findings in Patients with Systemic Sclerosis: Is There An Association?
15:20 *MINNELLA ANGELO MARIA* Ocular Morpho functional parameters in ATTRv pre-symptomatic carriers and their variation over time
15:24 *MOSHFEGHI DARIUS* M. Vascular Tortuosity as a Biomarker for Disease Progression in Adults
15:28 *BOUSQUET ELODIE* Detection of PAMM and RIPL can prevent death and blindness
15:32 *CAMPBELL PETER* Oculomics in the neonatal intensive care unit
15:36 *CRINCOLI EMANUELE* Eye as the window to the human body: the role of artificial intelligence
15:40 Discussion

15.45-17.30 FLORETINA A-I DISTRICT: AI APPLIED TO OPHTHALMOLOGICAL DISEASES AND OCULOMICS
ORGANIZERS: BACHERINI DANIELA, PETO TUNDE
MODERATORS: SAVASTANO MARIA CRISTINA, TING DANIEL

15:45 *BACHERINI DANIELA* Introductive Talk
15:48 **AI IN OPHTHALMOLOGY:**
15:48 *TING DANIEL* AI for Retina: Where are we now?
15:54 *ZARRANZ-VENTURA JAVIER* Current Status and Practical Considerations of Artificial Intelligence Use in Screening and Diagnosing Retinal Diseases: Vision Academy Retinal Expert Consensus
16:00 *SAVASTANO MARIA CRISTINA* Regulatory Issues and Challenges to Artificial Intelligence Adoption
16:06 *ROMANO ANDRÉ* Practical Steps to Implement AI in Your Ophthalmic Practice
16:12 *CAMPBELL PETER* AI for ROP: Bringing Technology from Bench to Bedside
16:18 *VUJOSEVIC STELA* AI in Retinal Clinical Trials
16:24 *TING DANIEL* ChatGPT Enters the Room: What It Means for Patient Counseling, Physician Education, Academics, and Disease Management

THURSDAY 5 DECEMBER

SANTA CROCE ROOM

16:30 **AI IN OCULOMICS:**
16:30 *COUTURIER AUDE* AI and Deep Learning for Retinal Imaging
16:36 *PETO TUNDE* Artificial Intelligence and Deep Learning in Systemic Diseases
16:42 *LENGYEL IMRE* Advances in Image Analysis for Neurodegenerative Diseases
16:48 *CRINCOLI EMANUELE* Artificial Intelligence to Analyze the Retinal Vascular Network: The Future of Cardiovascular Risk Assessment Based on Oculomics?
16:54 **AI SOFTWARE COMPANIES:**
16:54 *KUTZER CORNELIA* **RetInSight** - AI in Retinal Disease: The Future is Now
17:00 *JOVIC NATAŠA* **RETINA-AI** - From Data to Insights: The Role of AI to Improve Patient Outcomes
17:06 *SEIGEL MATT* **Bitfount** - Transforming Clinical Trials and Collaborative Research with Privacy-Preserving AI
17:12 *BRADDON MARK* **Altris** - AI-Driven Biomarker Tracking: Enhancing your patient outcomes
17:18 Discussion

SAN FREDIANO ROOM

13.15-14.00 FREE PAPERS - HIGHLIGHTED NEW DRUGS DME
CHAIRS: CHEUNG GEMMY, LUPIDI MARCO

13:15 *MUNK MARION* Immune response of Muller cells under diabetic conditions: the jak-stat signaling pathway as a potential new target
13:18 *CHEUNG GEMMY* Clinical impact of OCT-A images enhanced by a newly developed ai denoising program for retinal vascular visualization.
13:21 *WOLF SEBASTIAN* Brolucizumab for the treatment of proliferative diabetic retinopathy: 54-week results from the condor study
13:24 *PEARCE IAN* Faricimab in dme: results from the rhone-x long-term extension trial
13:27 *PARRAVANO MARIACRISTINA* Global real-world clinical and anatomical outcomes with faricimab in treatment-naïve patients with neovascular age-related macular degeneration or diabetic macular edema from a multi-country prospective non-interventional study: the voyager study
13:30 *LUPIDI MARCO* Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (DME) and neovascular age-related macular degeneration (NAMD)
13:33 *DHOOT DILSHER* 48 week results from the helios phase 1 trial evaluating intravitreal otx-tki for non-proliferative diabetic retinopathy
13:36 Discussion

14.00-15.00 FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 1
CHAIRS: KAISER PETER, LANZETTA PAOLO, VADALÀ MARIA

14:00 *PETO TUNDE* Impact of age and treatment type on hyeperreflective material and hypertransmission into the choroid development in anti-VEGF therapy
14:03 *VADALÀ MARIA* TALON, a phase IIIb study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 64-week results
14:06 *PEARCE IAN* Treatment patterns, visual outcomes and safety in eyes with neovascular age-related macular degeneration (NAMD) and diabetic macular edema (DME) treated with faricimab in the uk: 1-year results from the faricimab real-world evidence (farwide) study
14:09 *CHEUNG GEMMY* Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b/4 salween trial
14:12 *DHOOT DILSHER* Robust vision gains and anatomical improvement with extended faricimab dosing and potential q20w dosing in treatment-naïve patients with NAMD in tenaya/lucerne
14:15 *LANZETTA PAOLO* "Reduction in pigment epithelial detachments with faricimab vs aflibercept in patients with treatment-naïve NAMD: a tenaya/lucerne post hoc analysis "
14:18 *ZARRANZ-VENTURA JAVIER* Key baseline disease characteristics in neovascular age-related macular degeneration were not predictive of dosing interval extension of aflibercept 8 mg: a post-hoc 96-week pulsar analysis

THURSDAY 5 DECEMBER

SAN FREDIANO ROOM

14:21 *PATEL PRAVEEN* Pulsar post-hoc analysis: fluid-free status with aflibercept 8mg at weeks 16, 48, and 96 by baseline crt and bcva
14:24 *LANZETTA PAOLO* Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg and 2 mg in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Phase 3 trials
14:27 *KAISER PETER* A pulsar phase 3 trial post-hoc analysis: evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal phase 3 trials for NAMD
14:30 *HEINRICH DOMINIC* Clinical impact of the port delivery system with ranibizumab (PDS) on fibrosis in patients with neovascular age-related macular degeneration (NAMD) in the phase 3 archway trial
14:33 Discussion

15.00-15.45 FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 2
CHAIRS: CHAKRAVARTHY USHA, HEIER JEFFREY S., HO ALLEN

15:00 *STANGA PAULO EDUARDO* Subretinal delivery of investigational abbv-rgx-314 for neovascular age-related macular degeneration (NAMD): a phase ii pharmacodynamic study
15:03 *HO ALLEN* Subretinal delivery of investigational abbv-rgx-314 as a gene therapy for neovascular age-related macular degeneration (NAMD): interim results of bilateral dosing from a fellow eye study
15:06 *CHAKRAVARTHY USHA* EYP-1901 (vorolanib intravitreal insert), a bioerodible, sustained-delivery intravitreal insert for neovascular age-related macular degeneration: preclinical development to pivotal phase 3 trials
15:09 *WYKOFF CHARLES C.* Ixoberogene soroparvovec (ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration: phase 2 luna study update
15:12 *HEIER JEFFREY S.* Unlocking structure/function relationships in dry AMD/GA: central subdomain preservation and visual acuity protection with c1q inhibition
15:15 *ALMEIDA DAVID* Post-marketing data support a differentiated safety profile of avacincaptad pegol (acp) for geographic atrophy (GA) secondary to AMD
15:18 *KUPPERMANN BARUCH* Reduction in risk probability of persistent vision loss with avacincaptad pegol in geographic atrophy: 2-year results from the gather2 trial
15:21 *STANGA PAULO EDUARDO* Prevention of visual acuity loss and preservation of photoreceptors by anx007 in dry age-related macular degeneration (AMD)/geographic atrophy (ga) in the phase 2 archer trial, including in patients with less advanced disease
15:24 *ZUCCARINI SILVIO* Ophthalmic Iontophoresis treatment for topical delivery of lutein, Slowing/preventing Progression of AMD
15:27 Discussion

SANTO SPIRITO ROOM

13.00-14.15 EPISCLERAL SURGERY COURSE: THE IMPORTANCE OF THE BASICS
ORGANIZERS: GIANSANTI FABRIZIO, TOGNETTO DANIELE
CHAIRS: AVITABILE TERESIO, HEIMANN HEINRICH

13:00 *SCORCIA VINCENZO* The importance of having a preoperative surgical plan
13:05 *REIBALDI MICHELE* What surgical instruments do I need?
13:10 *MASTROPASQUA RODOLFO* Surgical steps of scleral buckling
13:15 *BOSCIA FRANCESCO* How to visualize the tears and holes intraoperatively: schepens vs chandelier
13:20 *MARIOTTI CESARE* When and how to place a scleral buckling
13:25 *TOGNETTO DANIELE* When and how to place a radial sponge
13:30 *HUSSAIN RUMANA* When and how to place segmental circonferential sponge
13:35 *GIANSANTI FABRIZIO* The drainage of subretinal fluid: tip and tricks
13:40 *BONFIGLIO VINCENZA* Use of Intraocular gas during scleral buckling surgery
13:45 *LANZETTA PAOLO* Intraoperative complications and management
13:50 *ROMANO MARIO* Clinical Cases
13:55 Discussion

THURSDAY 5 DECEMBER

SANTO SPIRITO ROOM

14.15-15.15 FACTORS INFLUENCING CLINICAL AND SURGICAL OUTCOMES IN RHEGMATOGENOUS RETINAL DETACHMENT

ORGANIZER AND MODERATOR: DELL'OMO ROBERTO
MODERATORS: REIBALDI MICHELE, ROMANO MARIO

14:15 ***FERRARA MARIANTONIA*** The concept of integrity: outer retinal bands disruption
14:20 ***MASTROPASQUA RODOLFO*** The concept of integrity: retinal displacement
14:25 ***GOVETTO ANDREA*** The concept of integrity: outer retinal folds
14:30 ***COASSIN MARCO*** Why pneumatic retinopexy should be chosen in uncomplicated RRD cases
14:35 ***MURA MARCO*** Why pars plana vitrectomy should be chosen in uncomplicated RRD cases
14:40 ***BONFIGLIO VINCENZA*** Why scleral buckle should be chosen in uncomplicated RRD cases
14:45 ***CAPOROSSI TOMASO*** Why combined tecniques should be chosen in uncomplicated RRD cases
14:50 ***VAN OVERDAM KOEN*** Potential advantages of VCR removal
14:55 ***DELL'OMO ROBERTO*** Potential disadvantages of VCR removal
15:00 Discussion

15.15-16.15 CURRENT APPLICATIONS OF SUBTHRESHOLD LASER IN RETINAL DISEASES

ORGANIZERS: TOTO LISA, MASTROPASQUA RODOLFO

15:15 ***CHHABLANI JAY*** Introduction: Current role and standardization of subthreshold laser and its potential for future use
15:23 ***TOTO LISA*** Utilization of subthreshold laser in CSCR in the presence of alternative treatment options
15:31 ***PILOTTO ELISABETTA*** Subthreshold micropulse yellow laser in diabetic macular edema- alternative, conjunctive and/or preventive
15:39 ***IOVINO CLAUDIO*** Experiences of subthreshold laser use in RVO and postsurgical macular edema
15:47 ***CHHABLANI JAY - AMOROSO FRANCESCA*** Practical session for participants showing subthreshold treatment strategies
16:02 Discussion

SAN LORENZO ROOM

13.00-14.00 FREE PAPERS - ARTIFICIAL INTELLIGENCE

CHAIRS: REITER GREGOR, TING DANIEL, VIRGILI GIANNI

13:00 ***EL ASHRY AHMED*** The future of ophthalmology: a review of ai applications and demonstration of a novel ai-powered tool
13:03 ***DÍAZ ALJARO PABLO*** Development of artificial intelligence based systems (ai4ret) for the diagnosis of macular pathologies and edema in optical coherence tomography images in a public health system.
13:06 ***ANASTASI MARCO*** Comparing the ability of large language models to diagnose and manage common medical retina and vitreoretinal presentations
13:09 ***ZEINAB ELSANABARY*** Value of artificial intelligence in OCTA
13:12 ***AFONSO JOÃO*** Outer retinal bands segmentation in healthy human subjects using deep convolutional neural networks
13:15 ***NERI GIOVANNI*** Deep learning model for automatic detection of different types of microaneurysms in diabetic retinopathy
13:18 ***SEAH WEI HING*** A machine deep learning model evaluating non-perfusion areas in ultra-wide field swept-source optical coherence tomography angiography in diabetic retinopathy.
13:21 ***OZTURK MINE*** Performance of artificial intelligence platforms on age-related macular degeneration evaluation
13:24 ***BARTOLOMEO NICOLÒ*** OCT biomarker quantification as short-term outcome predictors of intravitreal faricimab injections in naïve patients with neovascular age-related macular degeneration
13:27 ***GOLAN NILI*** Identifying and localization of geographic atrophy in near-infrared reflectance images using artificial intelligence
13:30 ***VALSECCHI NICOLA*** Three-dimensional choroidal vessels assessment in healthy eyes: a novel deep-learning approach

THURSDAY 5 DECEMBER

SAN LORENZO ROOM

13:33 *TIOSANO ALON* Automatic identification and segmentation of pachychoroid on optical coherence tomography, using ai
13:36 Discussion

14.00-15.15 FREE PAPERS - RETINAL DETACHMENT
CHAIRS: DE CILLA' STEFANO, PERTILE GRAZIA

14:00 *LAZZERINI ANDREA* Role of ultrasound examination in retinal breaks detection in eyes with media opacities
14:03 *MAVRIKAKIS EMMANOUIL* Small gauge vitrectomy for rhegmatogenous retinal detachment: 3 year results in the covid era
14:06 *NASER MOHAMED NAEEM* Scleral buckle and vitrectomy 2 in 1
14:09 *ALMEIDA DAVID* Outcomes of primary vitrectomy for rhegmatogenous retinal detachment: interventional retrospective consecutive case series of 116 patients with no post-operative positioning
14:12 *AHMED BENNIS* Anatomical and functional outcomes of recurrent retinal detachment surgery following pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment.
14:15 *TARTARO RUGGERO* Segmental buckle and air tamponade for rhegmatogenous retinal detachment recurrence with localized pvr grade c: a case report
14:18 *BENCHEKROUN BELABBES SAAD* Combined phacoemulsification, vitrectomy, and scleral indentation for chorioretinal detachment: a surgical case
14:21 *YASSINE MALEK* Anatomical and functional outcomes of the multilayered inverted internal limiting membrane flap for concurrent macular hole and rhegmatogenous retinal detachment: a retrospective study
14:24 *MENGHINI MORENO* Morphological and functional macular assessment after pars plana vitrectomy for rhegmatogenous retinal detachment
14:27 *PANICO CLAUDIO* Scleral buckle evacuative puncture with endolaser: long term results
14:30 *PIGNATELLI FRANCESCO* Trans-scleral plugs fixated fil SSF IOL implant combined with 25g vitrectomy and SF6 tamponade in eyes with rhegmatogenous retinal detachment and secondary aphakia
14:33 *MANSOUR AHMED* Closed funnel retinal detachment … the approach
14:36 *ONDER TOKUC ECEM* Visual and anatomical outcomes after vitrectomy for macular hole-associated retinal detachment
14:39 *KARAHAN EYYUP* Comparison of gas and silicone tamponades in terms of lower quadrant recurrence in patients who underwent pars plana vitrectomy for rhegmatogenous retinal detachment
14:42 *BALDASCINO ANTONIO* Use of citicoline as a neuroprotective agent in patients undergoing vitrectomy and silicone oil tamponade following retinal detachment
14:45 *VITA STEFANO* Formation of hyper-viscous sticky oil emulsion during direct pfcl-silicone oil exchange and extrusion management
14:48 *ZANZOTTERA EMMA* Intraocular perfluorodecalin and silicone oil tamponade (double filling) in the management of complicated retinal detachment: an update to the 2022 report
14:51 *DAVIDOVIC SOFIJA* Pars plana vitrectomy in bilateral combined rhegmatogenous and traction retinal detachment in patient with concomitant syphilis and HIV infection - case report
14:54 Discussion

15.15-16.15 FREE PAPERS - TRAUMA, ENDOPHTHALMITIS, COMPLEX SURGERY
CHAIRS: CEREDA MATTEO GIUSEPPE, FAYYAD FAISAL, VAIANO AGOSTINO

15:15 *GEBKA ANDRZEJ* Optic pit maculopathy - an attempt to define the problem.
15:18 *FRANCESCHI ALESSANDRO* No optic pit macular retinoschisis associated with macular hole and chorioretinal scars: a case report.
15:21 *MAKARCHUK KANSTANTSIN* Surgical treatment of the reccurent optic disc pit
15:24 *CARLÀ MATTEO MARIO* Choroid involvement secondary to optic disc pit maculopathy: OCT analysis and evolution after surgical treatment
15:27 *DE LUCA MARCO* Temporary iris-diaphragm in a globe injury characterized by traumatic aniridia, aphakia and retinal detachment
15:30 *MICHAEL KALEENA* The combination of bilateral subluxed lenses, retinal detachment from multiple giant retinal tears and macular tears from blunt trauma
15:33 *CHWIEJCZAK KATARZYNA* Secondary repair of ruptured globe in no perception of light scenario: is it worth the effort?

THURSDAY 5 DECEMBER

SAN LORENZO ROOM

15:36 *CRISCUOLO DANIELE* Severe scleritis following iatrogenic trauma: a case report of a surgical complication
15:39 *QURESHI MADYAN* Penetrating eye injury repair
15:42 *UMAR CAHIT IKBAL* Endophthalmitis: multivariate analysis of factors affecting anatomical and visual prognosis
15:45 *DRAGO GABRIELE* Acute endophthalmitis after intravitreal injection of anti-VEGF agents or dexamethasone implant: retrospective analysis
15:48 *MAVRIKAKIS EMMANOUIL* Management of endophthalmitis following cataract surgery
15:51 *MAGLIOZZI PATRIZIO* Early vitrectomy for acute postoperative endophthalmitis: experience of a tertiary referral centre
15:54 Discussion

ORSANMICHELE ROOM

14.00-15.00 AUTOIMMUNE RETINOPATHIES
ORGANIZER: TUFAIL ADNAN
CHAIR: MUNK MARION

14:00 *TUFAIL ADNAN* Autoimmune retinopathy – introduction - paraneoplastic and immunotherapy induced
14:10 *MUNK MARION* What to we understand about the causes of autoimmune retinopathy?
14:20 *SARRAF DAVID* AZOOR, AIR and Systemic Autoimmune Disease
14:30 *CALCAGNI ANTONIO* The Devil is in the Details: Electrophysiology in the Diagnosis and Management of Autoimmune Retinopathies
14:40 *LEROY BART* IRD vs Autoimmune – When to test?
14:50 Discussion

15.00-16.00 MACULAR DYSTROPHIES
ORGANIZER: ZUR DINAH
CHAIR: AUDO ISABELLE

15:00 *NAGIEL AARON* X-linked Retinoschisis - Gene Therapy Trials
15:05 *LEROY BART* X-linked Retinoschisis - Efficacy of Carbonic Anhydrase Inhibitors
15:10 *AUDO ISABELLE* Overview of maculopathy genetics
15:15 *BORRELLI ENRICO* Mitochondrial Retinal Dystrophy
15:20 Discussion
15:25 *ZUR DINAH* Macular Dystrophies mimicking AMD
15:30 *QUERQUES GIUSEPPE* Leptovitelliform Maculopathy
15:35 Discussion
15:40 *ZAMBROWSKI OLIVIA* Macular Changes in generalized retinal dystrophies
15:45 *BARAK ADIEL* Retinal pigment epithelium cell replacement therapy
15:50 Discussion

16.00-17.00 FUNCTION AND MORPHOLOGY IN GEOGRAPHIC ATROPHY
ORGANIZER: PILOTTO ELISABETTA

16:00 *PILOTTO ELISABETTA* Introduction
16:04 *BORRELLI ENRICO* Choroid in Geographic Atrophy
16:12 Q&A
16:14 *MIDENA EDOARDO* Macular function in Geographic Atrophy: beyond visual acuity
16:22 Q&A
16:24 *PILOTTO ELISABETTA* More than one phenotype of Geographic Atrophy
16:32 Q&A
16:34 *REITER GREGOR* AI-based monitoring of the progression of Geographic Atrophy
16:42 Q&A
16:44 Panel Discussion: Geographic Atrophy: revisited clinical endpoints
16:59 *PILOTTO ELISABETTA* Close

Make remarkable happen

Transforming lives with pioneering ocular gene therapy

beacon therapeutics

beacontx.com

FRIDAY 6 DECEMBER

SANTA MARIA NOVELLA ROOM

08.00-12.30 LIVE SURGERY

MODERATORS FROM AUDITORIUM: CHARLES STEVE, D'AMICO DONALD J., EL RAYES EHAB, MURA MARCO, PRIGLINGER SIEGFRIED, ROMANO MARIO, STEEL DAVID H., VAJZOVIC LEJLA

MARINO ANTONIO LIVE SURGERY FROM *ITALY (Rome)*
TOGNETTO DANIELE LIVE SURGERY FROM *ITALY (Rome)*
CEREDA MATTEO GIUSEPPE LIVE SURGERY FROM *ITALY (Rome)*
PAROLINI BARBARA LIVE SURGERY FROM *ITALY (Rome)*
BOSCIA FRANCESCO LIVE SURGERY FROM *ITALY (Rome)*
SAVASTANO ALFONSO LIVE SURGERY FROM *ITALY (Rome)*
COPPOLA MICHELE LIVE SURGERY FROM *ITALY (Rome)*
SCORCIA VINCENZO LIVE SURGERY FROM *ITALY (Rome)*
CARETTI LUIGI LIVE SURGERY FROM *ITALY (Rome)*
MATONTI FREDERIC LIVE SURGERY FROM *FRANCE (Marseille)*
DEVIN FRANCOIS LIVE SURGERY FROM *FRANCE (Marseille)*
BECHRAKIS NIKOLAOS LIVE SURGERY FROM *GERMANY (Essen)*
FIORENTZIS MILTIADIS LIVE SURGERY FROM *GERMANY (Essen)*

12.30-13.15 LUNCH SYMPOSIUM (ALCON) - EYE TO EYE

MODERATOR: RIZZO STANISLAO

Alcon

12:30 *RIZZO STANISLAO* Welcome and introductions
12:34 *POURNARAS JEAN-ANTOINE* The CONSTELLATION innovations
12:47 *COUTURIER AUDE - DEMIREL SIBEL* Enhancing your procedure with Hypervit
13:00 *MISHEV LUKAN* Elevating VR surgery with NGENUITY 1.5
13:13 *RIZZO STANISLAO* Closing statement

SAN GIOVANNI ROOM

08.00-08.45 DIABETIC RETINA IMAGING: NEW BIOMARKERS

CHAIRS: FUJIMOTO JAMES, SIVAPRASAD SOBHA, VUJOSEVIC STELA, WYKOFF CHARLES C.

8:00 *CHEUNG CAROL* New OCT Classification of DME
8:04 *PANOZZO GIACOMO* Prognostic value of OCT biomarkers for DME treatment. Post hoc analysis of a retrospective Italian multicenter study
8:08 *PARRAVANO MARIACRISTINA* Prognostic imaging biomarkers in DME treated with anti-VEGF: an AI perspective
8:12 *SIVAPRASAD SOBHA* One year follow-up of diabetic macular ischaemia
8:16 *HWANG YUNCHAN* Quantification of capillary blood flow speeds in diabetic retinopathy using variable interscan time analysis (VISTA) OCTA
8:20 *HUANG DAVID* AI-enhanced OCTA reveals malformed and nonperfused capillaries in diabetic retinopathy
8:24 *WYKOFF CHARLES* C. Retinal Non-Perfusion in Diabetic Retinopathy: Clinical Relevance & the Dream of Reperfusion
8:28 *VUJOSEVIC STELA* Assessing the link between the macula and peripheral ischemia progression in diabetic retinopathy by multimodal imaging
8:32 *Panel discussion* Debate: is retinal non perfusion a biomarker that we cannot miss in new classification systems?

08.45-09.30 DIABETIC MACULAR EDEMA: TREATMENT 1

CHAIRS: BANDELLO FRANCESCO, BRESSLER SUSAN, HEIER JEFFREY S., KUPPERMANN BARUCH

8:45 *PETO TUNDE* Caring for diabetic macular edema (DME) patients in the new era – from systemic to local treatment
8:49 *BRESSLER SUSAN* Biosimilars for Retinal Disease- Subgroup Analyses and Switching Patients

FRIDAY 6 DECEMBER

SAN GIOVANNI ROOM

8:53 ***LOEWENSTEIN ANAT*** Outcomes With Aflibercept 8 mg and 2 mg by Prior DME Treatment Status: A Subgroup Analysis of the Phase 2/3 PHOTON Trial
8:57 ***FRAGIOTTA SERENA I***ntraretinal edema in tractional maculopathies
9:01 ***AWH CARL*** Update on the Port Delivery System for DME and Diabetic Retinopathy
9:05 ***RIEMANN CHRISTOPHER D.*** Fluocinolone Acetonide - The Little Pellet That Could. Why Don't We Use This More Frequently?
9:09 ***RUIZ MORENO JOSÉ MARIA*** Biomarkers for switching to Dexamethasone Implant for the treatment of Diabetic Macular Edema in real clinical practice. A multicentric study
9:13 ***BATTAGLIA PARODI MAURIZIO*** Brolucizumab in DME: from Clinical trials to real life experience
9:17 Discussion

09.30-10.15 BREAKFAST SYMPOSIUM (ZEISS) - CLINICAL UTILIZATION OF DIAGNOSTICS AND SURGICAL VISUALIZATION TO ADDRESS MYOPIC COMPLICATIONS

MODERATOR: ROMANO MARIO

9:30 ***ROMANO MARIO*** Introduction
9:32 ***BORRELLI ENRICO*** The utility of diagnostic imaging to for tractional retinal complications in high myopia
9:41 ***CHEUNG GEMMY*** The role of multimodal imaging for myopic choroidal neovascularization
9:50 ***STALMANS PETER*** Surgical management of high myopia: considerations, techniques, and visualization
9:59 ***ROMANO MARIO*** Benefits of integrating diagnostics and surgical visualization in myopia
10:08 Panel discussion

10.15-11.00 DIABETIC MACULAR EDEMA: TREATMENT 2 - UNDER THE PATRONAGE OF S.I.R.

CHAIRS: DO DIANA V., KOROBELNIK JEAN-FRANÇOIS, MIDENA EDOARDO, PILOTTO ELISABETTA,SADDA SRINIVAS

10:15 ***MIDENA EDOARDO*** "Precision ophthalmology": tailoring DME treatment
10:19 ***RACHITSKAYA ALEKSANDRA*** Faricimab: Hard Exudates in Yosemite/Rhine Diabetic Macular Edema (DME) Clinical Trials
10:23 ***LENG THEODORE*** Real-World effectiveness of Faricimab in patients: 12-Month outcomes from the FARETINA Study
10:27 ***LATTANZIO ROSANGELA*** New benchmarks in the management of DME
10:31 ***FERRONE PHILIP*** Outcomes With Aflibercept 8 mg and 2 mg for DME By Baseline BCVA 20/50 or Worse or 20/40 or Better in the PHOTON Trial
10:35 ***KOROBELNIK JEAN-FRANÇOIS*** IOP and Glaucoma-related Outcomes With Aflibercept 8 mg and 2 mg in Patients With DME Through Week 96 in PHOTON
10:39 ***SADDA SRINIVAS*** Impact of residual fluid on visual outcomes in diabetic macular edema
10:43 ***DO DIANA V.*** Update on Aflibercept 8mg for Diabetic Macular Edema: The PHOTON Study
10:47 Debate: durability, multitarget approach, or synergic effect of different treatments?

11.00-12.30 RETINA FUTURA - SESSION 1 - UNCONDITIONAL SUPPORT OF OCULAR THERAPEUTIX

CHAIRS: RIZZO STANISLAO, HEIER JEFFREY S., KAISER PETER, VAJZOVIC LEJLA

11:00 Introduction by the Program Chairs
11:05 **Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates**
11:05 ***AWH CARL*** EB-105: A Novel Trispecific Fusion Antibody for Retinal Disease
11:09 ***RACHITSKAYA ALEKSANDRA*** Impact of GLP-1 Receptor Agonists on Chronic Eye Conditions Including Non-Exudative AMD
11:13 ***BEHAR COHEN FRANCINE*** Glibenclamide is Neuroprotectant Against AMD
11:17 ***AUGUSTIN ALBERT*** An overview of ONS-5010 (bevacizumab gamma) as ophthalmic formulation of bevacizumab
11:21 ***REGILLO CARL D.*** EYP-1901 for Maintenance Treatment of Neovascular AMD: Phase 2 DAVIO 2 End-of-Study 12-Month Results

FRIDAY 6 DECEMBER

SAN GIOVANNI ROOM

11:25 *TUFAIL ADNAN* Beyond VEGF-A inhibition: will blocking VEGF-C and VEGF-D lead to better outcomes?
11:29 *DO DIANA V.* OTX-TKI–The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
11:33 Panel Discussion & Transition to next Session
11:45 **Innovations in siRNA and Gene Therapies for AMD**
11:45 *BAKRI SOPHIE* J. Gene Therapy for Neovascular AMD by Subretinal and Suprachoroidal Delivery of ABBV-RGX-314 Including Fellow Eye Data
11:49 *FISCHER DOMINIK* Efficacy and Safety of Ixoberogene Intravitreal Gene Therapy for Neovascular AMD: Phase 2 LUNA Trial Study Results
11:53 *MUNK MARION* First Results of the Phase 2 BETTER Trial Using Intravitreal ISTH0036: a Selective TGF-2–Blocking Antisense in AMD and DME
11:57 *QUEZADA RUIZ CARLOS* Development of 4D-150 for Retinal Vascular Diseases
12:01 Panel Discussion & Transition to next Session
12:10 **Spotlight on Inherited Retinal Diseases (IRDs)**
12:10 *FERRONE PHILIP* Gildeuretinol Slows Progression of Stargardt Disease: The TEASE Program
12:14 *STANGA PAULO EDUARDO* Subretinal Gene Therapy AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Result
12:18 *MONES JORDI* Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN)
12:22 Panel Discussion

12.45-13.30 LUNCH SYMPOSIUM (ABBVIE) - SHAPING THE FUTURE OF DME AND RVO: FROM PATHOPHYSIOLOGY TO PERSONALISED CARE

CHAIR: MIDENA EDOARDO

12:45 *MIDENA EDOARDO* Chair welcome and introduction
12:48 *ZARRANZ-VENTURA JAVIER* Individualised approaches in DME and RVO: Inflammation and early treatment
12:53 *REHAK MATUS* Biomarkers in focus: Advancing care in RVO
12:58 *LUPIDI MARCO* State of play in DME: Current perspectives on biomarkers
13:03 *MIDENA EDOARDO* Looking to the future: The role of AI in DME management
13:08 Discussion led by Chair Professor Midena
13:28 *MIDENA EDOARDO* Closep

13.30-15.00 RETINA FUTURA - SESSION 2 - UNCONDITIONAL SUPPORT OF OCULAR THERAPEUTIX

CHAIRS: RIZZO STANISLAO, HEIER JEFFREY S., KAISER PETER, VAJZOVIC LEJLA

13:30 **Advancements in Geographic Atrophy (GA): Current and Emerging Therapies**
13:30 *DE-BOER CHARLES* Oral Medications for Dry AMD
13:34 *HASSAN TAREK* Glycomimetic Nanoparticle AVD-104 in the Management of GA From AMD: Anatomic Outcomes
13:38 *RIEMANN CHRISTOPHER D.* OpRegen: Embryonic Stem Cell Derived Therapy for Dry AMD and GA
13:42 *VAJZOVIC LEJLA* Fas Inhibition with ONL1204 for the Treatment of GA Secondary to AMD: Results from a Phase 1b Study
13:46 *KAISER PETER* C1q inhibition with ANX007: Functional and Structural Protection in dry AMD / GA via a Novel Neuroprotective Mechanism
13:50 Panel Discussion & Transition to next Session
14:00 **Diabetic Retinal Diseases and Retinal Detachment**
14:00 *NGUYEN QUAN DONG* Outcomes of the HORNBILL Study: Phase 1/2a Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
14:04 *LOEWENSTEIN ANAT* OCS-01: An emerging topical treatment option for DME
14:08 *RIBEIRO RAMIRO* DURAVYU in diabetic eye disease
14:12 *DHOOT DILSHER* HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR

FRIDAY 6 DECEMBER

SAN GIOVANNI ROOM

14:16 *BORKAR DURGA* Intravitreal Fas inhibitor ONL1204 for Macula-off Rhegmatogenous Retinal Detachment: Results of a Phase 2 Clinical Trial
14:20 Panel Discussion and Transition
14:30 **Late breakers**
14:30 *VAJZOVIC LEJLA* ABBV-RGX-314: A one-time in-office gene therapy for the treatment of diabetic retinopathy and the prevention of DME, PDR & other vision threatening complications; the Phase II ALTITUDE® Study
14:34 *KAISER PETER* New clinical and nonclinical analyses reveal silicone oil is associated with intraocular inflammation following intravitreal administration of Abicipar Pegol
14:38 Panel Discussion
14:45 **Session Awards**
- Newcomer of the Year Award
- Most Innovative Science Award
- Most Clinically Impactful Award

15.00-15.45 AFTERNOON SYMPOSIUM (ROCHE) - CHANGING THE DME GAMEPLAN WITH FARICIMAB - DUAL PATHWAY, DRYING AND DURABILITY

CHAIR: PEARCE IAN

15:00 *VUJOSEVIC STELA* Dual Pathway: The Difference With Dual Pathway Inhibition
15:10 *RACHITSKAYA ALEKSANDRA* Drying: Achieving Disease Control
15:20 *DINAH CHRISTIANA* Durability: Reducing Treatment Burden
15:30 Discussion
15:40 *PEARCE IAN* Closing Remarks

15.45-16.45 DIABETIC RETINOPATHY TREATMENT

CHAIRS: AREVALO J. FERNANDO, BRESSLER SUSAN, FAYYAD FAISAL, REGILLO CARL D.

15:45 *BOSCIA FRANCESCO* Early Pars-Plana Vitrectomy (PPV) for Complications of Proliferative Diabetic Retinopathy (PDR)
15:50 *BRESSLER SUSAN* Common Misconceptions Regarding Treatment of Proliferative Diabetic Retinopathy
15:55 *TUFAIL ADNAN* Real world progression rates of diabetic retinopathy and impact of anti-VEGF therapy
16:00 *PETO TUNDE* Best practice in caring for those with diabetes with additional needs: those who are pregnant, those on dialysis, the over 90 years olds....
16:05 *AREVALO J. FERNANDO* What if Diabetic Retinopathy Patients are Lost to Follow-Up?
16:10 *OSHIMA YUSUKE* Fibrovascular Membranes dissection for proliferative diabetic retinopathy: How much can you leave it as it is?
16:15 *REGILLO CARL D.* Two-year outcomes form the Pagoda (DME) and Pavilion (DR) phase 3 trials of the port delivery system with ranibizumab
16:20 *FAYYAD FAISAL* PDR Retinal Detachment: The challenging cases
16:25 *CAPOROSSI TOMASO* Fovea-Sparing Internal Limiting Membrane Peeling in Tractional Diabetic Macular Edema
16:30 Discussion

16.45-17.45 WET AMD IMAGING 1

CHAIRS: KAISER PETER, PAULEIKHOFF DANIEL, STAURENGHI GIOVANNI

16:45 *FUJIMOTO JAMES* Topographic measurement of the sub-retinal pigment epithelium space in normal aging and age-related macular degeneration using high-resolution OCT
16:49 *PILOTTO ELISABETTA* Central Retinal Thickness in wet AMD revisited
16:53 *PAULEIKHOFF DANIEL* Choroidal changes under long term anti-VEGF therapy in nAMD
16:57 *QUERQUES GIUSEPPE* Microvascular changes in treatment naïve non-exudative macular neovascularization complicated by exudation

FRIDAY 6 DECEMBER

SAN GIOVANNI ROOM

17:01 *SAVASTANO MARIA CRISTINA* Exudative AMD: Morphology of MNVs and clinical implications
17:05 *VIGGIANO PASQUALE* Topographical quantification of hyperreflective foci may predict the development of macular atrophy in patients with neovascular age-related macular degeneration
17:09 *GALE RICHARD* Developing a deep learning convolutional neural network to detect active neovascular age-related macular degeneration; comparing YorkMac and AutoML
17:13 *KUTZER CORNELIA* Fluid monitoring in wet and dry AMD in clinical practice
17:17 *VAVVAS DEMETRIOS* Proteomics in AMD
17:21 *SARRAF DAVID* OCTA Evaluation of MNV: Is it Necessary?
17:25 Discussion

17.45-18.45 WET AMD TREATMENT 1
CHAIRS: HO ALLEN, LANZETTA PAOLO, KOROBELNIK JEAN-FRANÇOIS

17:45 *ZUR DINAH* Retinal fluid dynamics and visual outcomes in neovascular AMD: A large longitudinal study across early and later treatment phases in two tertiary settings
17:49 *BORRELLI ENRICO* Exploring Macular Atrophy in Neovascular AMD: Focusing on Type 3 Macular Neovascularization
17:53 *SOLER VINCENT* The Reinforced Treat-and-Extend Protocol for Exudative Age-Related Macular Degeneration: Retrospective Assessment of 24-Month Real-World Outcomes in France
17:57 *EANDI CHIARA* Faricimab Efficacy in Type 1 Macular Neovascularization
18:01 *LOEWENSTEIN ANAT* Comparing Real-World Outcomes: Faricimab Post-bevacizumab (2nd Line) vs. Post-aflibercept/ranibizumab (3rd Line) in Exudative Diseases Treatment
18:05 *KITCHENS JOHN* Real world experience with faricimab and aflibercept 8mg
18:09 *SARAO VALENTINA* Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes
18:13 *VERITTI DANIELE* Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect
18:17 *ERGINAY ALI* SwitchAI Study: Use of RetinSight Artificial Intelligence software for monitoring wAMD patients switched from anti-VEGF to faricimab, primary results from three french centers
18:21 *VIOLA FRANCESCO* Comparative analysis of short-term lesion-drying efficacy in exudative AMD
18:25 Discussion

SANTA CROCE ROOM

13.45-14.45 HOW DO I DO IT
ORGANIZER: EL RAYES EHAB
PANEL: FIGUEROA MARTA, PRIGLINGER SIEGFRIED, OSHIMA YUSUKE, RIEMANN CHRISTOPHER D., MACLAREN ROBERT, ROMANO MARIO, GARCÍA-ARUMÍ JOSÉ, ECKARDT CLAUS

14.45-15.45 EPIRETINAL MACULAR MEMBRANES
CHAIRS: FARALDI FRANCESCO, GIANSANTI FABRIZIO, REIBALDI MICHELE, WOLFENSBERGER THOMAS

14:45 *AL-DIBHI HASSAN* Epiretinal membrane stable or with good vision – Is surgery required?
14:49 *GIANSANTI FABRIZIO* Role of vitreous detachment in epiretinal membrane peeling: multimodal imaging and microperimetry study
14:53 *REIBALDI MICHELE* Insights into predictors of visual performance in patients with idiopathic epiretinal membrane
14:57 *WILLIAMSON TOM* Computerised methods for mapping of metamorphopsia in vitreoretinal disorders
15:01 *PAROLINI BARBARA* Should we change the timing of surgery for epiretinal membranes (ERMs)?
15:05 *LE MER YANNICK* Peeling: the results of a prospective randomized study on ILM removal in macular membrane surgery
15:09 *MAVI YILDIZ AYSEGUL* Tangential foveal displacement following temporal inverted ILM flap technique: 12 months results

FRIDAY 6 DECEMBER

SANTA CROCE ROOM

15:13 *CAPONE ANTONIO* Visual Outcomes in Pseudophakic Eyes Following Vitrectomy for Epiretinal Membrane
15:17 *GOVETTO ANDREA* Postoperative evolution of metamorphopsia in epiretinal membrane: does the surgical technique matter?
15:21 *FARALDI FRANCESCO* Macular Toxicity in vitreoretinal surgery
15:25 *PRIGLINGER SIEGFRIED* VRI and spectacle independence - What can we offer patients with VRI diseases and a desire to be spectacle free?
15:29 Discussion

15.45-17.00 RETINAL DETACHMENT - UNDER THE PATRONAGE OF GIVRE

CHAIRS: AUGUSTIN ALBERT, BOSCIA FRANCESCO, CHARLES STEVE, DE MOLFETTA VITO, PILERI MARCO ANDREA, ROSSI TOMMASO

15:45 *STEEL DAVID* H. Risk factors for retinal detachment after cataract surgery
15:49 *SOLER VINCENT* Meteorological factors and rhegmatogenous retinal detachment in metropolitan France
15:53 *TOSI GIAN MARCO* Impact of untreated lattice degeneration on retinal detachment incidence in 2024
15:57 *ROSSI TOMMASO* The proteomics of retinal detachment: new insights
16:01 *WILLIAMSON TOM* Adjustments to gas injections in pneumatic retinopexy, a GEMs study
16:05 *DE SMET MARC* Air tamponade for retinal detachments in patients living at altitude
16:09 *CHARLES STEVE* Do not combine buckles with vitrectomy, use extended vitreous base laser
16:13 *AUGUSTIN ALBERT* Is there still a place for scleral buckling for retinal detachment
16:17 *WOLF ARMIN* Outcomes after air tamponade for retinal detachment (RD)
16:21 *NIKOLAKOPOULOS ATHANASIOS* Special Consideration and techniques in treating True Giant Tears
16:25 *BADAWI ABDULRAHMAN* Outcomes of Rhegmatogenous retinal detachments in Marfan syndrome patients at specialized eye centre
16:29 *BONFIGLIO VINCENZA* Structural and vascular retinal changes secondary to different subretinal fluid drainage techniques during pars plana vitrectomy for rhegmatogenous retinal detachment. A prospective monocentric study
16:33 *REZENDE FLAVIO* Irreversible Hypotony Secondary to Early Post-Op Vitreous Hemorrhage in Primary RD
16:37 *BOSCIA FRANCESCO* Surgical management and outcome of massive hemorrhagic retinal detachment
16:41 *LAZIC RATIMIR* Retinal Detachment Management in Choroidal Coloboma Patients
16:45 Discussion

17.00-17.45 ENDOPHTHALMITIS - UNDER THE PATRONAGE OF AIMO - SISO

CHAIRS: AVITABILE TERESIO, BALESTRAZZI ALESSANDRA, GARCÍA-ARUMÍ JOSÉ, KITCHENS JOHN

17:00 *KITCHENS JOHN* Efficiencies in and out of the OR
17:04 *FIORE TITO* Mobile unidirectional airflow device to reduce air contamination in an intravitreal injection setting
17:08 *HEIMANN HEINRICH* Is a day 1 postoperative visit required for routine vitreoretinal surgery cases?
17:12 *CHANDRA AMAN* Sterile endophthalmitis after pars plana vitrectomy
17:16 *AVITABILE TERESIO* Immediate vitrectomy for acute postoperative endophthalmitis
17:20 *GINI GIAMPAOLO* How should you approach a Post-operative Endophthalmitis based on Presentation and Available Resources?
17:24 *MICHIELETTO PAOLO* 10-years experience of vitrectomy for endophthalmitis
17:28 *GARCÍA-ARUMÍ JOSÉ* Surgical management of endophthalmitis
17:32 Discussion

17.45-18.45 LATEST UPDATE ON INTRAOCULAR TAMPONADES - UNDER THE PATRONAGE OF ESASO

MODERATORS: CHARLES STEVE, GUARNACCIA GIUSEPPE, ROMANO MARIO

17:45 *WILLIAMSON TOM* What effects do different gas injection methods have on gas dynamics, a GEMs study
17:49 *WOLFENSBERGER THOMAS* Can the use of pure SF6 gas in retinal detachment surgery reduce its climate impact?
17:53 *WILLIAMSON TOM* Effects of altitude on intra-ocular gas dynamics, a GEMs study
17:57 Round table - Discussion
18:07 *ROMANO MARIO ITEMS* score and SO complications: results from a multicentric prospective study

FRIDAY 6 DECEMBER

SANTA CROCE ROOM

18:11 *CHARLES STEVE* Avoid virtually untreatable silicone oil macular edema (SOME), remove oil in 1-2 months if possible
18:15 *MARIOTTI CESARE* Clinical and AI-based structural assessment of macular impairment in rhegmatogenous retinal detachment treated with different silicon oil endotamponades
18:19 *STEEL DAVID H.* Conventional versus heavy silicone oil in complex primary retinal detachments
18:23 *ZURMAN PETER* Evaluation of 3 new Hydrogel Vitreous Substitutes in phthitis eyes
18:27 *WILLIAMSON TOM, WOLFENSBERGER THOMAS, SZURMAN PETER, STEEL DAVID H.* Round table – Case Presentation

SAN FREDIANO ROOM

08.00-09.30 RESIDENT'S COURSE 1 (SOU COURSE)
CHAIRS: MASTROPASQUA LEONARDO, SOUIED ERIC

8:00 *AZZARO LORENZO* A black macular hole
8:03 Discussion
8:04 *BARONE VINCENZO* Hyperacute macular edema
8:07 Discussion
8:08 *BORZI' LEONARDO* A retinal detachment: was it the right choice?
8:11 Discussion
8:12 *BUSONI CHIARA* Macular edema in RVO: is the visual prognosis always the same?
8:15 Discussion
8:16 *CARROZZI CHIARA* A curious case of iris heterochromia
8:19 Discussion
8:20 *CHISARI DOMENICO* Sub-retinal abscess in young patient
8:23 Discussion
8:24 *CHISCI ENEA* Uveitis Masquerade Syndrome
8:27 Discussion
8:28 *CIARMATORI NICOLO'* Case of surgical treatment of submacular hemorrhage
8:31 Discussion
8:32 *CRISCUOLO DANIELE* tbd
8:35 Discussion
8:36 *DE LUCA LAURA* Unveiling the link: predictive value of OCT findings in central serous chorioretinopathy
8:39 Discussion
8:40 *DE LUCA MARTINA* Case on Ocular Oncology
8:43 Discussion
8:44 *DE SANTI NICOLA* Acute bilateral reduction of visual acuty after hysteroannexectomy
8:47 Discussion
8:48 *DEL FABBRO SEBASTIANO* Multifocal vitelliform lesions associated with mitochondrial retinopathy
8:51 Discussion
8:52 *DERACO FLORIANA* Nightmare in scleral buckle surgery
8:55 Discussion
8:56 *FANTUZZI MARTINA* Unilateral Vitreoretinal Lymphoma mimicking Herpetic Acute Retinal Necrosis
8:59 Discussion
9:00 *FEBBRARO SIMONE* Autosomal dominant Wolfram-like Syndrome: a promising ophthalmological finding in its differential diagnosis
9:03 Discussion
9:04 *FORTE PAOLO* Retinal case
9:07 Discussion
9:08 *GROTTO ALBERTO* Who turned the lights off?
9:11 Discussion
9:12 *HU LORENZO* Telemedicine in Ophthalmology: home monitoring in patients with maculopathy
9:15 Discussion
9:16 Final Discussion

FRIDAY 6 DECEMBER

SAN FREDIANO ROOM

09.30-10.30 TIPS AND TRICKS FOR OCT READING
ORGANIZER: VAVVAS DEMETRIOS

9:30 *VAVVAS DEMETRIOS* Basic OCT reading
9:35 *NUDLEMAN ERIC* OCT and Vitreous
9:40 *LOEWENSTEIN ANAT* Home OCT
9:45 *SPAIDE RICHARD* OCT AMD vs Pachychoroid
9:50 *BEHAR COHEN FRANCINE* OCT in CSR
9:55 *MILLER JOHN* OCTA in diabetic retinopathy
10:00 *TUFAIL ADNAN* Inflammation Uveitis
10:05 *SADDA SRINIVAS* Ischemic OCT
10:10 *WAHEED NADIA* Artifacts of OCTA
10:15 *STAURENGHI GIOVANNI* Tips and Tricks GA and/ or myopic
10:20 *VAJZOVIC LEJLA* Intraoperative OCT
10:25 *BERROCAL AUDINA M.* Pediatric OCT

10.30-11.30 AI-BASED MEDICAL IMAGING
ORGANIZER: SCHMIDT-ERFURTH URSULA
MODERATORS: LEINGANG OLIVER, STANGA PAULO EDUARDO

10:30 *STANZEL BORIS* Automated monitoring in nAMD and DME
10:42 *STANGA PAULO EDUARDO* Detecting disease activity in GA by automated monitoring
10:54 *LEINGANG OLIVER* Precision and reliability of automated disease monitoring
11:06 *LEINGANG OLIVER* Correlation of retinal function with anatomical features on OCT imaging
11:18 Discussion

11.30-12.30 CROSSFIRE - INTERESTING CASE DISCUSSION BASED ON IMAGING
ORGANIZER: CHHABLANI JAY
PANELISTS: CHEUNG GEMMY, LANZETTA PAOLO, SADDA SRINIVAS

BOUSQUET ELODIE presenter
BREAZZANO MARK presenter
CICINELLI MARIA VITTORIA presenter
RUIZ MORENO JOSÉ MARIA presenter
SACCONI RICCARDO presenter
VALSECCHI NICOLA presenter

13.15-14.00 LUNCH SYMPOSIUM (INTALIGHT)
CHAIRS: EL MAFTOUHI ADIL, ROMANO ANDRÉ, ROSEN RICHARD

Intalight

13:15 *ROSEN RICHARD* The Power of the Periphery- Widefield OCT/OCTA
13:30 *ROMANO ANDRÉ* The New Frontier: Dream OCT Pioneering the Next Generation of Ophthalmology
13:45 *EL MAFTOUHI ADIL* Multimodal UWF OCT : New Gold Standard?

14.00-14.45 MYOPIA: PATHOGENESIS AND IMAGING
CHAIRS: PANOZZO GIACOMO, RUIZ MORENO JOSÉ MARIA, TUFAIL ADNAN

14:00 *BEHAR COHEN FRANCINE* Mechanisms of myopic staphyloma
14:04 *TUFAIL ADNAN* Macular Curve and Dome shape configuration: Structure and Genetics association in a population study
14:08 *RUIZ MORENO JOSÉ MARIA* Macular posterior staphyloma as a biomarker of severity and progression of myopic maculopathy
14:12 *COHEN YVES SALOMON* Atypical staphylomas
14:16 *INTROINI UGO* Central bouquet hemorrhages in high myopia
14:20 *SACCONI RICCARDO* The «sponge sign» as feature of inflammatory choroidal neovascularization in myopia: one-year clinical outcomes

FRIDAY 6 DECEMBER

SAN FREDIANO ROOM

14:24 *ERGINAY ALI* Role of Ultra-widefield OCT in high myopia
14:28 *LEO SEO WEI* ROP and myopia
14:32 *TING DANIEL* Artificial Intelligence in Retinal Imaging for Myopia
14:36Discussion

14.45-15.45 MYOPIA PREVENTION
CHAIRS: BUZZONETTI LUCA, MASTROPASQUA LEONARDO, NUCCI PAOLO, RESNIKOFF SERGE

14:45 *RESNIKOFF SERGE* Updates on the epidemiology of myopia: are the original predictions still valid?
14:49 *BUZZONETTI LUCA* First italian survey on treatment of myopia progression
14:53 *VIRGILI GIANNI* Interventions for myopia control in children: a living systematic review and network meta-analysis
14:57 *RESNIKOFF SERGE* Elimination of myopia and high myopia as a global health problem: illusion or imperative?
15:01 *NUCCI PAOLO* Eye misalignment in myopic eyes: diagnosis and treatment
15:05 *MASTROPASQUA LEONARDO* Refractive surgery and Myopia progression control: a way to go?
15:09 **Optical Defocus strategies:**
15:09 *OHLENDORF ARNE* **ZEISS VISION** - 1 year clinical results from China and Europe with ZEISS MyoCare
15:15 *VAGGE ALDO* **ESSILOR** - H.A.L.T. Technology to control myopia progression: monotherapy and combined treatment
15:21 *RONZONI MATILDE* **HOYA** - The evidence that builds trust: the values of DIMS technology
15:27 Discussion

15.45-16.30 AFTERNOON SYMPOSIUM (ZEISS VISION CARE) - ZEISS LENS SOLUTION FOR MYOPIA MANAGEMENT: AN IN-DEPTH DISCUSSION
MODERATOR: NUCCI PAOLO

15:45 *ABBATE CARLO* Welcome
15:47 *NUCCI PAOLO* Introduction. The new defocus lenses work
Round table:
15:52 *KAYMAK HAKAN* What is important to know about refractive errors and axial progression?
16:00 *OHLENDORF ARNE* Lens design & C.A.R.E. Technology: what makes the ZEISS MyoCare lenses unique?
16:08 *BUZZONETTI LUCA* Clinical experience in Italy with "myopia control" lenses: a game changer?
16:16 Panel Discussion and Q&A
16:28 *ABBATE CARLO* Summary and closing remarks

16.30-17.15 PATHOLOGIC MYOPIA
CHAIRS: CHOW DAVID, OSHIMA YUSUKE, PAROLINI BARBARA

16:30 *SADDA SRINIVAS* OCT features of lattice degeneration
16:34 *MALTSEV DMITRII* Scleral involvement in lattice retinal degeneration: optical coherence tomography study
16:38 *STALMANS PETER* Prophylactic vitrectomy to prevent retinal detachment after lens surgery in high myopia
16:42 *CHOW DAVID* Scleral Imbrication - evolving usage
16:46 *AL SABTI KHALID* A modified surgical approach for macular surgery in myopic macular hole with AXL >32 mm
16:50 *PANOZZO GIACOMO* Myopic Traction Maculopathy (MTM): when it is usually stable and when surgery may be indicated
16:54 *OSHIMA YUSUKE* A multicenter survey on the risk factors and therapeutic outcomes of macular hole formation after vitrectomy for myopic traction maculopathy
16:58 *PRIGIONE GUIDO* Surgical management in MTM: when, how, and what to expect
17:02 *TORO MARIO* Factors influencing anti-VEGF treatment burden in myopic choroidal neovascularization: a multicenter study
17:06 *PAROLINI BARBARA* MTM staging system and treatment with 15 years follow up
17:10 Discussion

FRIDAY 6 DECEMBER

SAN FREDIANO ROOM

17.15-18.45 REGIONAL AND INDUSTRY PERSPECTIVES ON THE MANAGEMENT OF VITREOUS FLOATERS AND OPACITIES

ORGANIZERS AND MODERATORS: D'AMICO DONALD J.,STANGA PAULO EDUARDO

17:15 *BACHERINI DANIELA* Anatomy of the vitreous and its relevance in an ageing and increasingly myopic population
17:25 *SPAIDE RICHARD* Imaging the vitreous
17:35 *BROWN DAVID* The American Way
17:45 *PATELLI FABIO* The European Way
17:55 *STANGA PAULO EDUARDO* Therapeutic Refractive Vitrectomy and YAG vitreolysis for the treatment of Vitreous Floaters and Opacities (VFO)
18:05 *HALLEN PAUL* An industry perspective on the need of better imaging and treatment technologies
18:15 *D'AMICO DONALD J.* Clinical cases illustrating how their management has changed in recent years
18:25 Round Table Discussion

SANTO SPIRITO ROOM

07.00-08.00 MORNING SYMPOSIUM (TowardPi) - 400kHz OFFICIALLY COMES, APPLICATION OF CE CLEARED TowardPi OCT

TOWARD π
Medical Technology

GUESTS: ROSSI TOMMASO, ERGINAY ALI, GOVETTO ANDREA, HAOUCHINE BELKACEM, ZHOU JIAN

7:00 *ROSSI TOMMASO* Introduction
7:05 *ROSSI TOMMASO* 400kHz OCT/OCTA retinal displacement: a new diagnostic opportunity
7:15 *ERGINAY ALI* UWF OCT/OCTA for retina pathologie
7:25 *GOVETTO ANDREA* The visualization of the peripheral vitreous: a game changer
7:35 *HAOUCHINE BELKACEM* Avantages of Yalkaid swept source OCT in clinical practice
7:45 *ZHOU JIAN* What makes TowardPi different
7:55 Q&A

08.30-09.45 NEW ROLE OF MULTIMODAL IMAGING IN POSTERIOR NON-INFECTIOUS UVEITIS

CHAIRS: ACCORINTI MASSIMO, DE SMET MARC, NGUYEN QUAN DONG

8:30 *JAMPOL LEE MERRILL* Are all white spot syndromes the same? Distinguishing the various entities
8:39 *FABIANI CLAUDIA* Results of the IUSG Survey on the Need for Imaging Modalities
8:48 *SPAIDE RICHARD* New Insights into Multimodal Imaging for Multifocal Choroiditis
8:57 *INVERNIZZI ALESSANDRO* Multimodal Imaging in Uveitis: Updates
9:06 *AREVALO J. FERNANDO* Correlation between Choriocapillaris Vascular Density and VA in Patients with Birdshot Chorioretinitis Using SS-OCTA
9:15 *INVERNIZZI ALESSANDRO* The impact of Immunomodulatory Treatment on Atrophy Growth and iCNV secondary to MFC
9:24 *KARACA IRMAK* Importance of Baseline Fluorescein Angiography for Patients Presenting to Tertiary Uveitis Clinic
9:33 Panel Discussion

09.45-11.00 INFECTIOUS UVEITIS: TIP AND TRICKS FROM LABORATORY TO MANAGEMENT

CHAIRS: ACCORINTI MASSIMO, DE SMET MARC, NGUYEN QUAN DONG

9:45 *MUNK MARION* Unveiling the Molecular Nexus of Ocular Tuberculosis: Mycobacterium Proteins, Ocular Autoimmunity & Immune Receptor Dynamics
9:54 *CIMINO LUCA* Updates on Therapy for Ocular TB
10:03 *MISEROCCHI ELISABETTA* How to Survive in the "Jungle" of Retinitis: Clinical and Multimodal Imaging Approach
10:12 *MATSUMIYA WATARU* Early Vitrectomy Using 25-gauge or 27-gauge Microincision Vitrectomy System for Acute Retinal Necrosis
10:21 *SAENGSIRINAVIN AIM-ON* Role of Mass Spectrometry in the Diagnosis of Infectious Uveitis
10:30 *THAN NGOC TRONG TUONG* Application of Corticosteroid and Immunomodulatory Therapy in Infectious Uveitis

FRIDAY 6 DECEMBER

SANTO SPIRITO ROOM

10:39 ***THNG ZHENG XIAN*** Novel Management of Cystoid Macular Edema Secondary to Immune Recovery Uveitis in Eyes with Infectious Retinitis
10:48 Panel Discussion

11.00-12.00 SYMPOSIUM (EVERADS) - FURTHER PROGRESS ON SUPRACHOROIDAL DELIVERY FOR OCULAR THERAPEUTICS

EVERADS THERAPY

SYMPOSIUM DIRECTOR AND MODERATOR: NGUYEN QUAN DONG
SYMPOSIUM CO-DIRECTOR: BARAK YOREH
MODERATOR: DO DIANA V.

11:00 ***NGUYEN QUAN DONG*** Introduction to the Symposium: Goals and Objectives
11:03 ***DE SMET MARC*** Suprachoroidal Delivery: An Effective Approach for Ocular Therapeutics
11:10 ***BARAK YOREH*** Other Approaches for Suprachoroidal Delivery
11:17 ***DHOOT DILSHER*** Suprachoroidal ABBV-RGX-314 for Retinal Vascular Diseases
11:24 ***OR CHRISTOPHER*** Suprachoroidal Axitinib for Neovascular AMD
11:31 ***DRAWNEL FAYE*** Suprachoroidal Belzupacap Sarotalocan (Bel-sar) for Choroidal Melanoma
11:38 ***ALMEIDA DAVID*** Suprachoroidal Therapy for Geographic Atrophy
11:45 ***DE-BOER CHARLES*** Mechanisms to Enhance Suprachoroidal Delivery: A Perspective
11:52 Panel Discussion: Future of Suprachoroidal Delivery for Ophthalmic Diseases

12.00-13.15 CURRENT AND POTENTIALLY FUTURE THERAPY FOR NON-INFECTIOUS UVEITIS

CHAIRS: ACCORINTI MASSIMO, NGUYEN QUAN DONG, THNG ZHENG XIAN

12:00 ***SHAH RAJIV EDLAGAN*** Timing of Immunosuppressive Therapy
12:09 ***SEPAH YASIR*** Interleukin-6 Inhibition for Non-infectious Uveitis
12:18 ***NGUYEN QUAN DONG*** JAK Inhibition for Non-infectious Uveitis
12:27 ***YOO WOONG-SUN*** IL-17 Inhibition for Non-Infectious Uveitis
12:36 ***HUNG JIA-HORUNG*** Local Therapy for Inflammatory Macular Edema: Anti-Interleukin and Corticosteroid
12:45 ***MATSUMIYA WATARU*** Management of Acute Vogt-Koyanagi-Harada Disease with Moderate-Dose Oral Corticosteroids
12:54 ***ANOVER FRANCES ANDREA*** Subconjunctival Dexamethasone for Non-infectious Scleritis
13:03 Panel Discussion

14.45-15.45 ADVANCED RETINAL IMAGING CONSENSUS: EXPERT GUIDELINES AND STANDARDIZED TERMINOLOGY MASTERY

ORGANIZER AND CHAIR: MUNK MARION
CHAIR: PETO TUNDE

14:45 ***MUNK MARION*** Defining Clarity—OCTA Reporting Standards in Retinal Vascular Diseases
14:51 ***SARRAF DAVID, POPOVIC MARKO*** Large Retinal Capillary Aneurysm (LRCA) - A Delphi Consensus Nomenclature
14:57 ***INVERNIZZI ALESSANDRO*** The MUV Project—Setting the Gold Standard in Multimodal Imaging for Non-Infectious Posterior Uveitis
15:03 ***SCHWARTZ ROY*** Decoding AMD-Associated MNV Morphology—OCTA Nomenclature Standards
15:09 ***SADDA SRINIVAS*** Harmonizing Approaches to Quantifying the EZ—An Expert Overview
15:15 ***CHEUNG GEMMY*** International Consensus on Fibrosis in Neovascular AMD—A New Lexicon and Key Insights
15:21 Discussion

15.45-16.30 AFTERNOON SYMPOSIUM (ANNEXON) - PROTECTION OF FUNCTION AND STRUCTURE IN DRY AMD / GA WITH C1Q INHIBITION

ANNEXON biosciences

CHAIR: KAISER PETER

15:45 ***KAISER PETER*** C1q Driven Neurodegeneration: Impacts on Structure and Function
16:00 ***WYKOFF CHARLES C.*** ANX007: Visual Acuity Protection and Safety in the Phase 2 ARCHER Study
16:15 ***LOEWENSTEIN ANAT*** Linking Structure to Function: Protection of Vision Associated Structures with ANX007

FRIDAY 6 DECEMBER

SANTO SPIRITO ROOM

16.30-18.30 PIONEERING INNOVATION: MASTERING CLINICAL TRIALS AT FLORETINA 2024

ORGANIZERS AND MODERATORS: BAKRI SOPHIE J., VAJZOVIC LEJLA

16:30 Opening Remarks
SECTION: SETTING THE STAGE: FOUNDATIONS FOR CLINICAL TRIAL SUCCESS
16:35 ***LOEWENSTEIN ANAT*** Understanding the Motivation and Initial Steps in Clinical Trials
16:40 ***VAJZOVIC LEJLA*** Exploring the Landscape: Various Clinical Trial Options
16:45 ***HADZIAHMETOVIC MAJDA*** Diving into Investigator-Initiated Trials (IIT)
16:50 ***ETER NICOLE*** Building and Training an Effective Research Team
16:55 Discussion & Transition
SECTION: NAVIGATING THE PAPERWORK: AGREEMENTS AND BUDGETING
17:10 ***ZWEIFEL SANDRINE*** Demystifying the Clinical Trial Agreement (CTA): Purpose and Importance
17:15 ***BAKRI SOPHIE*** J. Budgeting for Clinical Trials: Strategies for Success
17:20 Discussion & Transition
SECTION: EXECUTING CLINICAL TRIALS: STRATEGIES FOR SUCCESS
17:30 ***MUNK MARION*** Effective Strategies for Recruiting Trial Participants
17:35 ***HOLZ FRANK*** Building a network of clinical study sites– experiences from the DOG working group of clinical study centers
17:40Discussion & Transition
RETINA FUTURA CLINICAL TRIAL SYMPOSIUM
Panel: BAKRI SOPHIE J., VAJZOVIC LEJLA, LOEWENSTEIN ANAT, ETER NICOLE, HOLZ FRANK
17:50 ***REED KIMBERLY*** C1Q inhibition in geographic atrophy: A novel approach
17:55 Discussion
17:58 ***PAKOLA STEVE*** RGX-314: One time gene therapy clinical programs for the treatment of neovascular age-related macular degeneration and diabetic retinopathy
18:03 Discussion
18:06 ***KAISER PETER*** SOL Program: Clinical Designs of OTX-TKI Trials for Wet AMD
18:11 Discussion
18:14 ***QUEZADA RUIZ CARLOS*** 4D-150 for People living with nAMD: The 4Front Global Development Program
18:19 Discussion
18:22 Final Discussion

SAN LORENZO ROOM

08.00-08.45 FREE PAPERS - TUMORS

CHAIRS: HEIMANN HEINRICH, PAGLIARA MONICA, PARROZZANI RAFFAELE

8:00 ***HERNANDEZ-SCOBELL ANAYATZIN*** From clarity to darkness: evolution of a choroidal mass and loss of ocular function over twelve months
8:03 ***RELIMPIO-LÓPEZ ISABEL*** Episcleral brachytherapy: experience from a referral center of intraocular tumours
8:06 ***SAMMARCO MARIA GRAZIA*** Challenging treatment for radiation retinopathy: our experience
8:09 ***ORESTE GIANMARCO*** Photodynamic therapy of vascular intraocular tumors: long term single centre experience.
8:12 ***VIVARELLI CHIARA*** Pars plana vitrectomy with feeder vessel ligation for retinal detachment secondary to retinal capillary hemangioblastoma: a retrospective study
8:15 ***RIVOLTA MARIA CHIARA*** Diagnostic delay in vitreoretinal lymphoma is a risk factor for cns involvement
8:18 ***RIVOLTA MARIA CHIARA*** Retro-mode imaging in vitreoretinal lymphoma
8:21 ***MATSUMIYA WATARU*** Association between retinal infiltration of vitreoretinal lymphoma and vitreous il-10 concentration
8:24 ***MOTTOLA FRANCESCO*** Neoplastic masquerade syndromes
8:27 ***EL MATRI KHALED*** Multimodal imaging of an atypical case of choroidal osteoma
8:30 Discussion

FRIDAY 6 DECEMBER

SAN LORENZO ROOM

08.45-09.45 FREE PAPERS - RETINAL VASCULAR DISEASES

CHAIRS: ERGINAY ALI, JAMPOL LEE MERRILL, LAVIA CARLO ALESSANDRO, SARAO VALENTINA

8:45 *FISCHER SARAH* Long-term treat-and-extend outcomes in cystoid macular edema due to retinal vein occlusion
8:48 *ZERBINATI MARTA* Long-term visual outcomes and optical coherence tomography biomarkers in eyes with macular edema secondary to retinal vein occlusion following anti-vascular endothelial growth factor therapy
8:51 *SPINKS JAMIE* Comparison of systemic risk factors for hrvo with brvo and crvo
8:54 *BOUCHIKH EL JARROUDI RACHID* Novel optical coherence tomography biomarkers and visual prognosis in retinal vein occlusion
8:57 *BOUCHIKH EL JARROUDI RACHID* Biomarkers monitoring by optical coherence tomography in patients diagnosed with retinal vein occlusions: 10 years of experience.
9:00 *DE SALVO GABRIELLA* OCT-Angiography features and flow-based classification of retinal artery macroaneurysms
9:03 *FROSTEGÅRD ANNA* Phase 2a/proof of concept study with anxv (recombinant human annexin a5) in patients with retinal vein occlusion
9:06 *DOGRUEL ECE* Factors affecting visual prognosis in patients with neovascular glaucoma secondary to retinal vascular diseases
9:09 *STRINGA FRANCESCO* Management of ischaemic retinal diseases and neovascular glaucoma: overview of practice from two tertiary centres in the uk
9:12 *LOMBARDO MARCO* Paracentral acute middle maculopathy: reverse engineering of a case
9:15 *ZIMMER KATARZYNA* Let's go with the flow? ocular changes in high risk pregnancies
9:18 *ZEINAB ELSANABARY* Recognizing post-partum retinopathies
9:21 *KARAGIANNIDOU ZOE* Grade iv hypertensive retinopathy and increased intracranial pressure in an adult with an extra-adrenal paraganglioma
9:24 *FORTE PAOLO* Incidence and localization of telangiectatic capillaries (telcaps) secondary to retinal vein occlusion treated with anti-VEGF monotherapy.
9:27 *MYLONA ELENA* Valsalva related subretinal haemorrhage in a patient with undiagnosed polypoidal choroidal vasculopathy
9:30 *ROMANO FRANCESCO* Characterizing vascular alterations in macular telangiectasia type 2: a comprehensive optical coherence tomography angiography study
9:33 *KADAYIFCILAR SIBEL* Adjunctive intravitreal therapy for coats' disease
9:36 *VALLEJO-GARCIA JOSE LUIS* Curcumin and bromelain: an effective help to subthreshold micropulse laser in patient with diabetic macular edema
9:39 Discussion

10.45-12.15 HIGH RESOLUTION OCT

ORGANIZERS AND MODERATORS: STAURENGHI GIOVANNI, COZZI MARIANO

10:45 *FUJIMOTO JAMES* Technology and analysis methods for high resolution OCT
10:54 *DOLZ-MARCO ROSA* Heidelberg Engineering Technologies
11:03 *CURCIO CHRISTINE* A. Anatomical correlation
11:12 *WAHEED NADIA* The comparison of UHR images with clinical device images
11:21 *SADDA SRINIVAS* High Resolution OCT of macular neovascularization
11:30 *COZZI MARIANO* Imaging Pseudoxanthoma Elasticum in High resolution
11:39 *STAURENGHI GIOVANNI* Basal Laminar Deposits in High Resolution
11:48 *INVERNIZZI ALESSANDRO* Retinal vessels in High Resolution
11:57 Discussion

12.15-13.15 AIORAO COURSE - INNOVATION IN THE IMAGINING OF RETINAL DISEASES: THE ROLE OF THE ORTHOPTIST

PRESIDENT: BLENGIO CARLA
MODERATORS: BALZANO ADRIANA, SCARICA ERICA

12:15 *CORRO' FRANCESCA* The Orthoptist and the Management of Retinopathy of Prematurity

FRIDAY 6 DECEMBER

SAN LORENZO ROOM

12:25 *PICCOLI GABRIELE* OCT- Angiography vs fluorescein angiography: complementary or alternative?
12:35 *CALANDRA MICHELA* Assestament of Macular Function Using Microperimetry in Macular Hole Surgery
12:45 *RIZZO ROBERTA* Orthoptic assessment of ab-externo retinal surgery
12:55 *PERILLO CARLO* How to combine the different diagnostic method in the diabetic retinopathy
13:05 Discussion

13.15-14.15 PACHYCHOROID IMAGING
CHAIRS: CHEUNG GEMMY, DEMIREL SIBEL, EANDI CHIARA, GAUDRIC ALAIN

13:15 *BANDELLO FRANCESCO* Pachycoroid Classification and Progression risk
13:20 *CHEUNG GEMMY* Incidence and risk factors for progression in pachychoroid spectrum diseases: a 2 year longitudinal cohort
13:25 *SPAIDE RICHARD* Blood Flow Measures in the Choroid
13:30 *CHHABLANI JAY* 3-Dimensional quantification of choroidal biomarkers
13:35 *BOUSQUET ELODIE* New insights into the pathophysiology of central serous chorioretinopathy
13:40 *PEIRETTI ENRICO* Mid-Phase Hyperfluorescent Plaques & CVI in CSCR
13:45 *EANDI CHIARA* Exploring the Factors Influencing Recurrence of Central Serous Chorioretinopathy using Machine Learning
13:50 *DEMIREL SIBEL* Non-Indocyanine Green Angiography Non-Invasive Diagnostic Criteria in the Differential Diagnosis of Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration: Sensitivity-Specificity Study
13:55 *CIARDELLA ANTONIO* Peripapillary pachicoroid syndrome, a poorly understood clinical entity
14:00 Discussion

14.15-15.30 PACHYCHOROID TREATMENT
CHAIRS: BEHAR COHEN FRANCINE, BOUSQUET ELODIE, LUPIDI MARCO

14:15 *BEHAR COHEN FRANCINE* Systemic metabolomics in patients with CSCR
14:20 *BAKRI SOPHIE J.* Evidence Based Update on Central Serous Retinopathy
14:25 *CHEUNG GEMMY* Aflibercept monotherapy vs Aflibercept combined with photodynamic therapy for PCV: a randomized controlled trial
14:30 *DEMIREL SIBEL* The role of PDT for the treatment of CentralSerous Chorioretinopahy with or without Choroidal neovascularization
14:35 *PETROPOULOS IOANNIS* New Setting for PDT no Dose : which results ?
14:40 *NICOLÓ MASSIMO, FORTE PAOLO* Correlation of anterior scleral substantia propria thickness with central serous chorioretinopathy phenotypes and photodynamic therapy response in caucasian patients
14:45 *MALTSEV DMITRII* Safety and Efficacy of Photodynamic Therapy with Chlorin E6 in Chronic Central Serous Chorioretinopathy
14:50 *LUPIDI MARCO* Functional and structural outcomes of combined PDT and eplerenon Vs PDT alone in chronic central serous chorioretinopathy
14:55 *TOTO LISA* Subthreshold Micropulse Laser in Chronic Central Serous Chorioretinopathy
15:00 *BOSCIA FRANCESCO* Pachyvitelliform maculopathy and neurosensory detachment associated with pachychoroid neovasculopathy regress with continuous long-term eplerenone treatment
15:05 Discussion

16.15-17.45 IMAGING TECHNOLOGICAL INNOVATIONS
CHAIRS: HUANG DAVID, KASHANI AMIR H., ROSEN RICHARD

16:15 *CARROLL JOSEPH* Structure-Function Relationships in the Human Fovea
16:20 *ERSÖZ GIRAY* Standardization of Choroidal Vascularity Index
16:25 *STANGA PAULO EDUARDO* New 200 kHz Single-Scan 26 mm Ultra-Widefield OCT Angiography (UWF OCTA) vs. UWF FFA in Proliferative Diabetic Retinopathy
16:30 *SPAIDE RICHARD* Measuring blood flow in the retina and choroid with OCT: Validity of Flow Measurements
16:35 *HUANG DAVID* Split-spectrum amplitude-decorrelation optoretinography

FRIDAY 6 DECEMBER

SAN LORENZO ROOM

16:40 *KASHANI AMIR H.* Ultrahigh resolution visible light OCT for detection of outer retinal pathology
16:45 *AZZOLINI CLAUDIO* United Nations roundtable on digital medicine in ophthalmology
16:50 *EL MAFTOUHI ADIL* Dynamic OCT-A in Macular diseases
16:55 *ROSEN RICHARD* Stalking the Wild Hyalocyte: En Face OCT and Adaptive Optics Insights into the Cellular Dynamic and Morphology of Vitreous Cortex Macrophages in the Living Eye
17:00 *CAMPBELL PETER* Ultra-widefield OCT in Adults and Children
17:05 *DE SMET MARC* Low cost widefield retinal imaging and its comparison to UWF in normal and diseased eyes
17:10 *PIRCHER MICHAEL* Improvements on adaptive optics optical coherence tomography and clinical applications
17:15 *MALTSEV DMITRII* Choriocapillaris perfusion assessed with OCTA may depend on eye color through the effects of projection artifact removal algorithm
17:20 *TOTH CYNTHIA* Widefield imaging with handheld OCT at point of care—the future is bright
17:25 *ROMANO ANDRÉ* Generative AI Enhancing OCT Imaging: Practical Benefits for Clinicians
17:30 Discussion

17.30-18.45 FREE PAPERS - ANTERIOR SEGMENT

CHAIRS: BARCA FRANCESCO, MERCIECA KARL, NIKOLAKOPOULOS ATHANASIOS, ROSA NICOLA

17:30 *ALSAEDI NASSER* Intracorneal encircling buckle migration: a case report
17:33 *MAKLED HEBATALLA* OCT scans artifacts in glaucoma patients
17:36 *MIGUEL ANA* Intra-operative OCT during glaucoma surgeries
17:39 *KHOYRATTY FADIL* DMEK graft dislocation
17:42 *SIMANTOV ILIYA* Home monitoring of intraocular pressure following intravitreal dexamethasone implant
17:45 *CIONE FERDINANDO* Comparison between dynamic contour tonometry and goldmann applanation tonometry correcting equations
17:48 *SCAMPOLI ALESSANDRA* Active-fluidics versus gravity-fluidics in uncomplicated cataract surgery: OCTA to estimate early changes in macular and optic disc microcirculation
17:51 *QURESHI MADYAN* Posterior polar cataracts: how many really require vitreoretinal intervention?
17:54 *DOTAN ASSAF* Posterior synechia formation after phacovitrectomy - predicting factors and the role of short-acting mydriatics
17:57 *STAMENKOVIC MIROSLAV* Spontaneous late dislocation of intraocular lens within the capsular bag in pseudoexfoliation syndrome- surgical options
18:00 *SMAHLIOU PETROS* Extended depth of focus intraocular lens implantation in patients with age-related macular degeneration
18:03 *GRISHCHENKO MAXIM* Results of implantation of multifocal and edof - IOLs in eyes with avitria.
18:06 *MAROLO PAOLA* Long-term surgical outcomes of scleral flap versus scleral pocket technique for sutureless intrascleral one-piece lens fixation
18:09 *PINTO FERREIRA NUNO* Visual and safety outcomes of the carlevale intraocular lens: insights from a multicentric study
18:12 *LA MANTIA ALBERTO* Refining delivery and positioning: a modified approach to fil ssf intraocular lens implantation using the “full reverse” technique
18:15 *EL ASHRY MOHAMED* Is carlevale lens the right tool for aphakia with no capsular support?
18:18 *LANDINI LUCA* Multifocal electroretinography changes in patients with late-stage age related macular degeneration (AMD) after smaller-incision new-generation implantable miniature telescope (SING IMT):
18:21 *SAVASTANO ALFONSO* SING IMT complications and their managment
18:24 *D'ONOFRIO NICOLA CLAUDIO* SING IMT in pseudophakic eyes: results of the first experiences
18:27 Discussion

FRIDAY 6 DECEMBER

ORSANMICHELE ROOM

08.00-09.00 MACULAR COMPLICATIONS DETERMINING SUBOPTIMAL OUTCOMES AFTER ANTI-VEGF THERAPIES FOR NEOVASCULAR AMD

ORGANIZERS AND MODERATORS: BORRELLI ENRICO, REIBALDI MICHELE
MODERATORS: BACHERINI DANIELA, SADDA SRINIVAS

8:00 ***CHEUNG GEMMY*** RPE tear: definition, differential diagnosis and risk factors
8:06 ***BORRELLI ENRICO*** Macular atrophy: definition, diagnosis and impact on visual acuity
8:12 ***STAURENGHI GIOVANNI*** Macular atrophy: risk factors and influence of treatment management
8:18 ***CHAKRAVARTHY USHA*** Macular fibrosis: definition and detection using multimodal vs. unimodal imaging
8:24 ***SADDA SRINIVAS*** Macular fibrosis/SHRM: impact on visual acuity
8:30 ***MASTROPASQUA RODOLFO*** Subretinal hemorrhage: risk factors and management
8:36 ***REITER GREGOR*** AI prediction of macular complications associated with suboptimal outcomes after anti-VEGF therapy for nAMD
8:42 Discussion

09.00-10.00 FIBROSIS AND MACULAR ATROPHY IN NAMD – TWO SIDES OF ONE MEDAL?

ORGANIZERS AND MODERATORS: PAULEIKHOFF DANIEL, SADDA SRINIVAS

9:00 ***CURCIO CHRISTINE A.*** Histology of macular atrophy secondary to neovascularization in age-related macular degeneration
9:10 ***CHAKRAVARTHY USHA*** Fibrosis under anti-VEGF therapy in nAMD
9:20 ***SADDA SRINIVAS*** Association between fibrosis and atrophy under longterm anti-VEGF therapy in nAMD
9:30 ***PAULEIKHOFF DANIEL*** Development and characteristics of Macular Atrophy under longterm anti-VEGF therapy in nAMD
9:40 ***INVERNIZZI ALESSANDRO*** Macular atrophy during longterm treatment in nAMD
9:50 Discussion

10.00-10.45 BREAKFAST SYMPOSIUM (EYEPOINT) - EYP-1901: SUSTAINED RELEASE PAN-VEGF RECEPTOR INHIBITOR (TKI) IN DEVELOPMENT

MODERATOR: LOEWENSTEIN ANAT

EyePoint

10:00 ***KUPPERMANN BARUCH*** Drug Delivery technologies and TKI MOA
10:15 ***HOLZ FRANK*** Davio 2 study results
10:35 ***LOEWENSTEIN ANAT*** Phase 3 study design
10:40 Panel discussion: Future of sustained release TKIs in wAMD

10.45-11.30 FREE PAPERS - EPIRETINAL MEMBRANES

CHAIRS: AVCI REMZI, FERRARA MARIANTONIA, FIGUEROA MARTA

10:45 ***GELORMINI FRANCESCO*** Is distance acuity enough to assess epiretinal membrane impact? investigating visual performance and OCT biomarkers in a prospective study
10:48 ***LIPPERA MYRTA*** Does 3D volumetric analysis outperform 2D linear measurements in predicting vision after surgery for epiretinal membranes? exploratory machine learning study.
10:51 ***QUARTA ALBERTO*** Exploring the role of macular pigment optical density in epiretinal membrane recovery
10:54 ***PERILLO CARLO*** Correlation between fundus autofluorescence and choroidal thickness e choroidal vascularity index in eye with epiretinal membrane treated with vitrectomy
10.57 ***SAVASTANO ALFONSO*** Refractive error after combined phaco-vitrectomy:
11:00 ***KHOYRATTY FADIL*** Safety and efficacy of intraoperative steroid use in erm surgery: a systematic review
11:03 ***PELLEGRINI MARCO*** Blue dye-assisted intraoperative optical coherence tomography for macular surgery
11:06 ***CULIERSI CAROLA*** Decreasing outer retina traumatism of ILM peeling in diabetic eyes with foveal sparing technique
11:09 ***STRINGA FRANCESCO*** Ganglion cell layer (gcl) and retinal nerve fiber layer (rnfl) alterations' patterns in macular diseases
11:12 ***LAVIA CARLO ALESSANDRO*** Factors influencing axial length measurement errors in eyes with cataract and epiretinal membranes
11:15 Discussion

FRIDAY 6 DECEMBER

ORSANMICHELE ROOM

11.30-12.45 FREE PAPERS - MACULAR HOLE

CHAIRS: NAWROCKA ZOFIA, PIRCHER MICHAEL, RADICE PAOLO, REIBALDI MICHELE

11:30 ***JIRO KOGO*** Clinical characteristics and surgical outcomes of full-thickness macular hole without focal vitreomacular traction
11:33 ***ADAMO GINEVRA GIOVANNA*** Macular hole surgery and retinal tectonics: the impact of internal limiting membrane peeling size on tangential retinal displacement
11:36 ***RINALDI MICHELE*** Changes in macular pigment optical density after full-thickness macular hole closure using inverted flap technique
11:39 ***NICOLETTI GASPARE ANTONIO*** Can an imperfect peeling in macular tractional syndrome have a good visual result in selected case? our experience.
11:42 ***ALMALIS MAHER*** The impact of internal limiting membrane peeling size on idiopathic macular hole repair
11:45 ***WAHEEB SAAD*** Delayed closure of a full-thickness macular hole following pars plana vitrectomy
11:48 ***YILMAZ EGE*** Macular hole formation secondary to pars plana vitrectomy: multivariate analysis of risk factors, clinical features and visual prognosis
11:51 ***OZCALISKAN SEHNAZ*** Free ILM flep for idiopathic macular hole associated with epiretinal membrane
11:54 ***ONDER TOKUC ECEM*** A novel surgical algorithm for recurrent and refractory macular holes
11:57 ***COLUCCIELLO MICHAEL*** "Reflections" from an apparent diagnosis of macular hole in an eye partially filled with gas after retinal detachment repair
12:00 ***ALTALBISHI ALAA*** Capsule flap as an alternative scaffold in refractory macular hole cases
12:03 ***MUS ERIK*** Temporal arcuate relaxing retinotomy for persistent full-thickness macular holes: our experience
12:06 ***BIANCHI EDUARDO*** Incomplete/failed macular hole (mh) closure after induction of macular detachment technique for the treatment of persistent idiopathic mhs: rescue therapy with a plug of human amniotic membrane(ham).
12:09 ***AKSOY FUNDA EBRU*** Management of recurrent macular holes with human amniotic membrane
12:12 ***IEZZI RAYMOND*** Removable amniotic membrane patching (ramp) for the treatment of complex macular holes
12:15 ***CATANIA FIAMMETTA*** Lamellar macula hole and choriocapillaris impairment: natural course and imaging characteristics in pathologic myopia and pachychoroid pigment epitheliopathy
12:18 ***DE SANTI NICOLA*** Amniotic membrane transplant in a patient with atrophic macular hole
12:21 ***FIORE TITO*** Concomitant induction of macular detachment and amniotic membrane transplant to treat chronic full-thickness macular hole
12:24 ***EHNAIDY ABDELRAOUF*** A double peeling, lhep careful peeling and mebranectomy combined with ILM multi flaps inversion, air tamponade and one-day prone positioning for the treatment of lamellar macular hole
12:27 Discussion

13.45-14.45 NEW CONCEPTS IN THE EVALUATION OF EPIRETINAL MEMBRANES

ORGANIZER AND MODERATOR: SARRAF DAVID
MODERATOR: GOVETTO ANDREA

13:45 ***FOSSATARO FEDERICA*** OCT Prognostic Biomarkers of ERM Outcome
13:55 ***GOVETTO ANDREA*** En Face OCT of the HFL to Assess ERM
14:05 ***FEO ALESSANDRO*** Foveation and EIFL
14:15 ***FOSSATARO CLAUDIA*** Degenerative (LHEP) versus Tractional ERM
14:25 ***CABRAL DIOGO*** Tractional versus Degenerative versus Exudative Fluid
14:35 Discussion

14.45-15.45 RETINAL DEBATES

ORGANIZER AND MODERATOR:
LESNIK-OBERSTEIN SARIT

14:45 **Debate: Early vitrectomy in diabetic retinopathy**
14:45 ***BOSCIA FRANCESCO*** Early vitrectomy in diabetic retinopathy - For
14:55 ***FERRARA MARIANTONIA*** Early vitrectomy in diabetic retinopathy - Against
15:05 Discussion

FRIDAY 6 DECEMBER

ORSANMICHELE ROOM

15:15 **Debate: Encirclement is obsolete**
15:15 *HUSSAIN RUMANA* Encirclement is obsolete - For
15:25 *LORENZI UMBERTO* Encirclement is obsolete - Against
15:35 Discussion

15.45-16.45 SURGICAL TECHNIQUE FOR SUBRETINAL DELIVERY OF GENE THERAPY
ORGANIZER AND CHAIR: DELLA CORTE MICHELE
CHAIRS: FISCHER DOMINIK, MACLAREN ROBERT, WAHEED NADIA

15:45 *STANGA PAULO EDUARDO* Gene Therapy with Transvitreal Subretinal Delivery: pre-op assessment and my surgical technique
15:50 *FISCHER DOMINIK* Vector distribution during ocular gene therapy – surgical and clinical implications
15:55 *BAINBRIDGE JAMES* Gene therapy in infants with AIPL1-associated severe retinal degeneration
16:00 *ROMANO MARIO* Subretinal bleb fluidics
16:05 *STEEL DAVID H.* Parameters affecting bleb morphology during subretinal injections
16:10 *MACLAREN ROBERT* Surgical techniques in retinal gene therapy
16:15 *NAGIEL AARON* Implementing subretinal gene therapy in your practice: Clinic, perioperative, and surgical considerations
16:20 *VAJZOVIC LEJLA* Surgical Pearls and Pitfalls for Subretinal Gene therapy Delivery
16:25 *WAHEED NADIA* Subretinal gene therapy, perils and promise
16:30 Discussion

16.45-18.45 NEAR LIVE SURGERY COURSE
ORGANIZER AND MODERATOR: PERTILE GRAZIA
MODERATOR: GOTZARIDIS STRATOS

16:45 *STANGA PAULO EDUARDO* presenter
16:55 *WOLFENSBERGER THOMAS* presenter
17:05 *SZURMAN PETER* presenter
17:15 *SAVASTANO ALFONSO* presenter
17:25 *GOTZARIDIS STRATOS* presenter
17:35 *BERROCAL AUDINA M.* presenter
17:45 *FIGUEROA MARTA* presenter
17:55 *ROSSI TOMMASO* presenter
18:05 *HEIMANN HEINRICH* presenter
18:15 *BOSCIA FRANCESCO* presenter
18:25 *PERTILE GRAZIA* presenter
18:35 Discussion

PALAZZO VECCHIO ROOM

08.30-10.30 WET LAB - ALCON - GROUP A
TUTOR: LORENZI UGO, AMANTEA CAMILLA

10.45-12.45 WET LAB - ALCON - GROUP B
TUTOR: COLONNA ANDREA, BASILE SIMONA

14.30-16.30 WET LAB - ALCON - GROUP C
TUTOR: BESOZZI GIANLUCA, AMANTEA CAMILLA

16.45-18.45 WET LAB - ALCON - GROUP D
TUTOR: LORENZI UGO, COLONNA ANDREA

MAT-IT-ACP-2024-00006 | November 2024

astellas

Every day of lost vision is one too many

Geographic atrophy affects 5 million people globally.[1]

50%
of patients lose up to 2 lines of vision on BCVA, within 2 years of diagnosis.[2]

44%
require assistance with daily activities.[3]

Astellas has made a **long-term commitment** to people with vision loss: to build a brighter future in which retinal diseases that cause blindness, including **geographic atrophy**, are treatable, and ultimately preventable.

Visit the **Astellas booth** to learn more.



BCVA, Best corrected visual acuity.

[1] Boyer DS, et al. Retina. 2017;37(5):819-835.

[2] Chakravarthy U, et al. Presented at: The Macula Society 46th Annual Meeting; February 15-18, 2023; Miami, FL.

[3] Patel PJ, et al. Clin Ophthalmol. 2020;14:15-28.



Florence
December 5,6,7 and 8, 2024

Fortezza da Basso

FLORetina 2024
ICOOR
12° International Congress on OCT and OCT angiography

FRIDAY 6 DECEMBER

PALAZZO STROZZI ROOM

09.00-10.30 WET LAB - BAUSCH & LOMB - GROUP A
TUTOR: DE CILLA' STEFANO

BAUSCH + LOMB

10.45-12.15 WET LAB - BAUSCH & LOMB - GROUP B
TUTOR: DE CILLA' STEFANO, GUIGOU SEBASTIEN

BAUSCH + LOMB

13.00-14.30 WET LAB - BAUSCH & LOMB - GROUP C
TUTOR: PRIMAVERA VITO

BAUSCH + LOMB

14.45-16.15 WET LAB - BAUSCH & LOMB - GROUP D
TUTOR: LO GIUDICE GIUSEPPE, REJDAK ROBERT

BAUSCH + LOMB

16.30-18.00 WET LAB - BAUSCH & LOMB - GROUP E
TUTOR: CARETTI LUIGI

BAUSCH + LOMB

PALAZZO RUCELLAI ROOM

13.30-15.00 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 1
TUTOR: BAZIN LOIC

BVI

15.15-16.45 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 2
TUTOR: GUIGOU SEBASTIEN

BVI

OPTHEA

Aiming to Elevate the Standard of Care in Wet AMD

SATURDAY 7 DECEMBER

SANTA MARIA NOVELLA ROOM

08.00-12.30 LIVE SURGERY
MODERATORS FROM AUDITORIUM: CHARLES STEVE, D'AMICO DONALD J., ECKARDT CLAUS, GOTZARIDIS STRATOS, MORALES CANTÓN VIRGILIO, PAROLINI BARBARA, RACHITSKAYA ALEKSANDRA, RADICE PAOLO, TOGNETTO DANIELE, VAJZOVIC LEJLA

PATELLI FABIO LIVE SURGERY FROM *ITALY (Pisa)*
MASTROPASQUA RODOLFO LIVE SURGERY FROM *ITALY (Pisa)*
ROMANO MARIO LIVE SURGERY FROM *ITALY (Pisa)*
BARCA FRANCESCO LIVE SURGERY FROM *ITALY (Pisa)*
RIZZO STANISLAO LIVE SURGERY FROM *ITALY (Pisa)*
MARIOTTI CESARE LIVE SURGERY FROM *ITALY (Pisa)*
AL SABTI KHALID LIVE SURGERY FROM *ITALY (Pisa)*
EL RAYES EHAB LIVE SURGERY FROM *ITALY (Pisa)*
DI SIMPLICIO SANDRO LIVE SURGERY FROM *ITALY (Pisa)*
MERCIECA KARL LIVE SURGERY FROM *ITALY (Pisa)*
CHELAZZI PAOLO LIVE SURGERY FROM *ITALY (Rome)*
MURA MARCO LIVE SURGERY FROM *ITALY (Rome)*
FERRARA VINCENZO LIVE SURGERY FROM *ITALY (Rome)*
CAPOROSSI TOMASO LIVE SURGERY FROM *ITALY (Rome)*

12.30-13.15 LUNCH SYMPOSIUM (ROCHE) - CHANGING THE NAMD GAMEPLAN WITH FARICIMAB - DUAL PATHWAY, DRYING AND DURABILITY
CHAIR: SADDA SRINIVAS

12:30 *VERITTI DANIELE* Dual Pathway: The Difference With Dual Pathway Inhibition
12:40 *STANZEL BORIS* Drying: Achieving Disease Control
12:50 *PARRAVANO MARIACRISTINA* Durability: Reducing Treatment Burden
13:00 Discussion
13:10 *SADDA SRINIVAS* Closing Remarks

13.15-14.15 RETINAWS
ORGANIZER: REZAEI KOUROUS

PANEL: AL SABTI KHALID, BOSCIA FRANCESCO, COUTURIER AUDE, FRANKLIN ALAN, GUIGOU SEBASTIEN, HAI LU, PATELLI FABIO, PERTILE GRAZIA, SAIDKASIMOVA SHOHISTA

SAN GIOVANNI ROOM

08.00-09.00 VASCULAR PATHOLOGIES
CHAIRS: GAUDRIC ALAIN, ROSEN RICHARD, SCORCIA VINCENZO

8:00 *ZUR DINAH* Good initial visual acuity in patients with macular edema due to retinal vein occlusion – management and outcomes
8:04 *MIERE ALEXANDRA* Changes in retinal perfusion with aflibercept for central retinal vein occlusion: the two-year prospective observational HERMES study
8:08 *INVERNIZZI ALESSANDRO* The Impact of Cataract Surgery in Patients Receiving Intravitreal Therapy for Retinal Vein Occlusion
8:12 *GAUDRIC ALAIN* Update on acute choroidal ischemia
8:16 *BALČIŪNIENĖ VILMA JŪRATĖ* Peripheral exudative hemorrhagic chorioretinopathy: diagnostic and therapeutic challenges
8:20 *FULDA GRAUE EMILIANO* Peripheral Exudative Hemorrhagic Chorioretinopathy in the Mexican Population
8:24 *SCORCIA VINCENZO* Long term follow-up in macular teleangectasia type 1: 10 years experience

SATURDAY 7 DECEMBER

SAN GIOVANNI ROOM

8:28 ***BAKRI SOPHIE*** J. Update on Mactel clinical trials
8:32 ***WYKOFF CHARLES C.*** Encapsulated Cell Therapy for MacTel Type 2: Implantation and Removal Due to Fibrous Tissue Proliferation
8:36 ***ROSEN RICHARD*** Restoring the Light! - Enhancins Management of Retinal Artery Occlusion with the ROCKET Protocol
8:40 ***RUIZ BILBAO SUSANA*** Clinical Outcomes of a Retinal Stroke Code in the Emergency Department of a Tertiary Care Hospital
8:44 Discussion

09.00-09.45 WET AMD IMAGING 2 - UNDER THE PATRONAGE OF EURETINA

CHAIRS: ETER NICOLE, LOEWENSTEIN ANAT

9:00 ***BAUMAL CAROLINE*** AMD mimickers-tips to diagnosis
9:05 ***CHAKRAVARTHY USHA*** DLS or SIRE or both in predicting progression to neovascular AMD what are their uses
9:10 ***KOROBELNIK JEAN-FRANÇOIS*** OCT and OCTA in AMD: do we need more?
9:15 ***QUERQUES GIUSEPPE*** Reticular pseudodrusen disappearance after development of macular neovascularization
9:20 ***RACHITSKAYA ALEKSANDRA*** Impact of home OCT on Management of nAMD Patients
9:25 ***BANDELLO FRANCESCO*** Quantitative Multimodal Imaging Characterization of Intraretinal Cysts vs Degenerative Pseudocysts in Neovascular Age-Related Macular Degeneration
9:30 Discussion

09.45-10.30 BREAKFAST SYMPOSIUM (BAYER) - INNOVATION IN RETINAL CARE: THE TURNING POINT IS NOW

CHAIR: MIDENA EDOARDO
PANEL: DO DIANA V., GALE RICHARD, KITCHENS JOHN, LANZETTA PAOLO

9:45 Welcome and introductions
9:48 Challenges from the clinic: what do we see in practice?
9:58 A new era with aflibercept 8mg: translating data to real-world practice
10:23 Shifting the curve: latest data with aflibercept 8mg
10:28 Summary and close

10.30-11.30 WET AMD TREATMENT 2

CHAIRS: BROWN DAVID, GALE RICHARD, HEIER JEFFREY S., LOEWENSTEIN ANAT

10:30 ***LOEWENSTEIN ANAT*** Potential of Home OCT guided treatment of nAMD
10:34 ***ZWEIFEL SANDRINE*** Analysis of Aflibercept 8mg Real-World Data in Switzerland
10:38 ***HADZIAHMETOVIC MAJDA*** A Modular Multi-Task and Multi-Modal Deep Learning Framework to Determine Time for Starting Anti-VEGF Intervention for Neovascular Age-Related Macular Degeneration
10:42 ***MUNK MARION*** Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg
10:46 ***GALE RICHARD*** Intraocular pressure outcomes with intravitreal aflibercept 8 mg and 2 mg in patients with neovascular age-related macular degeneration through Week 96 of the PULSAR trial
10:50 ***PEARCE IAN FARWIDE*** UK 12 month experience – Largest Treatment Naïve Real World Dataset of Faricimab for NvAMD /DMO
10:54 ***LANZETTA PAOLO*** Aflibercept 8 mg in AMD. Sustained disease control in the PULSAR study
10:58 ***BRESSLER SUSAN*** Faricimab vs. Aflibercept for Neovascular AMD- Is it a Step Forward?
11:02 ***AWH CARL*** Update on the Port Delivery System for AMD
11:06 ***BROWN DAVID*** Drug clearance variability explains why many patients need more frequent intravitreal injections despite “longer-acting” agents
11:10 ***DE-BOER CHARLES*** Extended drug delivery to the posterior segment
11:14 Discussion

SATURDAY 7 DECEMBER

SAN GIOVANNI ROOM

11.30-12.30 NEW HORIZONS IN RETINAL DIAGNOSIS AND TREATMENTS

CHAIRS: BRUCKER ALEXANDER J., KAISER PETER, LOEWENSTEIN ANAT, RIZZO STANISLAO

11:30 *LEONI SEBA* - Eye on Innovation: Pathway to Transformative Solutions
11:36 *CAMARUDIN ROZINA* - A New Dawn on the Horizon in Vitreoretinal and Phaco Surgery
11:42 *MODY CHRISTOPHER* - Meeting the challenges of the AMD care pathway
11:48 *BESOZZI GIANLUCA* - Multicentric Clinical Trial - Vitreous Bioavailability and Anti-inflammatory Effect of a Nutraceutical Complex on patients affected by retinal pathologies (Vibia Study)
11:54 *CHIARUGI ALBERTO* - Lutein scleral iontophoresis
12:00 *ESPOSITO DAVID* - Targeting Fas Pathway: Approach to Geographic Atrophy
12:06 *DUKER JAY* - The Leader in Sustained Drug Delivery to the Retina
12:12 *LOVE DOUGLAS* - C1q inhibition: Functional and Structural Protection in dry AMD / GA via a Novel Neuroprotective Mechanism
12:18 *FISCHER LAURENT* - Ixo-vec: Addressing the Unmet Needs in wet AMD Treatment
12:24 Discussion

12.30-13.15 INTERMEDIATE AMD

CHAIRS: BAUMAL CAROLINE, DO DIANA V., GISBERT RICHARD, VIOLA FRANCESCO

12:30 *QUERQUES GIUSEPPE* Non-exudative fluid in intermediate age-related macular degeneration
12:34 *MIERE ALEXANDRA* Comparison of Choriocapillaris Perfusion in Intermediate AMD Using SS-OCTA and SD-OCTA
12:38 *KUPPERMANN BARUCH* Emerging pipeline for the treatment of intermediate Dry Age Related Macular Degeneration
12:42 *HUANG SUBER* Neurolongevity and advances in neuroprotective agents in dry AMD. A systematic review of therapies and management of retinal degenerations
12:46 *RINALDI MICHELE* Scleral iontophoresis of lutein: new frontier in the therapy of AMD-A
12:50 *SIVAPRASAD SOBHA* Intermediate AMD: findings from Intercept AMD
12:54 *BORRELLI ENRICO* Photobiomodulation in Intermediate AMD: Results from the LightWave I Multicentric Study
12:58 *DO DIANA V.* Photobiomodulation for Age-Related Macular Degeneration: Update on the LIGHTSITE III Trial
13:02 *GISBERT RICHARD* Photobiomodulation: Effect on Morphology and function in AMD
13:06 Discussion

13.15-14.00 LUNCH SYMPOSIUM (REGENXBIO) - 2017: BACK TO THE FUTURE

REGENXBIO

CHAIRS: BAKRI SOPHIE J., RIZZO STANISLAO, VAJZOVIC LEJLA

13:15 *STANGA PAULO EDUARDO* What We Have Learned 7 Years After the Introduction of Gene Therapy
13:23 *HO ALLEN* Subretinal injection, evolution of a technique: what has changed to make it safer and more effective
13:31 *VAJZOVIC LEJLA* Suprachoroidal Space: Exploring a New Environment
13:39 *BAKRI SOPHIE J.* Should we forget about the dear intravitreal injection?
13:47 Discussion

14.25-14.45 BRUNO LUMBROSO LECTURE LIVE

14:25 Introduction
14:30 *FAWZI AMANI* Using high resolution imaging to study the vasculature in diabetic retinopathy: journeys in pericytes and capillaries

14.45-15.30 GEOGRAPHIC ATROPHY: ANATOMICAL-FUNCTIONAL BIOMARKERS

CHAIRS: CARROLL JOSEPH, CURCIO CHRISTINE A., HOLZ FRANK, RACHITSKAYA ALEKSANDRA

14:45 *LENG THEODORE* Characterization of patients with geographic atrophy in the United States
14:49 *SARRAF DAVID* Drusen Hydration: Precursor to CRORA and GA

SATURDAY 7 DECEMBER

SAN GIOVANNI ROOM

14:53 ***PILOTTO ELISABETTA*** Hyperreflective Retinal Foci in Geographic Atrophy
14:57 ***CICINELLI MARIA VITTORIA*** The discrepancy between visual acuity decline and foveal involvement in Geographic Atrophy
15:01 ***RACHITSKAYA ALEKSANDRA*** The role of Microperimetry in Geographic Atrophy
15:05 ***WAHEED NADIA*** Repeatability and reproducibility of customized microperimetry grid analysis in patients with GA
15:09 ***WOLF SEBASTIAN*** Analysis of macular atrophy using artificial intelligence
15:13 ***KUPPERMANN BARUCH*** New pathways for enriching patient population and defining endpoints in clinical trial designs for Dry Age Related Macular Degeneration
15:17 ***BEGOVIC EMINA*** AMD Masqueraders: Case Examples and Lessons Learned
15:21 Expert Panel Discussion

15.30-16.30 AFTERNOON SYMPOSIUM (OCULAR THERAPEUTIX) - TKIS IN THE FUTURE OF RETINAL DISEASE MANAGEMENT

MODERATOR: LOEWENSTEIN ANAT

Ocular Therapeutix®

15:30 ***LOEWENSTEIN ANAT*** Welcome, Introductions, and Agenda
15:35 ***LOEWENSTEIN ANAT*** Unmet needs in Neovascular Age-Related Macular Degeneration and Diabetic Retinopathy
15:40 ***TUFAIL ADNAN*** What is a Tyrosine Kinase Inhibitor?
15:50 ***KUPPERMANN BARUCH*** Sustained release delivery polymers
15:55 ***VAJZOVIC LEJLA*** AXPAXLI for Treatment of nAMD: US and AUS Phase 1 Data
16:05 ***DHOOT DILSHER*** AXPAXLI for Treatment of DR: HELIOS Study
16:15 ***LANZETTA PAOLO*** AXPAXLI Global Trials: SOL-1 and SOL-R Study
16:25 Panel Discussion

16.30-18.10 DRY AMD: TREATMENT - UNDER THE PATRONAGE OF ASRS

CHAIRS: AWH CARL, FERRONE PHILIP, HASSAN TAREK, VAJZOVIC LEJLA

ASRS American Society of Retina Specialists

16:30 ***PEARCE IAN*** Pegcetacoplan 3yr Extension Trial (GALE) Data and post hoc analysis
16:34 ***SAVASTANO MARIA CRISTINA*** Dry AMD: what to know before starting treatment?
16:38 ***GALE RICHARD*** Simultaneous GA and CNV/MNV: Incidence, Characteristics and Treatments
16:42 ***BAUMAL CAROLINE*** The rationale of complement Inhibition in Geographic atrophy
16:46 ***FERRONE PHILIP*** Latest Developments with Pegcetocoplan in Geographic Atrophy
16:50 ***DA CRUZ LYNDON*** Stem cell transplantation in retinal diseases - further outcomes in RPE transplantation
16:54 ***GISBERT RICHARD*** Why RPE-Transplantation in Geographic Atrophy is problematic?
16:58 ***DI SIMPLICIO SANDRO*** SING IMT Telescopic IOL implantation for end stage GA; myth or reality?
17:02 ***SAVASTANO ALFONSO*** Results of the SICORD study for dry AMD
17:06 ***BARAK ADIEL*** 3D Printed Retinal Grafts: A Regenerative Solution for Geographic Atrophy
17:10 ***KUPPERMANN BARUCH*** Update on Safety and Efficacy of Avacincaptad Pegol for Geographic Atrophy Due to Age Related Macular Degeneration
17:14 Discussion

Panel Discussion

CHAIRS: AWH CARL, BANDELLO FRANCESCO, HOLZ FRANK, WYKOFF CHARLES C.

17:24 ***HOLZ FRANK*** Optical coherence tomography to function (OCT FX) Delphy Study: Global consensus on description and representation of the ellipsoid zone (EZ)in Dry Age-Related Macular Degeneration (AMD)
17:29 ***BASCHIERA FABIO*** BRIDGE: An across industry and academia workstream on clinical endpoints in ophthalmology
17:34 ***AWH CARL, WYKOFF CHARLES C., BANDELLO FRANCESCO, BERNARDINI RENATO, FASSER CHRISTINA*** Panel Discussion: Building newer relatioship European retina specialist and regulatory authorities: a starting point

SATURDAY 7 DECEMBER

SAN GIOVANNI ROOM

18.10-19.00 NON-EXUDATIVE - NON NEOVASCULAR AMD
CHAIRS: QUERQUES GIUSEPPE, SARRAF DAVID, WAHEED NADIA, ZWEIFEL SANDRINE

18:10 *SARRAF DAVID* Clinical Significance of Drusen Distribution and Morphology
18:14 *WAHEED NADIA* Ultrahigh resolution OCT features of normal aging and dry AMD
18:18 *SACCONI RICCARDO* OCT predictors of progression to neovascular vs atrophic AMD
18:22 *ERGINAY ALI* Spontaneous evolution of Non-vascular Pigment Epithelium Detachment (PED)
18:26 *PARRAVANO MARIACRISTINA* Structural Biomarkers Influencing the Lifecycle of Drusenoid Pigment Epithelial Detachments and the Development of Macular Complications
18:30 *SADDA SRINIVAS* Risk factors for progression of acquired vitelliform lesions in AMD
18:34 *CURCIO CHRISTINE A.* Fundus autofluorescence at the beginnings and end-stages of AMD
18:38 *HOLZ FRANK MACUSTAR* Study: Clinical Endpoints and Study Designs for Intermediate AMD Trials
18:42 *ZWEIFEL SANDRINE* Association of subretinal drusenoid deposits/ reticular pseudodrusen with retinal vessel caliber and cardiovascular disease
18:46 *LENGYEL IMRE* Calcified Drusen and atrophy: good correlation between OCT and post-mortem tissue
18:50 Discussion

SANTA CROCE ROOM

14.45-15.45 SURGICAL AMD TREATMENT
CHAIRS: MARIOTTI CESARE, STALMANS PETER, GIANSANTI FABRIZIO

14:45 *GARCÍA-ARUMÍ JOSÉ* Surgical management of submacular hemorrhage
14:50 *MARIOTTI CESARE* Highlighting the importance of sub-retinal Vs intravitreal TPA for macular hemorrhage displacement in neovascular AMD
14:55 *VERITTI DANIELE* Submacular hemorrhage during neovascular age-related macular degeneration: a meta-analysis and meta-regression on the use of tPA and anti-VEGFs
15:00 *RAPIZZI EMILIO* Efficacy and safety of pars plana vitrectomy, subretinal rt-PA and partial air tamponade in the management of macular hemorrhage secondary to age related macular degeneration
15:05 *CHEUNG GEMMY* Anti-VEGF monotherapy vs Anti-VEGF with pneumatic displacement for submacular hemorrhage in nAMD: a case control study
15:10 *STALMANS PETER* First results of robotic subretinal tPA injection to treat submacular hemorrhage
15:15 *GIANSANTI FABRIZIO* Visual outcomes, safety and psycological impact of the new miniature telescope Implant for bilateral advanced AMD
15:20 *LE MER YANNICK* PRIMA system for geographic atrophy: implantation and surgical pearls
15:25 *HOLZ FRANK* Functional outcome of the PRIMA microstimulation system in patients with geographic atrophy due to AMD
15:30 *PATELLI FABIO* Suberetinal hemorrhage in AMD: treatment options
15:35 Discussion

15.45-16.45 MACULAR HOLE: PRIMARY
CHAIRS: LESNONI GUIDO, NAWROCKA ZOFIA, REIBALDI MICHELE, SZURMAN PETER

15:45 *DE SMET MARC* Macular holes - what lies beyond hole size defines outcome
15:49 *TOGNETTO DANIELE* Unveiling the results: a predictive score for postoperative outcomes in macular hole surgery
15:53 *MORALES CANTÓN VIRGILIO* Decision analysis in macular hole surgery
15:57 *REIBALDI MICHELE* Ultrastructural aspects of the inner limiting membrane and correlation with staining pattern in idiopathic macular holes
16:01 *STALMANS PETER* Treatment of vitreomacular traction using an intravitreal gas bubble
16:05 *FIGUEROA MARTA* Vitreous surgery for impending macular holes
16:09 *TABANDEH HOMAYOUN* Distal ILM Flap Techniques for Macular Holes
16:13 *SZURMAN PETER* How to enhance Retinal Survival after macular hole repair?
16:17 *CHANDRA AMAN* Secondary Macular holes: A Multicentre study

SATURDAY 7 DECEMBER

SANTA CROCE ROOM

16:21 *KOSS MICHAEL* Correlation of Function and OCT shapes after macular hole surgery with or without ILM Flap
16:25 *CARETTI LUIGI* OCT-A evaluation of retinal vascular changes following ILM peeling for ERM
16:29 Discussion

16.45-17.45 MACULAR HOLE: REFRACTORY
CHAIRS: CAPOROSSI TOMASO, GOTZARIDIS STRATOS, MAHMOUD TAMER

16:45 *KAISER PETER* Surgery for complicated macular holes
16:50 *MATONTI FREDERIC* Refractory macular holes and lyophilized amniotic membranes: personal experience
16:55 *MEYER CARSTEN H.* Macular Hydrodissection for persisting macular holes: Indication, preparation and outcome
17:00 *CAPOROSSI TOMASO* AM as adjuvant in chronic and large macular hole
17:05 *GARCÍA-ARUMÍ JOSÉ* Inverted flap combined with endoret in difficult macular holes
17:10 *MURA MARCO* Descemet membrane for large refractory macular holes
17:15 *GOTZARIDIS STRATOS* In office management of unclosed or reopened operated macula holes
17:20 *MAHMOUD TAMER* Macular holes global studies: Future directions
17:25 Discussion

17.45-18.45 FIX THAT RETINA BATTLE
ORGANIZERS AND MODERATORS: REZAEI KOUROUS, CHOW DAVID

BERROCAL AUDINA M., FORLINI MATTEO, KITCHENS JOHN Team 1
RACHITSKAYA ALEKSANDRA, MURA MARCO, SZURMAN PETER Team 2
VAJZOVIC LEJLA, BALI ERNESTO, REZENDE FLAVIO Team 3

SAN FREDIANO ROOM

08.15-09.15 UPDATE IN THE DIAGNOSIS OF INTRAOCULAR TUMORS (OCULAR ONCOLOGY DIAGNOSIS)
CHAIRS: HEIMANN HEINRICH, MIDENA EDOARDO

8:15 *AREVALO J. FERNANDO* Swept-source Optical Coherence Tomography and SS-OCT Angiography in eyes with Intraocular Tumors
8:20 *PELAYES DAVID* SS OCT a biomarkers in small pigment choroidal tumors
8:25 *HEIMANN HEINRICH* Clinical presentation of haemorrhagic choroidal melanoma
8:30 *MIDENA GIULIA* The prognostic value of aqueous humor biomarkers in choroidal melanoma
8:35 *PARROZZANI RAFFAELE* Radiation maculopathy: neuroinflammation vs ischemia
8:40 *MISEROCCHI ELISABETTA* Multimodal imaging in vitreoretinal lymphoma
8:45 *NAGIEL AARON* Benign Lobular INL Proliferations (BLIPs): Extended Spectrum of a Novel Intraretinal Tumor
8:50 Discussion

09.15-10.30 OCULAR ONCOLOGY TREATMENT
CHAIRS: BALESTRAZZI EMILIO, HEIMANN HEINRICH, PAGLIARA MONICA

9:15 *DAMATO BERTIL* Is it safe to defer treatment for small choroidal melanoma until growth is seen? (remote)
9:20 *FULDA GRAUE EMILIANO* Partial lamellar sclerouvectomy, consecutive serial cases in Latin American population
9:25 *HEIMANN HEINRICH* Tumour recurrences following surgical endoresection of choroidal melanoma
9:30 *PAGLIARA MONICA, ROSSI ERNESTO* Systemic Therapy for Primary Uveal Melanoma
9:35 *DAMATO BERTIL* Ocular surface side effects and complications of intraocular tumor treatment (remote)
9:40 *AVCI REMZI* Update on endoresection of retinal vasoproliferative tumors complicated with advanced exudative retinal detachment and proliferative vitreoretinopathy
9:45 *GINI GIAMPAOLO* Surgical approach to exudative retinal detachment secondary to retina vascular tumours
9:50 *HEIMANN HEINRICH* Reactivation of choroidal haemangioma following photodynamic therapy treatment
9:55 *NAGIEL AARON* Transcorneal Vitrectomy in Eyes with Regressed Retinoblastoma

SATURDAY 7 DECEMBER

SAN FREDIANO ROOM

10:00 *HADJISTILIANOU DORIS* Intraarterial tandem chemotherapy for bilateral retinoblastoma: decision making and outcome
10:05 Discussion

10.45-11.45 EN FACE OCT: CLINICAL APPLICATION AND PATHOANATOMICAL INSIGHTS
ORGANIZER AND MODERATOR: SARRAF DAVID
MODERATOR: SADDA SRINIVAS

10:45 *FEO ALESSANDRO* En Face OCT of the VitreoRetinal Interface and ILM tears and PIRD
10:55 *SADDA SRINIVAS* En Face OCT and the Evaluation of the Henle Fiber Layer
11:05 *BOUSQUET ELODIE* En Face OCT of PAMM: Systemic Implications
11:15 *VOICHANSKI SHILO* En Face OCT and the Trizonal Distribution of Drusen
11:25 *SARRAF DAVID* En Face OCT and the Analysis of Atrophy in AMD
11:35 Discussion

11.45-12.45 ARTIFICIAL INTELLIGENCE IN RETINA: A TRUSTED DEVELOPMENT OR A SMOKESCREEN
ORGANIZER AND MODERATOR: CHAKRAVARTHY USHA

11:45 Introduction
11:48 *PETO TUNDE* Has AI helped in the screening and diagnosis of DR?
11:56 *PFAU KRISTINA* Is there utility in AI for managing inherited retinal diseases?
12:04 *FERRARA DANIELA* AI-based GA growth prediction
12:12 *CHAKRAVARTHY USHA* Is there value in using AI in the analysis of data from EMR systems
12:20 *GLITTENBERG CARL* The Potential Uses of Generative Artificial Intelligence in Retinal Medicine
12:28 Sum up
12:31 Discussion

12.45-13.45 UNRAVELING BIOMARKERS IN DRY AGE-RELATED MACULAR DEGENERATION
ORGANIZERS: LOEWENSTEIN ANAT, TRIVIZKI OMER

12:45 *TRIVIZKI OMER* Opening Remarks and Overview of Biomarkers in Dry AMD
12:51 *HAGEMAN GREGORY S.* Molecular and Genetic Biomarkers in Dry AMD
12:57 *CHAKRAVARTHY USHA* Functional Biomarkers in Dry AMD
13:03 *SARRAF DAVID* Imaging Biomarkers: Insights from OCT and Beyond
13:09 *FERRARA DANIELA* Clinical and imaging predictors of GA growth
13:15 *GOLDSTEIN MICHAELLA* Case Study: Integrating Biomarkers in Clinical Practice
13:20 *BAUMAL CAROLINE* Case Study: Biomarkers in Action for Geographic Atrophy
13:25 *LOEWENSTEIN ANAT* Summary and Closure Remarks
13:35 Discussion

13.45-14.30 LUNCH SYMPOSIUM (ASTELLAS) - WHAT DOES THE FUTURE HOLD FOR THE MANAGEMENT OF GA?

astellas

13:45 *SADDA SRINIVAS* Welcome and introductions
13:48 *BANDELLO FRANCESCO* Where are we today with the management of GA?
13:58 *SIVAPRASAD SOBHA* How will AI change our management of GA?
14:08 *VAJZOVIC LEJLA* Is change on the horizon in GA management?
14:18 Panel discussion and Q&A
14:28 *SADDA SRINIVAS* Closing remarks

14.30-14.45 BRUNO LUMBROSO LECTURE FROM SAN GIOVANNI ROOM
14:30 *FAWZI AMANI* Using high resolution imaging to study the vasculature in diabetic retinopathy: journeys in pericytes and capillaries

SATURDAY 7 DECEMBER

SAN FREDIANO ROOM

VISION ACADEMY AT FLORETINA 2024 A BRAVE NEW WORLD: THE REAL IMPACT AND IMPLICATIONS OF THE EXTENDED TREATMENT PARADIGM

VISION ACADEMY

14.45-15.45 SESSION 1 - NEW TREATMENT REGIMENS

14:45 *KOROBELNIK JEAN-FRANÇOIS, LOEWENSTEIN ANAT* Welcome and introduction
Roundtable 1
14:50 *WONG DAVID, MUNK MARION, GALE RICHARD* Debate: Treatment regimens
15:00 *GALE RICHARD* Presentation: Extended treatment intervals
15:05 *GALE RICHARD, LOEWENSTEIN ANAT, CARNEIRO ÂNGELA, WONG DAVID, TALKS JAMES, KOROBELNIK JEAN-FRANÇOIS, MUNK MARION, LAM WAI-CHING* Roundtable 1 discussion
Roundtable 2
15:20 *SATIRTAV GUNHAL, LANZETTA PAOLO, KOROBELNIK JEAN-FRANÇOIS* Debate: Discontinuing anti-VEGF treatment in cases of success
15:30 *KOROBELNIK JEAN-FRANÇOIS, PAULEIKHOFF DANIEL, BEHAR COHEN FRANCINE, ŞATIRTAV GÜNHAL, CHATZIRALLI IRINI, LANZETTA PAOLO, ASLAM TARIQ* Roundtable 2 discussion

15.45-16.45 SESSION 2 - FOCUSING ON OUTCOMES

Roundtable 3
15:45 *ZUR DINAH, ZARRANZ-VENTURA JAVIER, ELDEM BORA* Debate: Residual fluid
15:55 *MIDENA EDOARDO* Presentation: Biomarkers of disease activity in AMD and DME
16:05 *MIDENA EDOARDO, ELDEM BORA, VIOLA FRANCESCO, ZUR DINAH, HOLZ FRANK, ZARRANZ-VENTURA JAVIER, KOROBELNIK JEAN-FRANÇOIS, ETER NICOLE* Roundtable 3 discussion
Roundtable 4
16:20 *JAKI MEKJAVIC POLONA* Presentation: IOP
16:25 *BANDELLO FRANCESCO* Presentation: Monitoring of the fellow eye
16:30 *JAKI MEKJAVIC POLONA, MIDENA EDOARDO, SERMET FIGEN, BANDELLO FRANCESCO, TSILIMBARIS MILTIADIS, BALČIŪNIENĖ VILMA JŪRATĖ, MUNK MARION* Roundtable 4 discussion

16.45-17.45 SESSION 3 - FOCUSING ON THE PATIENT: ADHERENCE TO TREATMENT AND MONITORING

Roundtable 5
16:45 *PEARCE IAN* Presentation: Factors affecting patient adherence to treatment
16:55 *PEARCE IAN, LOEWENSTEIN ANAT, ELDEM BORA, WONG DAVID, TALKS JAMES, ASLAM TARIQ, BALČIŪNIENĖ VILMA JŪRATĖ* Roundtable 5 discussion
Roundtable 6
17:15 *LOEWENSTEIN ANAT* Presentation: Remote patient monitoring as a means to secure adherence to treatment
17:25 *LOEWENSTEIN ANAT, VIOLA FRANCESCO, PEARCE IAN, TSILIMBARIS MILTIADIS, GALE RICHARD, WALDSTEIN SEBASTIAN, LAM WAI-CHING* Roundtable 6 discussion
17:40 *LOEWENSTEIN ANAT, KOROBELNIK JEAN-FRANÇOIS* Summary and Close

17.45-18.45 IVEG COURSE: THE PATIENT'S JOURNEY IN THE CHANGING LANDSCAPE OF AMD

INTRAVITREAL EXPERT GROUP

ORGANIZER AND CHAIR: LANZETTA PAOLO
CHAIRS: KUPPERMANN BARUCH, LOEWENSTEIN ANAT

17:45 *GALE RICHARD* Novel pharmacotherapies for wet AMD, from trials to clinical practice
17:53 *CHEUNG GEMMY* Rethinking the treatment regimens
18:01 *KITCHENS JOHN* When a switch is needed: new options and new parameters
18:09 *KUPPERMANN BARUCH* Combining wet AMD and GA treatment
18:17 *LOEWENSTEIN ANAT* Artificial Intelligence and home monitoring
18:25 *LANZETTA PAOLO* The trajectory: challenges and opportunities
18:33 Discussion

SATURDAY 7 DECEMBER

SANTO SPIRITO ROOM

08.00-09.00 THE "GAME" OF GENES

ORGANIZERS: KOSTIC MAJA, MENDOZA CARLOS
CO-DIRECTOR: LEROY BART

8:00 ***KOSTIC MAJA*** Opening Remarks
8:03 ***MENDOZA CARLOS*** Clinical and Molecular Diagnosis of Inherited Retinal Diseases
8:10 ***LEROY BART, KOSTIC MAJA, MENDOZA CARLOS*** The Clue Of Electronegativity
8:25 ***HADZIAHMETOVIC MAJDA, KOSTIC MAJA, LEROY BART, VAJZOVIC LEJLA*** The Phenomenon of Central Vision loss
8:40 ***BERROCAL AUDINA M., HADZIAHMETOVIC MAJDA, MENDOZA CARLOS*** The Throne of Genes
8:55 ***MENDOZA CARLOS*** Closing Remarks

09.00-09.45 INHERITED RETINAL DISEASES IMAGING AND DIAGNOSIS

CHAIRS: DOLLFUS HELENE, HADZIAHMETOVIC MAJDA, KEEGAN DAVID, TESTA FRANCESCO

9:00 ***KOSTIC MAJA*** Visualizing the Unseen: Imaging Modalities for Deeper Insights into Inherited Retinal Diseases
9:04 ***BANDELLO FRANCESCO*** The Superficial Capillary Plexus Perivascular Gliosis in Retinitis Pigmentosa Revealed by Multimodal Retinal Imaging
9:08 ***SIMONELLI FRANCESCA*** Chorioretinal atrophy impact after gene therapy for RPE65-related inherited retinal dystrophy
9:12 ***CARROLL JOSEPH*** Longitudinal assessment of OCT-based measures of foveal cone structure in achromatopsia
9:16 ***FERRONE PHILIP*** Ophthalmologic Presentations of Incontinentia Pigmenti
9:20 ***KEEGAN DAVID*** A phenotypic and genotypic analysis of Bestrophin maculopathy / retinopathy in Irish population
9:24 ***MURRO VITTORIA*** Widefield imaging in PXE related retinopathy
9:28 ***HADZIAHMETOVIC MAJDA*** Risk Factors associated with worsening morphology and visual outcomes in eyes with Adult-Onset Foveomacular Vitelliform Dystrophy
9:32 ***BADAWI ABDULRAHMAN*** Cone dystrophy associated with autoimmune polyglandular syndrome type 1
9:36 Discussion

09.45-10.30 BREAKFAST SYMPOSIUM (JOHNSON&JOHNSON) - INHERITED RETINAL DISEASES – WHERE DO WE STAND?

Johnson&Johnson

CHAIRMAN: IAROSSI GIANCARLO
DISCUSSANT: COLOMBO LEONARDO

9:45 ***IAROSSI GIANCARLO*** Introduction
9:50 ***SIMONELLI FRANCESCA*** IRDs Patient pathway: introduction and focus on X-linked Retinitis Pigmentosa
10:00 ***BANFI SANDRO*** The role of genetic testing – from labs to clinic
10:10 ***PARMEGGIANI FRANCESCO*** The disease burden in XLRP
10:20 ***COLOMBO LEONARDO*** Panel discussion

10.30-11.30 INHERITED RETINAL DISEASES TREATMENTS

CHAIRS: FISCHER DOMINIK, MACLAREN ROBERT, SIMONELLI FRANCESCA

10:30 ***LEO SEO WEI*** Update on inherited retinal disorders
10:34 ***MACLAREN ROBERT*** Gene therapy for X-linked retinitis pigmentosa
10:38 ***PETROU PETROS*** Gene therapy for RPE65
10:42 ***TESTA FRANCESCO*** Cystoid macular edema in Retinitis Pigmentosa: prevalence and association with causative genes
10:46 ***PARMEGGIANI FRANCESCO*** Inflammation in retinitis pigmentosa and translational therapeutic perspectives
10:50 ***SIMONELLI FRANCESCA*** Multicentric longitudinal study in Usher Syndrome IB: disease course and implication for gene therapy
10:54 ***NASSISI MARCO*** Retrospective natural history study of RPGR-related cone- and cone-rod dystrophies
10:58 ***FISCHER DOMINIK*** Impact of subretinal surgery on RPE and other ocular structures

SATURDAY 7 DECEMBER

SANTO SPIRITO ROOM

11:02 ***CAPUTO GEORGES*** Vitrectomy in X-linked retinoschisis
11:06 ***BERROCAL AUDINA M.*** Update on pediatric gene therapy at the Bascom Palmer Eye Institute
11:10 ***CICINELLI MARIA VITTORIA*** Prevalence, features and outcomes of type 1 neovascularization in eyes with angioid streaks
11:14 Discussion

11.30-12.30 INHERITED RETINAL DYSTROPHY: FROM DIAGNOSIS TO THERAPY

ORGANIZER: TESTA FRANCESCO
CHAIR: SIMONELLI FRANCESCA

11:30 ***LEROY BART*** Challenges in clinical diagnosis of inherited retinal dystrophies
11:40 ***DOLLFUS HELENE*** Diagnosis of inherited retinal dystrophies in complex cases: the role of the genetic test
11:50 ***IOVINO CLAUDIO*** Multimodal Imaging in inherited retinal dystrophies
12:00 ***ROSSI SETTIMIO*** Surgical approach for RPE65-related inherited retinal dystrophy in real-life
12:10 ***TESTA FRANCESCO*** Update on Clinical Trials in inherited retinal dystrophies
12:20 Discussion

12.30-13.15 CLINICAL TRIALS IN RETINAL GENE THERAPY

ORGANIZER: MACLAREN ROBERT

12:30 ***FISCHER DOMINIK*** RPE65 gene therapy
12:36 ***MACLAREN ROBERT*** RPGR gene therapy and the Biogen clinical trials
12:42 ***TESTA FRANCESCO*** RPGR gene therapy and the MeiraGTx clinical trials
12:48 ***STANGA PAULO EDUARDO*** RPGR gene therapy and the Beacon clinical trials
12:54 ***ABDALLA MARAM*** Reversal of anatomical degeneration following RPGR gene therapy
13:00 ***LEROY BART*** CEP290 and antisense oligonucleotide gene therapy clinical trials
13:06 Discussion

13.15-14.00 TRANSFORMING RETINAL SURGERY- INTRODUCTION INTO SURGICAL ROBOTICS SYSTEMS: THE FUTURE IS HERE

ORGANIZER AND MODERATOR: BARZELAY AYA
MODERATOR: SCHWARTZ STEVEN D.

13:15 ***SCHWARTZ STEVEN D.*** Introduction to Robotic Surgery in Retinal Surgery
13:25 ***BARZELAY AYA*** Types of Robots for Retinal Surgery
13:32 ***BARZELAY AYA*** Automatic vs Teleoperation
13:39 ***BARAK ADIEL*** New technologies at the OR
13:49 ***BARZELAY AYA*** Designing Trajectories for Surgical Procedures
13:54 ***BARZELAY AYA, SCHWARTZ STEVEN D.*** Clinical Applications and Case Studies, Future Directions and Challenges

14.00-14.45 GLAUCOMA IN VITREORETINAL SURGERY

ORGANIZERS AND CHAIRS: FIGUS MICHELE, MARCHINI GIORGIO

14:00 Introduction
14:02 ***PIERRO LUISA*** New insigths on lamina cribrosa curvature and perfusion in healthy eyes according axial lenght
14:06 ***ROSA NICOLA*** Echography of the optic nerve in glaucoma
14:10 ***GOTZARIDIS STRATOS*** In office management of post glaucoma surgery hypotony
14:14 ***MERCIECA KARL*** Clinical outcomes of the Paul glaucoma implant in patients with refractory glaucoma
14:18 ***SAVASTANO ALFONSO*** Tricks for Baerveldt implant in secondary glaucoma after vitreoretinal surgery
14:22 ***TOGNETTO DANIELE*** Ahmed Glaucoma Valve implant in glaucoma after vitreoretinal surgery
14:26 ***RATNARAJAN GOKULAN*** ECP and its Versatility across the spectrum of Glaucoma Disease: Anterior and Posterior Approaches
14:30 ***BOSCIA FRANCESCO*** XEN implant for glaucoma occurring as complication of pars plana vitrectomy
14:34 Discussion

SATURDAY 7 DECEMBER

SANTO SPIRITO ROOM

14.45-16.00 PRE AND INTRAOPERATIVE IMAGING

CHAIRS: FARALDI FRANCESCO, FRIBERG THOMAS, RIEMANN CHRISTOPHER D.

14:45 ***BROWN DAVID*** Using pre-operative circumpapillary RNFL OCT as a "treasure map" to plan and facilitate PVD creation in vitreoretinal surgery
14:50 ***TOTH CYNTHIA*** Realistic expectations and sensible applications of OCT in retinal surgery now and in the future
14:55 ***FERRARA MARIANTONIA*** Multimodal imaging for detection of SO emulsion and correlation with the ITEMS score
15:00 ***BREAZZANO MARK*** Comparison of ultra-widefield retinal imaging modalities in eyes with vitreous opacities from asteroid hyalosis
15:05 ***RUSSO ANDREA*** Augmented reality in eye surgery
15:10 ***RIEMANN CHRISTOPHER D.*** Intraoperative OCT: Useful Adjunct or Expensive Gimmick
15:15 ***VAJZOVIC LEJLA*** Intraoperative OCT-Guidance During Transvitreal Subretinal Therapy Delivery
15:20 ***COPPOLA MICHELE*** Intraoperative OCT assisted vitrectomy in retinal detachment treatment
15:25 ***MASTROPASQUA RODOLFO*** New visualization systems in VR surgery
15:30 ***MATONTI FREDERIC*** Fluorescent surgery: where do we stand?
15:35 ***DI SIMPLICIO SANDRO*** Can fluoroscopic vitrectomy and intraoperative FFA be a game changer?
15:40 ***EL MAFTOUHI ADIL*** Modern Vitreous Imaging with High depth OCT
15:45 Discussion

16.00-16.45 DIGITAL SURGERY

CHAIRS: CHARLES STEVE, FEKRAT SHARON, KITCHENS JOHN

16:00 ***MASTROPASQUA RODOLFO*** Is head-up surgery just a trend or the future of VR surgeons?
16:04 ***KOSS MICHAEL*** Update on the spectrum of digital microscopes in ophthalmology
16:08 ***NERINCKX FANNY*** Robotic retinal surgery: a first in human study with a robotic telemanipulation system
16:12 ***FEKRAT SHARON*** Selection of a digital visualization system
16:16 ***AL-DIBHI HASSAN*** Vitreoretinal Surgery Ergonomics
16:20 ***BARAK ADIEL*** The Byeonics One Exoscope: A Transformative Tool for Vitreoretinal Surgeries
16:24 ***STALMANS PETER*** Improving your surgical outcome using Zeiss Artevo and Resight
16:28 ***FERRARA VINCENZO*** How Digital Surgery has changed my choices
16:32 ***RIEMANN CHRISTOPHER D.*** Digital Surgery: Barriers to Entry, Tips, Tricks, and Pitfalls
16:36 Discussion

16.45-17.45 OPTIMIZING THE USE OF VITAL DYES IN VITREORETINAL SURGERY

ORGANIZERS AND MODERATORS: FARALDI FRANCESCO, ROMANO MARIO
PANEL: DELL'OMO ROBERTO, SZURMAN PETER, WOLF ARMIN

16:45 ***DELL'OMO ROBERTO*** The importance of vitreous staining: influence of vitreous cortex remnants removal on retinal integrity in eyes with primary rhegmatogenous retinal detachment
16:49 ***FARALDI FRANCESCO*** How to optimize efficacy and safety of vitreous staining
16:53 Round table – Discussion
17:05 ***MAIA ANDRE*** Dyes properties and staining patterns of diseases of vitreoretinal interface
17:09 ***FERRARA MARIANTONIA*** The impact of blue dye formulation on staining efficacy: sinking agents and BBG-derivates
17:13 ***ROMANO MARIO*** Intraoperative coupling of light and vital dyes: surgical implications
17:17 ***SZURMAN PETER*** Update on safety profile of vital dye formulations
17:21 ***MISHEV LUKAN*** Optimizing dye-assisted visualization with digital image filtering
17:25 ***PERTILE GRAZIA*** How to stain highly myopic interface
17:29 Round table – Case Presentation

SATURDAY 7 DECEMBER

SANTO SPIRITO ROOM

17.45-18.45 MASTERING INTRAOPERATIVE OCT FOR VITREORETINAL SURGERIES

ORGANIZER AND MODERATOR: BARAK ADIEL
MODERATOR: SCHWARTZ SHULAMIT

17:45 ***BARAK ADIEL*** Current available surgical microscope integrated OCT: Technology and applications
17:55 ***SCHWARTZ STEVEN D.*** The Future of Intraoperative OCT - Upcoming Technologies and tips for enhanced use
18:05 ***SCHWARTZ SHULAMIT*** The role of intraoperative OCT for vitreoretinal OR in real life setting
18:15 ***MATONTI FREDERIC*** Is intraoperative OCT a game changer?
18:25 Discussion

SAN LORENZO ROOM

08.30-09.30 SYMPOSIUM BY NATIONAL LOW VISION REHABILITATION CENTRE, WHO COLLABORATION CENTER TITLE: "VISION REHABILITATION'S NEW TECHNOLOGIES: IMPACT AND EFFICACY"

ORGANIZERS AND CHAIRS: AMORE FILIPPO, TURCO SIMONA

8:30 Introduction
8:32 ***MARIOTTI SILVIO PAOLO*** Vision Rehabilitation: can technology overcome geographical barriers and deliver in the context of 2030 health agenda
8:40 ***VILLANI GIANFRANCESCO*** Telemedicine and Tele-rehabilitation in Low Vision
8:48 ***KOSS MICHAEL*** Update on Photobiomodulation
8:56 ***SILVESTRI VALERIA*** An innovative approach for people living with visual field defects
9:04 ***DEUTSCH NATHAN*** Lighthouse Tech - a novel smart eyewear device for people living with vision impairment
9:12 ***VIRGILI GIANNI*** The impact of Vision Rehabilitation: Questionnaire's outcomes
9:20 Q&A – Debate

09.30-10.15 FREE PAPERS - UVEITIS 1

CHAIRS: THNG ZHENG XIAN, VANNOZZI LORENZO

9:30 ***PEREZ JIMENEZ YANNY STEFEN*** Macrophages-like cells increase in vivo in active uveitis and respond to anti-inflammatory treatment
9:33 ***CHIOSI FLAVIA*** Idiopathic macular neovascularization under the age of 40 years: progression biomarkers and morphological characterization
9:36 ***LINGARDO STEFANO*** The pitchfork sign: a comparative structural OCT study in patients affected by inflammatory and non-inflammatory choroidal neovascularization
9:39 ***TOMASCHEK LORENZO*** Outcomes of different treatment approaches in post-surgical macular edema
9:42 ***GIANCIPOLI ERMETE*** Twelve-months outcomes and OCT biomarkers of intravitreal dexamethasone implant in pseudophakic eyes with post-vitrectomy cystoid macular edema (pcme), refractory to medical therapy
9:45 ***MIRABELLA GIUSEPPE*** Acute-onset optic disc neovascularization in acute anterior uveitis
9:48 ***INTERLANDI EMANUELA*** Bilateral panuveitis: a challenging case
9:51 ***MITRUT IZABELA*** Scleral windows for uveal effusion syndrome
9:54 ***DAMIANI FRANCESCO*** A rare ocular manifestation of systemic sclerosis.
9:57 ***BARRESI COSTANZA*** Fern-like retinal vasculopathy in intermediate uveitis: pathogenesis, natural history, and clinical implications
10:00 ***FAIA LISA*** 36-month data from the calm registry: a real-world analysis of chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant
10:03 Discussion

SATURDAY 7 DECEMBER

SAN LORENZO ROOM

10.45-11.30 FREE PAPERS - UVEITIS 2
CHAIRS: INTERLANDI EMANUELA, INVERNIZZI ALESSANDRO, MATSUMIYA WATARU

10:45 *BELLETTI MATTEO* Uveitis mystery case: what lies under the BALAD?
10:48 *PATEL ANAMIKA* OCT features of BALAD in ocular toxoplasmosis
10:51 *SALVELLI ANTONIO* Reactivation of ocular toxoplasmosis in immunosuppressed neurosarcoidosis: a case report
10:54 *PATEL ANAMIKA* Focal hyaloid precipitates in ocular tuberculosis
10:57 *SCANDALE PIERLUIGI* The prognostic significance of acute henle fiber layer hyperreflectivity in placoid diseases
11:00 *LUCARELLI FLAVIA* Eyes can be the window of the soul (and ophthalmologists can save lives): late-presenting aids diagnosed after detection of a choroidal granuloma in a patient with disseminated, multifocal involvement
11:03 *IANNETTI LUDOVICO* Long-term functional outcomes following pars plana vitrectomy for retinal detachment due to acute retinal necrosis (arn): a case series.
11:06 *FOUAD YOUSEF* Is ARPE (krill disease) real?
11:09 *GAVRIC ANA URSULA* VZV and covid-19 shining together in the macula
11:12 *RAGUSA EMANUELE* All that glitters is not gold
11:15 *YILDIRIM MURATHAN* Pediatric endophthalmitis: a comprehensive analysis of clinical features, treatment, visual and anatomical outcomes
11:18 *MAUTONE LUCA* Anterior segment optical coherence tomography in eyes with endophthalmitis
11:21 Discussion

12.30-13.15 FREE PAPERS - SURGICAL TECH
CHAIRS: MORALES CANTÓN VIRGILIO, STEEL DAVID H., TORO MARIO

12:30 *GIANNUZZI FEDERICO* Ophthalmic surgical simulator: an effective and safe approach for trainees in vitreo-retinal surgery
12:33 *BRAVETTI GIORGIO ENRICO* "My first 100 vitrectomies": 2-year collaborative learning vitreoretinal fellowship experience in Switzerland
12:36 *HOUSTON STEVE* Live-streaming 3D vitreoretinal surgery to the metaverse
12:39 *PANICO CLAUDIO* Role of technology for minimally invasive eye surgery
12:42 *PARRULLI SALVATORE* Use of a laminar air flow device in a dedicated clean room setting for intravitreal injections
12:45 *TROISI MARIO* Evaluation of two novel riboflavin-based vital dyes for vitreoretinal surgery
12:48 *ALMEIDA DAVID* Near-real surgical specimens (NRSS): discovery and application of surgically-responsive ophthalmological biological tissues
12:51 *KOONG LIN RU* Tranexamic acid used to treat spontaneous post-operative suprachoroidal hemorrhage in a patient on vortioxetine
12:54 *ZAMPOGIANNI ANDRONIKI* Inverted internal limiting membrane flap for management of optic disc pit maculopathy
12:57 *PASTORE MARCO* Epiretinal membrane development after scleral buckling for primary rhegmatogenous retinal detachment
13:00 Discussion

13.15-13.45 FREE PAPERS - PEDIATRIC
CHAIRS: CAMPBELL PETER, LEPORE DOMENICO, LEO SEO WEI

13:15 *LEPORE DOMENICO* Efficacy and safety outcomes from the firefleye next study of children 3 years of age with retinopathy of prematurity (rop) treated with intravitreal aflibercept versus laser in the randomized firefleye study
13:18 *ALNABIHI AHMED* Safety and efficacy of combination therapy with anti–vascular endothelial growth factor and laser for retinopathy of prematurity: a systematic review and meta-analysis
13:21 *ALAMOUDI ANAS* Efficacy and safety of prophylactic agents in prevention of retinopathy of prematurity: a systematic review and meta-analysis of randomized controlled trials

SATURDAY 7 DECEMBER

SAN LORENZO ROOM

13:24 *MANSOUR AHMED* Evaluation of efficacy & outcomes of intra-vitreal ranibizumab injection in the treatment of aggressive posterior retinopathy of prematurity "ap-rop"
13:27 *YOUSSEF ABDELMASSIH* Risk factors for retinal detachment in marfan syndrome after pediatric lens removal
13:30 *K THEJASVIN* Restoring vision in paediatric traumatic submacular haemorrhage: successful visual recovery with submacular tpa injection following chorioretinal rupture
13:33 Discussion

13.45-15.00 PEDIATRIC RETINA
CHAIRS: BERROCAL AUDINA M., CAPUTO GEORGES, FERRONE PHILIP, MOSHFEGHI DARIUS M.

13:45 *PAROLINI BARBARA* The role of widefield imaging in pediatric retina surgery
13:50 *BERROCAL AUDINA M.* Hyaloid removal techniques in pediatric surgical retina
13:55 *CAPUTO GEORGES* Retinal detachment in Marfan's syndrome: prevention and treatment
14:00 *COPPOLA MICHELE* Vitreoretinal Treatment of Paediatric Ocular Trauma: our Experience and Presentation of a Challenging Case
14:05 *TOTH CYNTHIA* Recognize ischemic injury, viral infection and other conditions that can confound retinal diagnosis in newborn and preterm infants
14:10 *LEO SEO WEI* Ophthalmic sequelae of prematurity in adulthood
14:15 *CAPONE ANTONIO* Management of Late-Onset Capsular Fibrosis in Pseudophakic Adults with Pediatric Vasoproliferative Vitreoretinopathy
14:20 *CAMPBELL PETER* Choroidopathy of prematurity
14:25 *MURA MARCO* Pediatric retinal detachment
14:30 *NUCCI PAOLO* Optic nerve in children: a silent revolution
14:35 *HAI LU* Surgical management of pediatric tractional maculopathy in familial exudative vitreoretinopathy
14:40 *HAI LU* Ocular trauma related pediatric retinal detachment
14:45 Panel discussion on retinal detachment

15.00-16.00 FUTURE ROP
ORGANIZER AND MODERATOR: LEPORE DOMENICO
MODERATOR: CAPONE ANTONIO

15:00 *CAMPBELL PETER* Big data strategies for ROP
15:07 *TOTH CYNTHIA* New screening instruments
15:14 *FILIPPI LUCA* Beyond Propranolol: A Novel Strategy to Induce Physiological Retinal Vascularization in the mouse model of ROP
15:21 *NAGIEL AARON* Genetics in ROP
15:28 *NUDLEMAN ERIC* Cellular and molecular mechanism of retinal fibrosis
15:35 *MOSHFEGHI DARIUS M.* Time for new treatment criteria
15:42 Discussion

16.00-17.25 SURGICAL INNOVATIONS
CHAIRS: ECKARDT CLAUS, ROSSI TOMMASO, VAVVAS DEMETRIOS

16:00 *BARAK ADIEL* Advancing In-Office Suprachoroidal Injections: A Novel Device for Targeted Drug Delivery
16:05 *BARCA FRANCESCO* Safety outcomes of 25 and 27-gauge dual blade vitrectomy probe for idiopathic epiretinal membranes
16:10 *DA CRUZ LYNDON* Progress in robotic retinal surgery - novel mechanisms for intra-ocular dexterity
16:15 *PANICO CLAUDIO* Role of technology for minimally invasive eyesurgery
16:20 *RIEMANN CHRISTOPHER D.* Endoscopic PPV: Rationale, Past, Present and Future
16:25 *ROMANO MARIO* Interaction between Lutein-based dyes and light sources used in retinal surgery: risk factors and predictive effects
16:30 *ROSEN RICHARD* Occam's Laser!- A Novel Endolaser Solution for Chandelier Scleral Buckles
16:35 *ROSSI TOMMASO* Collagen Fragments through Vitreous cutters: a study

SATURDAY 7 DECEMBER

SAN LORENZO ROOM

16:40 ***VAVVAS DEMETRIOS*** Complex Vitrectomy in Boston Keratoprosthesis eyes
16:45 ***CEREDA MATTEO GIUSEPP***E Robotic Surgery with OCT distance sensor
16:50 ***COASSIN MARCO*** Single-piece S-plasty for small-incision IOL removal
16:55 ***GUIGOU SEBASTIEN*** Refractory Irvine-Gass syndrome: the suprachoroidal approach
17:00 ***CHARLES STEVE*** Scissors are still needed in diabetic TRDs
17:05 Discussion

17.25-18.45 RETINAL DETACHMENT WITH PVR

CHAIRS: COASSIN MARCO, D'AMICO DONALD J., RIEMANN CHRISTOPHER D., TOGNETTO DANIELE

17:25 ***GARCÍA-ARUMÍ JOSÉ*** Macular PVR
17:30 ***MURA MARCO*** Rhegmatogenous retinal detachment wi try PVR management
17:35 ***SPAIDE RICHARD*** Imaging the Vitreous with OCT
17:40 ***CEREDA MATTEO GIUSEPPE*** What can we learn from peripheral OCT in PVR complicated retinal detachment?
17:45 ***CHANDRA AMAN*** Macular PVR: a histopathological and clinical study
17:50 ***PATELLI FABIO*** Vitrectomy alone versus combined vitrectomy with scleral buckle in patients who underwent retinal detachment surgery
17:55 ***FAYYAD FAISAL*** Surgery for complicated Giant Retinal Tears with PVR
18:00 ***HASSAN TAREK*** Serial Relaxing Retinotomies in the Management of PVR
18:05 ***RIEMANN CHRISTOPHER D.*** Interim Report of the FIXER Trial: Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair
18:10 ***FERRARA VINCENZO*** Reducing PVR beyond chemistry
18:15 ***TOGNETTO DANIELE*** Clinical features and functional results after surgical management of macular PVR
18:20 ***D'AMICO DONALD J.*** Obstacles to Improved Visual Results in Complex Retinal Detachment Surgery
18:25 ***MAHMOUD TAMER*** Surgical approaches to RD-PVR-associated Mac holes
18:30 Discussion

ORSANMICHELE ROOM

08.00-08.45 FREE PAPERS - AMD TREATMENT 1

CHAIRS: MINNELLA ANGELO MARIA, VERITTI DANIELE

8:00 ***NERI GIOVANNI*** Comparison between financial costs of intravitreal anti-VEGF drugs injections in different settings: operating room vs medical office
8:03 ***ANASTASI MARCO*** Socioeconomic barriers to accessing anti-VEGF treatment in patients with AMD, DMO, and RVO
8:06 ***ULLA LORENA*** Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular AMD.
8:09 ***GIANCIPOLI ERMETE*** Five years outcomes and predictors of visual acuity change of a discontinuous anti-VEGF treatment in patients with neovascular-age related macular degeneration (N-AMD).
8:12 ***ABDIN ALAA DIN*** Factors influencing persistence to treatment in patients with retinal diseases undergoing intravitreal injections
8:15 ***ALMAMOORI FAWWAZ*** Non-neovascular subretinal fluid with serous retinal pigment epithelial detachment: (wait or treat)
8:18 ***FERRI ANDREA*** Serous avascular ped secondary to AMD complicated by sub-retinal fluid: the effects of anti-VEGF treatment
8:21 ***LANDE JULIETA*** Effect of photobiomodulation on vision-related quality of life and visual acuity in patients with nonexudative age-related macular degeneration: a real life study.
8:24 ***LATERZA MARIAPIA*** Photobiomodulation therapy in different retinal diseases
8:27 ***KILIC MUFTUOGLU ILKAY*** Vitrectomy for subretinal hemorrhage in neovascular AMD
8:30 ***BOSCIA GIACOMO*** Impact of Diabetes and Diabetic Retinopathy on Neovascular Exudative Age-related Macular Degeneration
8:33 Discussion

SATURDAY 7 DECEMBER

ORSANMICHELE ROOM

08.45-09.45 FREE PAPERS - DIABETIC RETINOPATHY IMAGING

CHAIRS: ARRIGO ALESSANDRO, CHEUNG CAROL, PEARCE IAN

8:45 ***KITCHENS JOHN*** Port delivery system with ranibizumab (pds) for continuous treatment in dme and dr: 2-year data from the phase 3 pagoda and pavilion trials
8:48 ***ARRIGO ALESSANDRO*** Retinal microaneurysms morphology and blood flow network connectivity in diabetic retinopathy as revealed by OCT angiography dense art scans.
8:51 ***KIM KIYOUNG*** Imaging biomarkers as predictors of response to treat-and-extend treatment in diabetic macular edema
8:54 ***ALMEIDA ANA CATARINA*** Can Clarus and Optos UWF images replace the standard 7-fields fundus photographs? comparison between the 3 devices
8:57 ***PINTO INÊS*** The impact of peripheral lesions in the diabetic retinopathy severity level using UWF images
9:00 ***PERILLO CARLO*** Difference visibility of biomarkers in diabetic retinopathy between high resolution and high speed OCT
9:03 ***STULOVA ANNA*** OCTA in detecting preclinical diabetic retinopathy progression: a 5-year prospective study
9:06 ***SHULMAN SHIRI*** Diabetic macular edema: epidemiology and risk factors in a large cohort
9:09 ***TASKIN GIZEM*** Early choroidal changes in eyes with panretinal photocoagulation with pascal and navilas for diabetic retinopathy
9:12 ***DI PARDO CAMILLA*** Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy OCT biomarkers in resolved dme
9:15 ***BELLISARIO GIOVANNI*** Silent but striking: multimodal ultrawidefield imaging in a diabetic patient.
9:18 ***TERMTE ALBA CHIARA*** Impact of anti-VEGF therapy on structural OCT parameters in AMD patients with and without diabetic retinopathy
9:21 ***MUNK MARION*** Effects of diabetic retinopathy on müller cells: a bioinformatics approach for metabolic and functional evaluation
9:24 ***SANTOS TORCATO*** One-year progression of capillary hypoperfusion in nonproliferative diabetic retinopathy: The CHART study
9:27 ***FANTAGUZZI FEDERICO*** Development of vision-threatening complications in diabetic retinopathy: one-year analysis of CHART study
9:30 Discussion

09.45-11.00 FREE PAPERS - DIABETIC RETINOPATHY TREATMENT

CHAIRS: PETO TUNDE, SIVAPRASAD SOBHA, ZWEIFEL SANDRINE

9:45 ***JEE DONGHYUN*** The relationship between blood vitamin a levels and diabetic retinopathy: a population-based study
9:48 ***VERDINA TOMMASO*** Micropulse yellow laser in diabetic macular edema: comparison of two different laser delivery methods with fixed parameters
9:51 ***ALGETHAMI AHMED*** Glycemic control (hba1c) level among patients undergoing surgical treatment for advanced diabetic retinopathy at tertiary referral center
9:54 ***PIGNATARO MARIA GRAZIA*** Long-term impact of diabetic retinopathy on response to anti-VEGF treatment in neovascular AMD
9:57 ***HANDSCHIN TRISTAN MICHAEL*** Intravitreal faricimab in a prospective treat-and-extend regimen study in diabetic macular edema with limited response to aflibercept
10:00 ***KUSUHARA SENTARO*** Six-month outcomes of removing subfoveal massive hard exudates through an intentional hole created temporal to the fovea
10:03 ***WAHEEB SAAD*** Real world experience with Faricimab for DME
10:06 ***CHEUNG NING*** Data-independent acquisition proteomics reveals tear protein alterations associated with anti-VEGF therapy response in diabetic macular edema
10:09 ***MANSOUR AHMED*** Modified in out approach in diabetic tractional retinal detachment
10:12 ***HAMZA SEZGIN*** First results of intravitreal therapy in patients with diabetic macular edema in a real-world study
10:15 ***PEHLIVANOGLU SEREN*** Early efficacy of dexamethasone implant on the biomarkers in patients with diabetic macular edema
10:18 ***SCAMPOLI ALESSANDRA*** Effects of faricimab loading phase on diabetic macular edema in real world setting: an OCT Angiography study

SATURDAY 7 DECEMBER

ORSANMICHELE ROOM

10:21 ***GHULAKHSZIAN AREVIK*** Intravitreal faricimab shows early reduction of hard exudates in diabetic macular oedema.
10:24 ***CORREIA NUNO*** Inflammatory biomarkers as predictors of positive response to fluocinolone acetonide in eyes with DME
10:27 Discussion

11.00-11.45 FREE PAPERS - MYOPIA

CHAIRS: COUTURIER AUDE, PAROLINI BARBARA, RUIZ MORENO JOSÉ MARIA

11:00 ***CARLÀ MATTEO MARIO*** Longitudinal progression of myopic maculopathy in a long-term follow-up: a natural history study of a European cohort
11:03 ***DEL FABBRO SEBASTIANO*** Dome-shaped macula curvature: definition, clinical characteristics and association with non-neovascular subretinal fluid
11:06 ***CARLÀ MATTEO MARIO*** Reading performances in highly myopic patients and correlation with the topography of atrophic maculopathy
11:09 ***VALASTRO ANTONIO*** Pars plana length measurement using AS-OCT in highly myopic eyes: implications for trocar placement
11:12 ***RUIZ MORENO JOSÉ MARIA*** Study design and rationale of poyang: a phase 3 randomised trial of faricimab for choroidal neovascularisation secondary to pathologic myopia
11:15 Disussion

12.00-13.00 FREE PAPERS - PACHYCHOROID

CHAIRS: BEHAR COHEN FRANCINE, LUPIDI MARCO

12:00 ***VALSECCHI NICOLA*** Three-dimensional choroidal vessels assessment in central serous chorioretinopathy
12:03 ***GIOIA MARCO*** The influence of brightness on choroidal vascularity index.
12:06 ***DE LUCA LAURA*** Unveiling the link: predictive value of OCT findings in central serous chorioretinopathy as choroidal thickness, photoreceptor alteration, and psychological correlations
12:09 ***MOSCARA FEDERICO*** OCT-based prediction of neovascularization in pachychoroid spectrum disease
12:12 ***PETRUZZELLA GIOVANNI*** Choriocapillaris flow in two different patterns of exudative type 1 macular neovascularization
12:15 ***CREMONESI PIERLUCA*** Flat irregular pigment epithelium detachments in central serous chorioretinopathy: a choroid insight.
12:18 ***OKUR ÖYKÜ*** Impact of clinical signs and imaging findings in development of bilateral central serous chorioretinopathy and identification of risk factors
12:21 ***BIAGINI FRANCESCO*** Pachychoroid pigment epitheliopathy in keratoconic eyes: prevalence and correlations with corneal, choroidal and scleral abnormalities.
12:24 ***ALOVISI CAMILLA*** Long-term outer retina modifications after micropulse laser treatment in chronic central serous chorioretinopathy
12:27 ***SALVELLI ANTONIO*** Choroidal remodeling after subthreshold micropulse laser in chronic central serous chorioretinopathy: midterm outcomes
12:30 ***BUI PATRICIA*** Long-term effect of photodynamic therapy on choroidal vascularity index versus choroidal thickness as biomarkers for chronic central serous chorioretinopathy
12:33 Discussion

13.00-13.45 FREE PAPERS - AMD IMAGING 1

CHAIRS: CICINELLI MARIA VITTORIA, GALE RICHARD, SCHWARTZ ROY

13:00 ***KIRKOVA RADINA*** OCT-A guided protocol for personalized treatment of neovascular age-related macular degeneration: a proposal
13:03 ***SEMENOVA NATALIYA*** Quantitative comparison of choriocapillaris imaging with different OCT devices
13:06 ***BERNI ALESSANDRO*** Updated guidelines for imaging the choriocapillaris in eyes with age-related macular degeneration using swept-source OCT Angiography

SATURDAY 7 DECEMBER

ORSANMICHELE ROOM

13:09 ***SERRA RITA*** Vascular remodeling of choroidal neovascularization under faricimab therapy for age-related macular degeneration
13:12 ***ARRIGO ALESSANDRO*** Quantitative optical coherence tomography detection of new neovascular branches and association with exudation recurrence in neovascular age-related macular degeneration.
13:15 ***CHISCI ENEA*** Predictive value of SHRM in real-world wAMD patients treated with brolucizumab versus aflibercept
13:18 ***LINGARDO STEFANO*** Extrafoveal hemorrhage simulating central bouquet on structural OCT in type 2 choroidal neovascularization: the extrafoveal cbh sign
13:21 ***DEGIRMENCI MEHMET FATIH KAGAN*** Retinal pigment epithelium elevation values as a marker in determining the anatomical prognosis and treatment regimen of type 2 macular neovascularization
13:24 ***OLIVIERI CHIARA*** Inter-reader and inter-modality variability in macular atrophy quantification in neovascular AMD: comparison of six imaging modalities
13:27 ***RICARDI FEDERICO*** Distinct pathways of macular atrophy in type 3 macular neovascularization associated with AMD
13:30 Discussion

13.45-14.30 LUNCH SYMPOSIUM (ESPANSIONE) - LM® LLLT PHOTOBIOMODULATION (PBM): EYE CARE FRONT AND BACK

espansione group

MODERATOR: BACHERINI DANIELA

13:45 ***GIANNACCARE GIUSEPPE*** Intro to PBM: A Journey From the Front to the Back of the Eye
14:00 ***BORRELLI ENRICO*** dAMD - Preliminary Insights from LightWave I Clinical Trial
14:15 ***DEMIREL SIBEL*** Beyond dAMD: Potential Applications in Other Retinal Diseases

14.30-14.45 BRUNO LUMBROSO LECTURE FROM SAN GIOVANNI ROOM

14:30 ***FAWZI AMANI*** Using high resolution imaging to study the vasculature in diabetic retinopathy: journeys in pericytes and capillaries

14.45-15.45 ULTRAWIDE OPTICAL COHERENCE TOMOGRAPHY - THE NEW FRONTIER

ORGANIZER: SPAIDE RICHARD

14:45 ***SPAIDE RICHARD*** Introduction to Ultrawidefield OCT
14:46 ***ERGINAY ALI*** Ultrawidefield OCTA in Diabetic Retinopathy
14:53 ***ROMANO FRANCESCO*** When You DREAM, what do you DReam abOCTA? Real-life advances in DR with a novel swept-source ultra-widefield device
15:00 ***COUTURIER AUDE*** Role of the vitreous and staphyloma in myopic macular schisis
15:07 ***STANGA PAULO EDUARDO*** Real world benefits of combining ultra widefield single-scan OCT angiography and ultra widefield fundus fluorescein angiography in retinal vasculopathies
15:14 ***SPAIDE RICHARD*** Imaging the vitreous with ultrawidefield OCT
15:21 ***FISHER YALE*** Image Distortion in Ultrawidefield OCT
15:28 ***BACHERINI DANIELA*** Ultrawidefield OCT in Peripheral Retinal Degenerations
15:35 ***CUSUMANO ANDREA*** New insights into Cefuroxime Ocular Toxicity Syndrome
15:39 Discussion

15.45-16.30 AFTERNOON SYMPOSIUM (NIKON) - TECHNOLOGY IN PEDIATRIC OPHTHALMOLOGY AND ONCOLOGY:ULTRAWIDEFIELD MULTIMODAL IMAGING

Nikon

15:45 ***HADJISTILIANOU DORIS*** Retinoblastoma and simulating lesions
15:54 ***BACCI TOMMASO*** Pediatric-retina: miscellaneous
16:03 ***RUBEGNI GIOVANNI*** Paradigmatic cases
16:12 ***LEPORE DOMENICO, AMORELLI GIULIA MARIA*** How Improve follow-up in the premature patients: UWF retinography/angiography
16:21 ***KUMM JOCHE, LEPORE DOMENICO*** Artificial Intelligence and FA in the management of pediatric retinal diseases

SATURDAY 7 DECEMBER

ORSANMICHELE ROOM

16.30-17.30 FUNDUS AUTOFLUORESCENCE IMAGING – A TOOL IN DIAGNOSIS AND DISEASE MONITORING

ORGANIZERS AND MODERATORS: GAL-OR ORLY, LOEWENSTEIN ANAT
MODERATOR: ZUR DINAH

16:30 ***HEIMANN HEINRICH*** Fundus Autofluorescence in intraocular tumors - what shouldn't be missed?
16:37 ***CHEUNG GEMMY*** Fundus Autofluorescence in Pachychoroid disease
16:44 ***ZUR DINAH*** Ultra-wide field Fundus Autofluorescence in monitoring progression of IRD
16:51 ***PICHI FRANCESCO*** The Role of Fundus Autofluorescence in monitoring posterior uveitis disorders
16:58 ***LUPIDI MARCO*** The Role of Fundus Autofluorescence in monitoring AMD patients – lesson learned
17:05 ***PETO TUNDE*** Autofluorescence of the peripheral retina in AMD

17.30-18.45 FREE PAPERS - INHERITED RETINAL DYSTROPHIES

CHAIRS: HUANG SUBER, LEROY BART, SIMONELLI FRANCESCA

17:30 ***SONJA CEKIC*** Optical coherence tomography biomarkers in inherited macular disorders- series of cases
17:33 ***LOMBARDO MARCO*** Cellular analysis of retinal pigment epithelium and photoreceptors by transscleral optical phase imaging in impg2-related inherited retinal dystrophy
17:36 ***AYATA SELIM*** Membrane-type frizzled related protein: a comprehensive analysis of genetic characteristics, phenotypic manifestations and impact on retinal microvasculature
17:39 ***EHRENZELLER CLARA*** Drusen volume as clinical outcome measure in subjects with malattia leventinese
17:42 ***ALTALBISHI ALAA*** Swept-source optical coherence tomography changes and visual acuity among Palestinian retinitis pigmentosa patients: a cross-sectional study
17:45 ***BELLONI BARONI LUCA*** OCT Analysis and macular pigment optical density assessment in patients affected by retinitis pigmentosa
17:48 ***PRÉTOT DOMINIQUE*** Retinal oxygen metabolic function in choroideremia and retinitis pigmentosa
17:51 ***MARTELLA SALVATORE*** Protein mediators in aqueous humor samples of retinitis pigmentosa patients: identification of potential biomarkers.
17:54 ***TOSCANI REBECCA*** Long-term outcomes of anti-VEGF therapy for macular neovascularization in PRPH2-associated retinopathy
17:57 ***CREMONESI PIERLUCA*** Ophthalmic manifestations and natural history of PRPH2 deletion-associated pattern dystrophy: a case series
18:00 ***ANTROPOLI ALESSIO*** Phenotypic and genotypic landscape of rp1l1-associated retinopathy
18:03 ***NUNZIATA ANNAMARIA*** WDR19-associated retinopathy presenting with adult-onset stargardt-like phenotype
18:06 ***ANTROPOLI ALESSIO*** Extensive macular atrophy with pseudodrusen-like appearance (EMAP): progression kinetics and late-stage findings
18:09 ***BIANCO LORENZO*** Full-field electroretinogram in extensive macular atrophy with pseudodrusen-like appearance (EMAP)
18:12 ***PANAGIOTOU EVANGELIA*** Phenotypic variability and evolution of mfsd8-related inherited retinal disease
18:15 ***BALDESI JACOPO*** Shwachman-diamond syndrome and concurrent rod-cone dystrophy: report of two cases and literature review
18:18 ***KIRKOVA RADINA*** Methylentetrahydrofolate reductase c677t mutation and the retinal and optic nerve head structure and function: an OCT-A study
18:21 ***FINOCCHIO LUCIA*** Tissue plasminogen activator-assisted vitrectomy and gas tamponade for submacular hemorrhage due to choroidal neovascularization secondary to angioid streaks: a case report
18:24 ***VOSKRESENSKAYA ANNA*** Dexamethasone intravitreal implant for Muller cell sheen dystrophy treatment. a clinical case.
18:27 Discussion



SATURDAY 7 DECEMBER

PALAZZO VECCHIO ROOM

08.30-10.30 ADVANCED WET LAB - ALCON - GROUP E
TUTOR: ROSSI SETTIMIO, SPINELLO ALFONSO

Alcon

10.45-12.45 ADVANCED WET LAB - ALCON - GROUP F
TUTOR: BORGIOLI VANNI, SCARONI NICOLÒ

Alcon

14.45-16.15 MASTERING YOUR MACHINE - ADVANCED PEARLS ON USING NGENUITY / CONSTELLATION
CHAIRS: CHOW DAVID, FERRARA VINCENZO, MISHEV LUKAN

14:45 *CHOW DAVID* Introduction and Theoretical Overview
15:15 *FERRARA VINCENZO* Practical Applications and Integration
15:45 *MISHEV LUKAN* Innovations and Advanced Techniques
16:15 Q&A Session

PALAZZO STROZZI ROOM

09.00-10.30 WET LAB - BAUSCH & LOMB - GROUP F
TUTOR: LA MANTIA ALBERTO

BAUSCH + LOMB

10.45-12.15 WET LAB - BAUSCH & LOMB - GROUP G
TUTOR:RUSSO ANDREA

BAUSCH + LOMB

13.00-14.30 WET LAB - BAUSCH & LOMB - GROUP H
TUTOR: SCORCIA VINCENZO

BAUSCH + LOMB

14.45-16.15 WET LAB - BAUSCH & LOMB - GROUP I
TUTOR: LO GIUDICE GIUSEPPE

BAUSCH + LOMB

PALAZZO RUCELLAI ROOM

13.30-15.00 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 3
TUTOR: BAZIN LOIC

BVI

15.15-16.45 BVI SURGICAL WET LAB - EXPERIENCE CLINICAL APPLICATIONS OF ENDOSCOPY IN VITREO-RETINA SURGERY - SLOT 4
TUTOR: BAZIN LOIC, GUIGOU SEBASTIEN

BVI



iCare ST500

A new era in slit lamp tonometry



- The world's first slit lamp mounted **rebound tonometer**
- A highly **accurate and reliable** technique
- Enhanced **patient comfort** and ease of use

icare | 20+ YEARS OF INNOVATION

Learn more

icare-world.com

iCare is a trademark of Icare Finland Oy. Icare Finland Oy, Icare USA, Inc., iCare World Australia Pty Ltd, China iCare Medical Technology Co. Ltd and Centervue S.p.A., are parts of Revenio Group and represent the brand iCare. iCare ST500 is a trademark or a registered trademark of Icare Finland Oy in the EU and the USA and/or other countries. Not all products, accessories, services or offers are approved in every market. Approved labelling and instructions may vary from one country to another. This material is intended for healthcare professionals only. © 2024 Icare Finland Oy. All rights reserved.

CE 0598

SUNDAY 8 DECEMBER

SANTA CROCE ROOM

08.30-09.30 MY SURGICAL TECHNIQUE 1: TIPS AND TRICKS IN PARS PLANA VITRECTOMY
CHAIRS: LANZETTA PAOLO, RIZZO STANISLAO, WILLIAMSON TOM

8:30 *WILLIAMSON TOM* Position of the ora serrata and adjustment of trochar positions for vitrectomy surgery
8:34 *ROSSI TOMMASO* A new infusion cannula for vitrectomy: fluid dynamics
8:38 *CARETTI LUIGI* Prospective randomized study comparing 23G and 27G vitrectomy in macular surgery
8:42 *BOSCIA FRANCESCO* Anterior segment-related poor visibility during vitreoretinal surgery
8:46 *DA CRUZ LYNDON* The role of vitreous/retinal and choroidal biopsy in the diagnosis and prognosis of retinal diseases
8:50 *MAVI YILDIZ AYSEGUL* Is temporal inverted ILM flap technique a viable choice for the treatment of macular holes associated with ERM?
8:54 *FERRARA VINCENZO* Does the way we treat the ILM has consequences on the final result? Clinical evidence
8:58 *MEYER CARSTEN H.* Pneumatic vitreous detachment in phacic eyes to treat small full thickness macular holes
9:02 *GINI GIAMPAOLO* Prevention and treatment of macular folds in retina detachment surgery
9:06 *EL RAYES EHAB* Cicatricial macular folds
9:10 Discussion

09.30-10.45 MY SURGICAL TECHNIQUE 2: TIPS AND TRICKS IN PARS PLANA VITRECTOMY
CHAIRS: EL RAYES EHAB, FARALDI FRANCESCO, GINI GIAMPAOLO, PANICO CLAUDIO

9:30 *PATELLI FABIO* Optic Pit maculopathy: surgical treatment
9:34 *FERRARA MARIANTONIA* Surgical approach optic disc pit maculopathy: results from a European multicentric study
9:38 *PETROU PETROS* Optic Disc pit maculopathy management
9:42 *RAPIZZI EMILIO* Minimally invasive approach for the tratement of optic pit maculopathy
9:46 *COPPOLA MICHELE* PFCL free pars plana vitrectomy in primary rhegmatogenous retinal detachment: an updated report
9:50 *REZENDE FLAVIO* Pre-PPV Pneumatic in Primary RD: Indications and Challenges
9:54 *FIORMONTE FABIO* The use of surgical ophthalmic sponge in retinal surgery
9:58 *LORENZI UMBERTO* Human amniotic membrane patches in complex vitreoretinal cases: traumatic eyes with choroidal scars, parapapillary tears, posterior and retracted tears, huge macular holes.
10:02*VAIANO AGOSTINO* Sudden visual loss after vitreoretinal surgery: a case report
10:06 *FORLINI MATTEO* Role of Heavy Silicone Oil as mid term tamponade in Inferior Retinal Detachment: efficacy and safety
10:10 *ROMANO MARIO* Optimizing surgical performance and safety in endoresction of uveal melanoma
10:14 *MURA MARCO* Treatment modalities for retinal capillary hemangioma
10:18 *AL SABTI KHALID* Surgery for Retinal vascular occlusion, a forgotten approach in the era of Anti-VEGF
10:22 *DEVIN FRANCOIS* When scleral buckling is useful or mandatory
10:26 Discussion

10.45-11.45 PROLIFERATIVE VITREORETINOPATHY: SURGICAL MANAGEMENT AND IMPROVED TECHNIQUES
ORGANIZER: GARCÍA-ARUMÍ JOSÉ

10:45 *GRABOWSKA ANNA* Macula in PVR
10:52 *EL RAYES EHAB* Pediatric PVR
10:59 *MURA MARCO* When and how to perform retinotomy
11:06 *WILLIAMSON TOM* Radial retinectomy
11:13 *GARCÍA-ARUMÍ JOSÉ* Tips and tricks in PVR
11:20 *RIZZO STANISLAO* Pharmacological therapy of PVR
11:27 Discussion

SUNDAY 8 DECEMBER

SANTA CROCE ROOM

11.45-13.00 SECONDARY IOL IMPLANTATION

ORGANIZERS: BOSCIA FRANCESCO, LANZETTA PAOLO
CHAIRS: CARLEVALE CARLO, GOTZARIDIS STRATOS

11:45 *BALI ERNESTO* Carlevale lens all said and done? yet an other suturless technique
11:50 *CIARDELLA ANTONIO* "Sutureless trans-scleral Carlevale IOL fixation. A consecutive case series, indications, complications
and functional results"
11:55 *FORLINI MATTEO* Limited anterior vitrectomy versus complete pars plana vitrectomy combined with secondary IOL implantation
12:00 *GARCÍA-ARUMÍ JOSÉ* How to solve the complications with Carlevale lenses
12:05 *GOTZARIDIS STRATOS* My most common complications with Carlevale lens
12:10 *PETROU PETROS* Scleral fixation IOLs: from salvation to premium IOL surgery
12:15 *PILERI MARCO ANDREA* How to spare endothelial cells loss in replacement of luxated IOL: my personal surgical technique
12:20 *BOSCIA FRANCESCO* Yamane IOL implantation: indications and tip & tricks
12:25 *LANZETTA PAOLO* Mini-invasive Carlevale IOL implantation: let's make it easy, fast and elegant
12:30 *SZURMAN PETER* Iris fixated IOLs – Pros and Cons for secondary implantation?
12:35 *VAIANO AGOSTINO* DMEK & FIL SSF IOL implantation: leak test & iris diaphragm reconstruction in vitrectomized eye
12:40 *VENTRE LUCA* SFIOL: which is the best choice?
12:45 Discussion

SAN FREDIANO ROOM

08.30-09.30 FONDAZIONE ITALIANA MACULA INTERNATIONAL CSCR COURSE

ORGANIZERS: BOUSQUET ELODIE, LUPIDI MARCO
PRESIDENTS: BEHAR COHEN FRANCINE, CARDILLO PICCOLINO FELICE, MARIOTTI CESARE

8:30 *CARDILLO PICCOLINO FELICE* Introduction
8:35 *LUPIDI MARCO* The hemodynamic theory in CSCR
8:40 *SARRAF DAVID* CSCR mechanisms of SRD appearance and persistence?
8:45 *MREJEN SARAH* The role of choroidal vein anomalies in CSCR
8:50 *BEHAR COHEN FRANCINE* Is there a choroidal neuropathy in CSCR?
8:55 *BOUSQUET ELODIE* Mid and late phase ICGA: what does it tell us on CSCR pathogenesis
9:00 *EANDI CHIARA* Conventional and novel classifications for CSCR
9:05 *NICOLÓ MASSIMO, FORTE PAOLO* Clinical management of CSCR: a comprehensive approach
9:10 *YZER SUZANNE* Alternative treatments to PDT: myth or reality
9:15 Discussion
9:25 *BEHAR COHEN FRANCINE, MARIOTTI CESARE* Closing remarks

09.30-10.30 PROGRESSION FROM INTERMEDIATE TO ADVANCED AMD: NOVEL IMAGING INSIGHTS AND TREATMENT

ORGANIZER AND CHAIR: QUERQUES GIUSEPPE
CHAIRS: PARRAVANO MARIACRISTINA, SACCONI RICCARDO

9:30 *QUERQUES GIUSEPPE* Introduction
9:35 *SARRAF DAVID* Trizone distribution of reticular pseudodrusen and drusen
9:40 *TUFAIL ADNAN* Biomarkers of progression to nAMD vs GA
9:45 *PARRAVANO MARIACRISTINA* High-risk lesions for exudative AMD
9:50 Discussion
10:00 *FRAGIOTTA SERENA* Phenotypic Characterization of GA Predictors of Development and Progression
10:05 *SACCONI RICCARDO PASCAL* clinical trial for reticular pseudodrusen
10:10 *ZWEIFEL SANDRINE* New treatments in iAMD: state-of-the-art
10:15 Discussion

SUNDAY 8 DECEMBER

SAN FREDIANO ROOM

10.30-11.30 RETICULAR PSEUDODRUSEN (RPD)
ORGANIZER AND CHAIR: TUFAIL ADNAN
CHAIR: ZWEIFEL SANDRINE

10:30 *ZWEIFEL SANDRINE* Clinical grading systems for RPD
10:40 *QUERQUES GIUSEPPE* RPD & AMD clinical implication
10:50 *TUFAIL ADNAN* Non-AMD associations of RPD
11:00 *SCHWARTZ ROY* Systemic considerations of RPD
11:10 *ROMANO FRANCESCO* EMAP and RPD
11:20 Discussion

11.30-12.30 YORIS BREAKING NEWS: FOCUS ON GEOGRAPHIC ATROPHY - UNCONDITIONAL SUPPORT OF APELLIS
CHAIRS: BACHERINI DANIELA, BORRELLI ENRICO, LUPIDI MARCO, MASTROPASQUA RODOLFO

11:30 *OLIVIERI CHIARA* Macular atrophy in neovascular AMD: reasons why it should be considered separately from GA
11:36 *QUEZADA RUIZ CARLOS* AI predicting outcomes in AMD
11:42 *MALTSEV DMITRII* OCT based techniques on measuring RPE damage
11:48 *BERNI ALESSANDRO* SS-OCTA imaging of High-Risk OCT biomarkers that predict disease progression in intermediate AMD
11:54 *BREAZZANO MARK* Mystery case of geographic atrophy
12:00 *NASSISI MARCO* Differential Diagnosis of atrophic maculopathies
12:06 *SACCONI RICCARDO* Characterization of neovessels in geographic atrophy
12:12 Discussion

12.30-13.15 ADVANCED IMAGING OF DIABETIC RETINOPATHY
CHAIRS: KEEGAN DAVID, MIDENA EDOARDO

12:30 *DEMIREL SIBEL* The role of inflammation in the pathogenesis of diabetic macular edema: Comparison of aqueous flare intensity, aqueous cytokine levels and imaging findings
12:35 *MIDENA EDOARDO* Hyperreflective retinal foci: a family with many members
12:40 *ERSÖZ GIRAY* Deterioration Patterns of Outer Retinal Layers in Diabetic Serous Macular Detachment
12:45 *KEEGAN DAVID* Impact of New Pregnancy Pathway in Diabetic RetinaScreen. A qualitative and quantitative analysis
12:50 *CHISCI ENEA* Teleretina screening for diabetic retinopathy
12:55 *TUFAIL ADNAN* Equity of AI algorithms to detect DR retinopathy: Results of head to head study of AI algorithms for Detecting Diabetic retinopathy
13:00 Discussion

SANTO SPIRITO ROOM

08.00-09.30 BASIC COURSE IN SURGICAL FUNDAMENTALS FROM YOUNG TO YOUNG
PRESIDENTS: RAPIZZI EMILIO, PERTILE GRAZIA
EXPERT CONVENOR: SAVASTANO ALFONSO
YOUNG CONVENOR: BAROSCO GUIDO

8:00 *MEYER CARSTEN H.* **Post-operative position**
8:00 *GABAI ANDREA* Face down
8:04 *SCAMPOLI ALESSANDRA* Tamponade the break
8:08 Discussion
8:12 *CLAES CARL* **How radical radical should be in shaving the base?**
8:12 *VAN DEN HEURCK JONAS* Very
8:16 *ANASTASI MARCO* Little, just enough to release tractions from the break
8:20 Discussion
8:24 **Management of subretinal fluid: should I eliminate all suberetinal fluid?**
8:24 *DI LEO LAURA* Yes, to achieve a dry retina

SUNDAY 8 DECEMBER

SANTO SPIRITO ROOM

8:28 ***PASTORE MARCO*** No, I can tolerate some subretinal fluid
8:32 Discussion
8:36 ***VAN OVERDAM KOEN*** **PFCL in detachment surgery: is it always necessary?**
8:36 ***RODELLA ANNA*** Yes, how to avoid subretinal PFCL
8:40 ***DANESE CARLA*** No, how to deal with a detached retina without PFCL
8:44 Discussion
8:48 ***EHRLICH RITA*** **Retinopexy: cryo or laser?**
8:48 ***KESHET YARIV*** Cryo. Under air or under PFCL?
8:52 ***MASARWA DUA*** Laser. Under air or under PFCL?
8:56 Discussion
9:00 ***GUIGOU SEBASTIEN*** **Buckle and Vitrectomy**
9:00 ***LORENZI UMBERTO*** Necessary in extreme cases of PVR
9:04 ***BAROSCO GUIDO*** NOT Necessary: New Endotamponades are very performant!
9:08 Discussion
9:12 ***KEEGAN DAVID*** **Diabetic hemovitreous and tractional / regamtogenous retinal detachment**
9:12 ***O'TUAMA BRIAN*** Anti VEGF before always
9:16 ***McGRATH ROBERT*** Attach the retina before and then we will see
9:20 Discussion
9:24 Closing Remarks

09.30-10.30 LAMELLAR MACULAR HOLE

CHAIRS: AVCI REMZI, FIGUEROA MARTA, GOVETTO ANDREA, NAWROCKA ZOFIA, ROSSI TOMMASO

9:30 ***DELL'OMO ROBERTO*** Natural history and surgical outcomes of lamellar macular hole
9:35 ***GOVETTO ANDREA*** Surgical approach in degenerative lamellar macular hole: do we really need endotamponade?
9:40 ***AVCI REMZI*** LHEP embedding surgery combined with single layer inverted ILM flab technique in lameller macular hole treatment
9:45 ***FIGUEROA MARTA*** Plasma Rich in Growth Factors (PRGF) for lamellar macular holes
9:50 ***PAROLINI BARBARA*** Results of surgery for degenerative lamellar macular holes
9:55 ***COUTURIER AUDE*** Outcomes of vitrectomy for lamellar macular hole
10:00 Debate: What is the Best Surgical Technique for Lamellar Macular Hole?

10.30-11.30 REVISITING OLD TECHNIQUES IN RETINAL SURGERY

ORGANIZER: EHRLICH RITA

10:30 ***NAWROCKA ZOFIA*** Subretinal BSS in treatment of diabetic macular edema
10:40 Discussion
10:45 ***SAIDKASIMOVA SHOHISTA*** Temporary suprachoroidal buckle in treatment of retinal detachment
10:55 Discussion
11:00 ***EHRLICH RITA*** Treating PVR cases under silicone oil without removing or exchanging oil
11:10 Discussion
11:15 ***BARAK ADIEL*** Use of chandelier in buckle surgery
11:25 Discussion

11.30-12.30 HOW TO DEAL WITH MACULAR EDEMA IN SURGICAL RETINAL PATHOLOGY: CLINICAL INSIGHTS AND MANAGEMENT

ORGANIZER AND MODERATOR: GOVETTO ANDREA
MODERATOR: ROMANO MARIO

11:30 ***GOVETTO ANDREA*** Microcystoid macular edema in epiretinal membrane: not a retrograde maculopathy
11:36 Discussion

SUNDAY 8 DECEMBER

SANTO SPIRITO ROOM

11:40 ***FRANCONE ANIBAL*** Is idiopathic ERM an inflammatory disease?The role of fluorescein angiography
11:46 Discussion
11:50 ***COUTURIER AUDE*** Epiretinal membrane-foveoschisis: pathophysiology and prognosis
11:56 Discussion
12:00 ***DEMIREL SIBEL*** Irvine-Gass after macular surgery: evaluation and management
12:06 Discussion
12:10 ***GOVETTO ANDREA*** Macular edema after lamellar macular hole surgical repair with the embedding technique: is epiretinal proliferation pro-inflammatory?
12:16 Discussion
12:20 ***FERRARA MARIANTONIA*** Macular edema in Silicone-Oil filled eyes: pathophysiology and management
12:26 Discussion

SAN LORENZO ROOM

08.30-09.30 EXPLORING THE LIMITS AND POTENTIAL OF OCT ANGIOGRAPHY IN RETINAL PATHOLOGIES: AN INSTRUCTIONAL IMAGING COURSE

ORGANIZER AND CHAIR: VIGGIANO PASQUALE
CHAIRS: BACHERINI DANIELA, BORRELLI ENRICO, MASTROPASQUA RODOLFO

8:30 ***BACHERINI DANIELA, MASTROPASQUA RODOLFO*** Introduction
8:40 ***BORRELLI ENRICO*** OCTA: really so useful in evaluating macular neovascularization secondary to AMD?
8:48 ***VIGGIANO PASQUALE*** Pachychoroid spectrum disease: primary or secondary role of the OCTA?
8:56 ***DEMIREL SIBEL*** Diabetic retinopathy: pay attention to the OCTA limits
9:04 ***ARRIGO ALESSANDRO*** OCTA in retinal vascular occlusion
9:12 ***BACHERINI DANIELA*** OCTA and vitreoretinal surgery
9:20 Discussion

09.30-10.30 COURSE OF CLINICAL RETINAL CASES. WOM-MYSTERY

ORGANIZERS AND MODERATORS: PECE ALFREDO, FOSSATARO FEDERICA
MODERATORS: SARRAF DAVID

9:30 ***FORLINI MATTEO*** Mystery case 1
9:37 ***FOSSATARO CLAUDIA*** Mystery case 2
9:44 ***FEO ALESSANDRO*** Mystery case 3
9:51 ***FOUAD YOUSEF*** Mystery case 4
9:58 ***RAMTOHUL PRITHVI*** Mystery case 5
10:05 ***ROMERO-MORALES VERONICA*** Mystery case 6
10:12 ***POPOVIC MARKO*** Mystery case 7
10:19 Discussion

10.30-12.00 RESIDENT'S COURSE 2 (SOU COURSE)

CHAIRS: MASTROPASQUA LEONARDO, BANDELLO FRANCESCO

10:30 ***IORIO SILVIA*** An Atypical Retinal Artery Occlusion
10:33 Discussion
10:34 ***KACERIK MIRKO*** tbd
10:37 Discussion
10:38 ***LAI ROBERTA*** Ocular Toxoplasmosis Phenotype in an IgM negative and IgG positive case
10:41 Discussion
10:42 ***LOMBARDO MARCO*** Real-World Use of Off-Label MVASI in the Treatment of Patients with Neovascular AMD and DME
10:45 Discussion
10:46 ***LOZZA FILIPPO*** Multimodal imaging in silicone oil-associated keratopathy
10:49 Discussion

SUNDAY 8 DECEMBER

SAN LORENZO ROOM

10:50 ***MARTINO DOMENICO*** Mystery Case
10:53 Discussion
10:54 ***MENZIO SARA*** A complex retinal case
10:57 Discussion
10:58 ***NUNZIATA ANNAMARIA*** WDR19-associated retinopathy presenting with adult-onset Stargardt-like phenotype
11:01 Discussion
11:02 ***PASSAMONTI MARZIA*** Beneath the Surface: a retinal mystery case
11:05 Discussion
11:06 ***PELLICANÒ ELENA*** A dip into the retina
11:09 Discussion
11:10 ***PIGNATARO MARIA GRAZIA*** tbd
11:13 Discussion
11:14 ***QUISISANA CHIARA*** Retinal and systemic manifestations in autosomal dominant KIF-11 retinopathy: report of two cases and literature review
11:17 Discussion
11:18 ***RAPINO GIUSEPPE*** Multimodal imaging of eyes treated with pneumatic retinopexy for rhegmatogenous retinal detachment
11:21 Discussion
11:22 ***RIZZO CLARA*** Dark Choroid in Best Vitelliform Macular Dystrophy associated with Bilateral Serous Macular Detachment
11:25 Discussion
11:26 ***ROSOLIA ANDREA*** Management of an accidental dexamethasone implant into the lens
11:29 Discussion
11:30 ***SEMERIO SILVIO*** An unexpected case of sudden visual loss
11:33 Discussion
11:34 ***SENESE IVANA*** Different shades of gray
11:37 Discussion
11:38 ***SERENI NICOLA*** Retinal neurovascular changes following COVID19 infection: a population OCTA study
11:41 Discussion
11:42 ***TANDA GIACOMO*** Central retinal vein occlusion and acute retinal necrosis caused by VZV in an immunocompetent patient
11:45 Discussion
11:46 Final Discussion

ORSANMICHELE ROOM

08.30-09.30 FREE PAPERS - VIDEO SESSION 1
CHAIRS: DI SIMPLICIO SANDRO, FORLINI MATTEO, HUSSAIN RUMANA

8:30 ***ALFOQAHAA MOUSA*** Iofbs- 4 ways
8:33 ***YASSINE MALEK*** Bimanual extraction of subretinal metallic foreign body with focal chorioretinectomy
8:36 ***BLATSIOS GEORGIOS*** Amniotic membrane transplantation for large traumatic choroidal rupture
8:39 ***TEIXEIRA CARLA*** Fluocinolone implant scleral fixation after anterior chamber migration
8:42 ***BENCHEKROUN BELABBES SAAD*** Combined phacoemulsification, vitrectomy, and scleral indentation for choroidal and retinal detachment: a surgical case
8:45 ***DOTAN ASSAF*** 5cm nail perforation
8:48 ***SANTORO MICHELE*** Combined surgery: temporary keratoprosthesis, PPV for retinal detachment, yamane technique for IOL implantation and full thickness corneal transplant
8:51 ***THIBAUD GARCIN*** An endogenous endophthalmitis with abscess of capsular bag
8:54 ***KILIAN RAPHAEL*** Glued IOL and sft-pupilloplasty: a beginner´s guide
8:57 ***POPESCU STELLA IOANA*** Complex association.pseudoexfoliative glaucoma and subluxated iol.surgical solution
9:00 ***ALSAWIDI KHALIFA*** Wending path
9:03 ***ABOUELSAAD MOHAMMAD*** A pvr case

SUNDAY 8 DECEMBER

ORSANMICHELE ROOM

9:06 ***ASSINE MALEK*** Surgical management of proliferative vitreo retinopathy : tips and tricks
9:09 Discussion

09.30-10.30 FREE PAPERS - VIDEO SESSION 2

CHAIRS: SCUPOLA ANDREA, TOSI GIAN MARCO

9:30 ***ABOUELSAAD MOHAMMED REFAAT*** An old giant tear
9:33 ***BRAVETTI GIORGIO ENRICO*** Errare humanum est… complex traumatic eye injury: management and complications
9:36 ***MOHAMMAD ASHRAF MAHROUS*** Transretinal drainage of suprachoroidal fluid
9:39 ***LA MANTIA ALBERTO*** Rhegmatogenous retinal detachment with choroidals in a monocular patient: is early intervention the best option?
9:42 ***BESOZZI GIANLUCA*** Autologous retinal transplant for a refractory macular hole
9:45 ***KAMAL BOUCHERMA*** Scleral plug for optic pit maculopathy without ILM peeling
9:48 ***DOTAN ASSAF*** 25g PPV for coloboma associated retinal detachment
9:51 ***ALFOQAHAA MOUSA*** Sub-ILM hemorrhage
9:54 ***DOTAN ASSAF*** 25g PPV intraoperative OCT guided sub-ILM hemorrhage ILM peel
9:57 ***DOTAN ASSAF*** 25g PPV intraoperative OCT guided subretinal tpa injection in smh
10:00 ***HABIB AHMED*** Management of macular fold after diabetic membranes removal
10:03 ***HABIB AHMED*** What i learned from intraoperative fluorescein angiography
10:06 Discussion

10.30-11.30 FREE PAPERS - AMD TREATMENT 2

CHAIRS: BOSCIA FRANCESCO, BREAZZANO MARK

10:30 ***PAPAYANNIS ALESSANDRO*** Standardized multidrug treat and extend protocol for neovascular age-related macular degeneration: a pharmacoeconomic perspective
10:33 ***BERETTA FEDERICO*** Two-years real-life experience of a tertiary center with intravitreal brolucizumab switch for treatment of exudative neovascular age-related macular degeneration
10:36 ***FURINO CLAUDIO*** Brolucizumab in pigment epithelium detachment secondary to AMD
10:39 ***DE SANTI NICOLA*** 56-week results from the TALON open-label extension, a phase IIIb/IV study of brolucizumab in a treat-and-extend regimen with maximum treatment intervals up to 20 weeks in patients with neovascular age-related macular degeneration
10:42 ***FORMENTI FEDERICO*** Efficacy and durability of faricimab in naïve eyes with neovascular age-related macular degeneration
10:45 ***LA SPINA CARLO*** Real-world use of faricimab for patients with neovascular age-related macular degeneration
10:48 ***AMBRESIN AUDE*** Pigment epithelial detachment as long-term predictors of functional and anatomical outcomes of intravitreal faricimab injections in naïve patients with neovascular age-related macular
10:51 ***ARRIGO ALESSANDRO*** Treat-and-extend 2.0: a modified treatment planning to improve real-life feasibility maintaining close fluids control with faricimab.
10:54 ***CARREIRA PEDRO*** Effect of high-dose intravitreal aflibercept in patients with NAMD: comparison of real-world outcomes with pharmacokinetic model
10:57 ***BAILEY CLARE*** Real-world effectiveness and safety of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema: design of the spectrum study
11:00 ***DE SALVO GABRIELLA*** Vision and anatomical outcomes following a loading dose of four intravitreal aflibercept or faricimab in naïve exudative age-related macular degeneration.
11:03 ***MAGLIOZZI PATRIZIO*** Subretinal injection of recombinant tissue plasminogen activator and gas tamponade to displace acute submacular haemorrhages secondary to age-related macular degeneration
11:06 ***DYSLI CHANTAL*** High resolution optical coherence tomography reveals details of regeneration after selective retina therapy
11:09 ***LOEWENSTEIN ANAT*** EYP-1901 (vorolanib intravitreal insert) versus aflibercept for previously-treated wet age-related macular degeneration: DAVIO 2 phase 2 1-year results
11:12 Discussion

TowardPi

FLOretina ICOOR 2024

Florence,
December 5, 6, 7 and 8, 2024
Fortezza da Basso

TowardPi Breakfast Symposium

400kHz officially comes, application of CE cleared TowardPi OCT

December 6th, 7:00am-8:00am Room Santo Spirito

UWF-OCTA acquired in 7-15 secs, up to 200°+, 10 billion voxel data, Choroid OCTA, Anterior Segment OCTA, 3D OCTA, laser spot detection, dynamic vitreous, 3D-CVI, retina curvature, comprehensive quantifications...

400kHz full range SS-OCTA officially comes to Europe! See how 400kHz speed OCTA changes the routine of practice. Towardpi invites you to attend our breakfast symposium, find the new clinical experience shared by prestigious users.

▶ Guests



Prof. Tommaso Rossi
Ophthalmology IRCCS Fondazione Bietti, Roma, Italy



Dr. Ali Erginay
Lariboisière Hospital, Paris, France



Dr. Andrea Govetto
Humanitas Gavazzeni and Castelli, Humanitas University, Bergamo, Italy



Dr. Belkacem Haouchine
Centre d'exploration de la Vision Rueil & Paris



Dr. Jian Zhou
TowardPi Medical

▶ Agenda

7:00 - 7:05	Introduction	
7:05 - 7:15	400kHz OCT/OCTA retinal displacement: a new diagnostic opportunity?	Prof. Tommaso Rossi
7:15 - 7:25	UWF OCT/OCTA for retina pathologies	Dr. Ali Erginay
7:25 - 7:35	The visualization of the peripheral vitreous: a game changer	Dr. Andrea Govetto
7:35 - 7:45	Avantages of Yalkaid swept source OCT in clinical practice	Dr. Belkacem Haouchine
7:45 - 7:55	What makes TowardPi different	Dr. Jian Zhou
7:55 - 8:00	Q&A	

Keep updated to the latest OCT technology. See you on Friday morning.

SUNDAY 8 DECEMBER

ORSANMICHELE ROOM

11.30-12.00 FREE PAPERS - OCULOMICS

CHAIRS: CRINCOLI EMANUELE, ZWEIFEL SANDRINE

11:30 ***VALMAGGIA PHILIPPE*** Eye and heart synchronisation: time-resolved dynamic optical coherence tomography with electrocardiographic coupling
11:33 ***YEO VANESSA*** The eye as a window to cardiovascular disease: a small case series and literature review of retinal ischaemic perivascular lesion (RIPL)
11:36 ***ABDIN ALAA DIN*** Cardio-ocular syndrome: retinal microvascular changes in acutely decompensated heart failure
11:39 ***DE LUCA MARTINA*** The correlation between retinal and choroidal thickness with age-related white matter hyperintensities in progressive supranuclear palsy
11:42 ***ROMANO ENRICO*** Neuroretinal and microvascular retinal features in dementia with lewy body assessed by optical coherence tomography angiography.
11:45 ***ZHUKOVA SVETLANA*** OCT-topography of retinal ganglion cell axon damage in glaukoma and neurological diseases as biomarker for differential diagnosis of optical neuropathies of various origins
11:48 ***FLINDRIS KONSTANTINOS*** Ocular manifestations in atypical hemolytic uremic syndrome : a case report
11:51 Discussion

12.00-12.45 FREE PAPERS - AMD IMAGING 2

CHAIRS: QUEZADA RUIZ CARLOS, RAMTOHUL PRITHVI

12:00 ***ZEINAB ELSANABARY*** Detection of silent CNV by OCTA
12:03 ***ARRIGO ALESSANDRO*** Quantitative multimodal imaging characterization of intraretinal cysts vs degenerative pseudocysts in neovascular age-related macular degeneration.
12:06 ***ROMANO FRANCESCO*** Choriocapillaris impairment in dry AMD: insights from swept-source oct angiography and associations with structural biomarkers.
12:09 ***BERNI ALESSANDRO*** Hyperreflective foci along the retinal pigment epithelium predict the onset of large choroidal hypertransmission defects in AMD
12:12 ***DE SALVO GABRIELLA*** Crocodile skin retinal appearance: miliary distribution of bilateral idiopathic multifocal retinal pigment epithelial detachments
12:15 ***FOTI CLAUDIO*** Predictors of macular atrophy secondary to serous ped collapse in eyes with type 3 neovascularization and AMD.
12:18 ***BARBIERI LUCREZIA*** Progression of geographic atrophy in age-related macular degeneration associated with the presence or absence of macular neovascularization
12:21 ***ARNON ROEE*** Near infrared reflectance to blue autofluorescence in patients with geographic atrophy due to age related macular degeneration
12:24 ***DANIEL RUDOLF MUTH*** Semi-automated long-term analysis of regional growth of geographic atrophy
12:27 ***HELLAND HANSEN BJØRN ANDRÉ HELLAND-HANSEN*** Foveal function tests - resolution and contrast sensitivity thresholds, and dynamic adaptation to luminance and contrast accurately differentiate early and moderate dry AMD from healthy controls: findings from a controlled clinical study
12:30 ***DAVEY PINAKIN*** Skin carotenoids cannot predict macular pigment optical density.
12:33 ***HOFFMANN SIMON*** Speckle variance optical coherence tomography angiography depends on distance to focus position
12:36 Discussion

PAN-VEGF INHIBITION AND BEYOND: THE PRESENT AND FUTURE OF RETINAL ANGIOGENESIS

THE PHYSIOLOGICAL SIGNIFICANCE OF VEGF

Vascular endothelial growth factor (VEGF) is a critical protein involved in angiogenesis and vascular development.[1] A member of the VEGF/platelet-derived growth factor (PDGF) family of extracellular signaling molecules, VEGF consists of (but is not limited to) several growth factor members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF).[1] VEGF ligands bind to the extracellular receptor domain of tyrosine kinase receptors in a highly targeted manner, with specific downstream effects.[1-3]

Owing to its relatively higher angiogenic effect,[4] VEGF-A has emerged as a common pharmacological target of anti-VEGF therapy. However, agents that selectively target VEGF-A, even at greater doses, may have a reduced mechanistic effect.

Beyond VEGF and PlGF, there are multiple other growth factors involved in the regulation of vascular homeostasis.[2] Of interest is the Tie-2 signaling pathway, which alongside VEGF, is involved in the regulation of angiogenic responses **(Figure 1)**.[5]

Angiopoietin-1 and Angiopoietin-2 (Ang-1 and Ang-2) are competitive ligands toward the Tie-2 receptor, with opposing effects.[2] Ang-1 is a growth factor that activates the Tie-2 receptor and promotes homeostasis. Conversely, Ang-2 is a partial agonist that acts as a competitive antagonist to Ang-1, thereby promoting vascular leakage.[5,2] Ang-1/Tie-2 signaling is involved in the prevention of inflammation, while the Ang-2/Tie-2 pathway can increase vascular instability and endothelial activation.[2]

CHALLENGES WITH THE STANDARD OF CARE

Despite the remarkable clinical benefits of anti-VEGF drugs, important unmet needs still exist in the management of retinal disease.[6] Dosing regimens may require frequent injections that can be burdensome to both patients and physicians and may lead to under-treatment due to poor patient adherence.[7]

Nonadherence may be due to treatment-related factors: a 2023 meta-analysis revealed that the top reason identified for patient nonadherence was dissatisfaction with treatment results (29.9%).[7] Though the criteria that define nonadherence to anti-VEGF therapy are wide-ranging, the overall pooled prevalence was found to be 28.0% (21.0% to 34.0%) at 12 months.[7]

A possible explanation for the limited vision gains relative to expectations may be the reduction in anti-VEGF injections in "real-world" settings compared with injections administered per clinical trial protocols.[8] Though there may be discrepancies in the durability of anti-VEGF agents in practice vs clinical development due to differences in disease activity criteria and monitoring in the trial setting,[9] the limited "real-world" response to anti-VEGF agents may also be related to their mechanism of action (MOA).

The potential consequences of selective VEGF blockade were explored by Cabral et al.[9] In one study (n=23), as would be expected, intravitreal bevacizumab was associated with reductions of VEGF-A concentration in aqueous humor. However, statistically significant increases were also observed in VEGF-C (165.93% increase) and six other vasogenic biomarkers (angiopoietin 2, endothelin 1, follistatin, HB-EGF, HGF, and interleukin 8) after a 2-month follow up. Because unbound VEGF-C binds to VEGF-R2 and -R3, there is still risk of VEGF receptor activation with agents that selectively bind to VEGF-A alone **(Figure 2)**.[10]

PAN-VEGF RECEPTOR INHIBITION


There are at least 58 known tyrosine kinase receptors in the human proteome[11] and more than 50 FDA-approved tyrosine kinase inhibitors (TKIs).[12] Though their clinical utility has been validated with existing indications and applications in oncology, TKIs represent a novel MOA in the treatment of retinal disease. Indeed, they demonstrate pan-VEGF receptor inhibition in a therapeutic area that otherwise lacks comprehensive VEGF blockade at the receptor level.

Though ophthalmic TKIs have been previously investigated in a variety of administration forms, several assets currently in development are administered via intra- or periocular injection.

Oral formulations of vorolanib have been investigated in participants with nAMD in phase 1, open-label dose escalation studies conducted at 5 US retinal clinics (NCT01674569)[13] and at 6 China sites (NCT02452385).[14] In a phase 2 study (NCT02348359; APEX), oral

FIGURE 1.

Pathways with key roles in angiogenesis regulate vascular stability and permeability.



vorolanib demonstrated non-inferiority in visual acuity compared with placebo and a decreased intravitreal injection burden.[15] However, elevations in alanine aminotransferase and aspartate aminotransferase were seen in all groups that received oral vorolanib. These systemic safety concerns were consistent with previously studied TKIs, indicating a potential pharmacological class effect.[16]

Now delivered in a sustained-release formulation via intravitreal injection, vorolanib has certain distinctions in drug delivery technology and pharmacokinetic profile. EYP-1901 (EyePoint Pharmaceuticals) uses a bioerodible formulation of Durasert® that consistently delivers therapeutic levels of vorolanib for up to approximately 9 months. After all the drug is released, the bioerodible Durasert matrix is designed to fully erode over time. EYP-1901 is also characterized by a rapid onset of release, followed by zero-order pharmacokinetics in which a constant amount of drug is eluted per unit time. Whereas some TKI molecules, such as axitinib, may have an untoward effect towards the Ang- Tie-2 pathway, vorolanib does not inhibit Tie-2 receptors at clinically relevant doses.[17]

EYP-1901 has been investigated in a phase 2 randomized, double-masked study for the treatment of nAMD (NCT05381948), which met its primary endpoint, demonstrating statistical non-inferiority change in best corrected visual acuity compared to aflibercept control and a favorable safety profile with no EYP-1901-related ocular or systemic serious adverse events. The trial also achieved key secondary endpoints, including an over 80% reduction in treatment burden, nearly two-thirds of eyes supplement-free up to six months and over 80% receiving only zero or one supplement up to six-months.[18]

As of current publication, EYP-1901 has been investigated in hundreds of study participants with no reported ocular or systemic SAEs.




FIGURE 2. A potential compensatory effect of selective VEGF-A blockade

Biomarker aqueous humor levels of VEGF-A and VEGF-C in patients with nAMD at 0, 1, and 2 months after bevacizumab intravitreal injection

FUTURE CONSIDERATIONS

The pathogenesis of neovascular retinal disease can be considered a multifaceted process that involves multiple signaling pathways and many growth factors, not limited to a single ligand such as VEGF-A. Though anti-VEGF treatments have revolutionized retinal disease management, the selective binding of VEGF ligands may represent insufficient long-term therapy in a significant percentage of patients. Understanding that the sub-optimal responses seen with first-line anti-VEGF agents may be inherently due to limitations of the drugs' MOA, novel agents that target complementary pathways may help optimize long-term patient outcomes, particularly as part of a sustainable dosing regimen.

COMING SOON

LUGANO & LUCIA

Global Phase 3 Trials in nAMD

EYP-1901 is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. EYP-1901 delivers vorolanib, a selective and patent-protected TKI, using EyePoint's proprietary sustained-release Durasert E™ technology. Please visit EyePoint Pharmaceuticals at: Booth #54 to learn more.

EYEPOINT

DISCLAIMER: EYP-1901 (vorolanib intravitreal insert) is an investigational medicinal product; it has not been approved by any health agencies or regulatory authorities in any country. Approval and timeline for marketing authorization is uncertain.

REFERENCES: **1.** Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. *Genome Biol.* 2005;6(2):209. **2.** Martinez-Alejo JM, Baiza-Duran LM, Quintana-Hau JD. Novel therapies for proliferative retinopathies. *Ther Adv Chronic Dis.* 2022;13:20406223221140395. **3.** Michaloski JS, Redondo AR, Magalhães LS, et al. Discovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors. *Sci Adv.* 2016;2(10):e1600611. **4.** Peach CJ, Mignone VW, Arruda MA, et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. *Int J Mol Sci.* 2018;19(4):1264. **5.** Hussain RM, Shaukat BA, Ciulla LM, et al. Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration. *Drug Des Devel Ther.* 2021;15:2653-2665. **6.** Wolf AT, Harris A, Oddone F, et al. Disease progression pathways of wet AMD: opportunities for new target discovery. *Expert Opin Ther Targets.* 2022;26(1):5-12. **7.** Shahzad H, Mahmood S, McGee S, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. *Syst Rev.* 2023;12(1):92. **8.** Ciulla TA, Hussain RM, Pollack JS, et al. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. *Ophthalmol Retina.* 2020;4(1):19-30. **9.** Zarbin M, Weng C, Souverain A, et al. An assessment of the impact of disease activity criteria on dosing interval assignment in clinical trial patients with nAMD. Paper presentation at: American Society of Retina Specialists (ASRS) Annual Meeting; July 28 – 1 August 1, 2023; Seattle, WA. **10.** Cabral T, Lima LH, Mello LGM, et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. *Ophthalmol Retina.* 2018;2(1):31-37. **11.** Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell.* 2010;141(7):1117-1134. **12.** Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine kinase inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 1, 2023. **13.** Jackson TL, Boyer D, Brown DM, et al. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. *JAMA Ophthalmol.* 2017;135(7):761-767. **14.** Cohen MN, O'Shaughnessy D, Fisher K, et al. APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneratin. *Br J Ophthalmol.* 2021;105(5):716-722. **15.** Data on file. EyePoint Pharmaceuticals, Inc. **16.** Tolentino MJ, Tolentino AJ. Investigational drugs in clinical trials for macular degeneration. *Expert Opin Investig Drugs.* 2022;31(10):1067-1085. **17.** Fabre M, Mateo L, Lamaa D, et al. Recent advances in age-related macular degeneration therapies. *Molecules.* 2022;27(16):5089. **18.** EyePoint Pharmaceuticals announces positive topline data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary Endpoints. EyePoint Pharmaceuticals, Inc. Published December 4, 2023. Accessed November 6, 2024. https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-positive-topline-data-phase-2.



Acknowledgements

DIAMOND

Alcon

BAYER

Roche

EMERALD

BAUSCH + LOMB

ZEISS

abbvie

RUBY

OFFHEALTH

astellas

Ocular Therapeutix

SAPPHIRE

Intalight

Apellis

ALFA INTES

EYEPOINT

DORC a ZEISS company

REGENXBIO

TOWARD π Medical Technology

espansione group

Théa let's open our eyes

ANNEXON biosciences

Johnson&Johnson

DOC

OPHTAGON

TOPAZ

icare For better perception

BVI

Nikon

optos

ADVERUM

EssilorLuxottica

VISIONIX

HEIDELBERG ENGINEERING

ONL THERAPEUTICS

SAMSARA VISION

ntc Novelty. Technology. Care.

NOVARTIS

SIFI

FBVISION OPHTHALMIC PHARMACEUTICALS

HOYA

KILABS

4DMT

AVICEDA THERAPEUTICS

beacon therapeutics

EVERADS THERAPY

OPTHEA

AMBER

BRUSCHETTINI
BIOPHARMA & OPHTHALMIC DIVISION

NIDEK

oertli
SWITZERLAND

Polyoftalmica
strumenti per l'oftalmologia

TEC MED

TOPCON Healthcare

MICRO CLEAR

Alkeus
PHARMACEUTICALS

Boehringer Ingelheim

MedOne

Mesofarma

ALCHIMIA

Bitfount

bulbitech
Next-generation diagnostics with eye-tracking

FIMAS

FRASTEMA OPHTHALMICS
Canon
CANON MEDICAL
OFFICIAL DISTRIBUTOR

imagine eyes

MILOFTALMICA

MOPTIM®

OCULUS SURGICAL

RETINSIGHT
AI TO EYE

TELEON®

EG®
STADA GROUP

STADA
Caring for People's Health

CSO®

FARMAPLUS
italia

e.janach®

JP
medical
publishers

salmoiraghi & viganò

fidia
EYE CARE

VISUfarma
the eye health company

Santen
A Clear Vision For Life®



FLORetina 2024

UNDER THE PATRONAGE OF

Gemelli

COMUNE DI FIRENZE

UNIVERSITÀ CATTOLICA del Sacro Cuore

ICOOR

12° International Congress on OCT and OCT angiography

CONFERENECE SECRETARIAT
AP MEETINGS s.r.l. Ph. + 39 031 461938 Fax + 39 031 4890516
Registered office: Via San Carlo, 23/B - 22070 Capiago Intimiano (CO) Headquarters: Piazza Catello 4, 22060 Carimate (CO)
e-mail: anna.porro@apmeetings.com - **www.apmeetings.com**